Manipulation of host cell signaling pathways and translation factors during poxvirus infection by Zaborowska, Izabela
 Manipulation of host cell signaling pathways and 
translation factors during poxvirus infection 
 
 
A thesis submitted for the degree of Ph.D. 
Dublin City University 
by 
Izabela Zaborowska M.Sc. 
 
 
 
The research work described in this thesis  
was carried out under the supervision of 
 
  Dr. Derek Walsh  
 
 
 
National Institute for Cellular Biotechnology 
Dublin City University 
Republic of Ireland 
 
2010 
  
 
 
 
 
 
 
 
 
 
 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Ph.D. is entirely my own work, that I have exercised 
reasonable care to ensure that the work is original, and does not to the best of my 
knowledge breach any law of copyright, and has not been taken from the work of others 
save and to the extent that such work has been cited and acknowledged within the text 
of my work. 
 
 
 
 
Signed: ______________________ ID No.: _______________ Date: ______________ 
 
 
 
 
 ABSTRACT 
 
 
Poxviruses are large double-stranded DNA viruses that replicate exclusively in the 
cytoplasm of infected cells in distinct sites termed viral factories, with Vaccinia Virus 
(VacV) acting as the laboratory prototype for those that infect humans. Despite 
encoding proteins responsible for DNA replication and mRNA transcription, like all 
viruses they remain dependent on the host-cell translational machinery to produce viral 
proteins. Although recent studies have shown that VacV stimulates mTOR activity and 
redistributes translation factors to viral factories, how this is accomplished and its 
importance to VacV replication remain unknown. 
 
Here, we demonstrate that VacV activates the PI3 kinase (PI3K) to stimulate its 
downstream substrate mTOR, thereby inactivating the translational repressor protein, 
4E-BP1. This provides the first evidence that VacV activates PI3K signal pathway in a 
manner distinct from other poxviruses studied, such as myxoma virus, which directly 
stimulates Akt activity in a PI3K-independent mode. Using specific inhibitors we 
dissect the role of various components of PI3K/Akt pathway and show that rapamycin-
insensitive mTORC1 and mTORC2 activity is responsible for stimulating the formation 
of the translation initiation factor, eIF4F, which drives cap-dependent translation in 
infected and uninfected cells. We also show that eIF4F is important but not absolutely 
essential for viral protein synthesis. In addition, we demonstrate that inactivation of the 
PI3K by either LY294002 or wortmannin does not cause apoptosis in human or monkey 
cell lines.  
 
In an attempt to understand how VacV causes the redistribution of host translation 
initiation factors to viral factories, we performed immunoprecipitation-based screens 
and identified the product of the VacV I3L gene, the single-stranded DNA (ssDNA) 
binding protein, I3 as interacting with eIF4F. We demonstrate that I3 binds eIF4G 
directly in vivo and in vitro within the eIF4G C-terminal domain. PAA, a DNA 
polymerase inhibitor that blocks viral factory formation and entry into late stages of 
infection, did not significantly affect the ability of I3 to interact with eIF4F, although it 
did block re-localization of these factors. Cloned I3 was able to mediate the binding of 
initiation factors to ssDNA in cell extracts, suggesting that I3 sequesters host translation 
factors within viral factories as they form. Our attempt to recover VacV ∆I3L mutants 
using the Vac-Bac/λ system was unsuccessful, suggesting that the I3L gene product (I3) 
is essential during VacV infection. 
 
Overall, our results provide new insights into how VacV manipulates host signaling and 
translation initiation factor function and their importance in viral protein synthesis and 
replication, highlighting a novel approach by a DNA virus to manipulate the host-cell 
translation initiation machinery. 
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 Abbreviations 
 
4E-BP                                                                                 
Ab 
ATP 
BrdU 
BSA 
BSC40                               
C2 domain                          
cDNA 
C-terminus 
DEPC 
DMEM 
DMSO 
DNA 
ds 
DNAse 
dNTP 
DTT 
EDTA 
eIF 
FBS 
FKBP12 
g 
GST 
HEK 
HEPES 
IC50                                                          
IPTG 
IRES 
kDa 
kb 
kbp 
M 
MAb 
MAPK 
 
 
- eIF4E-binding protein
- antibody 
- adenosine triphosphate 
- bromodeoxyuridine 
- bovine Serum albumin 
- monkey epithelial kidney cells 
- protein kinase C homology domain 2 
- complementary DNA 
- carboxy-terminus 
- diethyl pyrocarbonate 
- Dulbecco’s modified Eagle’s medium 
- dimethyl sulfoxide 
- deoxyribonucleic acid 
- double stranded 
- deoxyribonuclease 
- deoxynucleotide triphosphate 
- dithiothreitol 
- ethylene diamine tetracetic acid 
- eukaryotic initiation factor 
- fetal bovine serum 
- FK506-binding protein, molecular mass of 12 kDa 
- gram 
- glutathione-S-transferase 
- human embryonic kidney 
- N-[2-Hydroxyethyl]piperazine-N’-[2-ethanesulphonic acid] 
- inhibitory concentration 50% 
- isopropyl β-D-1-thiogalactopyranoside 
- internal ribosome entry site 
- kilo Daltons 
- kilobase 
- kilobase pair 
- mole 
- monoclonal antibody 
- microtubule associated protein kinase 
 Met 
Met-tRNAi 
min 
mRNA 
miRNA 
ml 
mm 
mM 
Mnk 
mTOR 
MW 
µ 
NHDF 
N-terminus 
OD 
P 
PAA 
PABP 
PBS 
PCR 
PDK1 
PI 
PI3K 
PIP2 
PIP3 
PtdIns 
PTEN 
raptor 
rictor 
RNA 
RNAse 
RNAi 
RNAsin 
rpm 
SDS 
SDS-PAGE 
sec 
- methionine 
- methionyl-initiator transfer ribonucleic acid 
- minute 
- messenger RNA 
- micro ribonucleic acid 
- mililitre 
- milimetre 
- mili mole 
- MAP kinase interacting kinase 
- mammalian target of rapamycin 
- molecular weight 
- micro 
- normal human diploid fibroblast 
- amino-terminus 
- optical density 
- phospho- 
- phosphonoacetic acid 
- poly(A)-binding protein 
- phosphate buffered saline 
- polymerase chain reaction 
- phosphoinositide-dependent kinase 1 
- phosphoinositide 
- phosphoinositide-3 kinase 
- phosphatidylinositol-4,5-biphosphate 
- phosphatidylinositol-3,4,5-triphosphate 
- phosphatidylinositol 
- phosphatase and tensin homolog deleted on chromosome 10 
- regulatory-associated protein of mTOR 
- rapamycin-independent companion of mTOR 
- ribonucleic acid 
- ribonuclease 
- RNA interference 
- ribonuclease inhibitor 
- revolution(s) per minute 
- sodium dodecyl sulphate 
- sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
- second 
 siRNA 
SSB 
ssDNA 
ssRNA 
TBS 
TCA 
TE 
TEMED 
UHP 
UTR 
V 
VacV 
VarV 
WB 
xg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- small interfering ribonucleic acid 
- single-strand DNA-binding 
- single-stranded DNA 
- single-stranded RNA 
- tris buffered saline 
- trichloroacetic acid 
- Tris-EDTA 
- N, N, N’, N’-tetramethyl-ethylenediamine 
- ultra high purity 
- untranslated region 
- volt 
- Vaccinia virus 
- Variola virus 
- Western blot 
- times gravity 
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1.1 The Poxviridae family 
Poxviruses are mysterious and fascinating microbes that distinguish themselves from 
other DNA viruses on account of their enormous size, complex morphology, and unique 
replication cycle in the cytoplasm.  Members of the family of poxviruses (Poxviridae) 
infect diverse genera of the animal kingdom from insects to mammals. Two of them, 
variola virus and molluscum contagiosum virus infect only humans, but other members 
of the family, such as monkeypox, can be transmitted from animals to humans as 
zoonoses and have been reported to subsequently transmit from human to human (Moss, 
2007).  
 
1.1.1 Classification of Poxviruses 
The Poxviridae are divided into two subfamilies: the poxviruses of vertebrates 
(Chordopoxvirinae) consisting of eight genera, and the poxviruses of insects 
(Entomopoxvirinae) consisting of three genera (Table 1.1). The genetic connection 
between poxvirus subfamilies was confirmed by DNA sequencing and bioinformatic 
analysis; moreover, a genetic relation with other large DNA viruses belonging to the 
families Asfaviridae, Iridoviridae, Phycodnaviridae, and recently discovered 
Mimiviruses has been suggested (Iyer et al., 2001; Suzan-Monti et al., 2006). 
Poxviruses pathogenic for humans belong to four diverse genera of the vertebrate 
poxvirus family, and the majority of them are orthopoxviruses. Therefore, the 
Orthopoxvirus genus has been of interest to scientists for many years, becoming the best 
known and the most widely studied amongst eleven genera comprising the Poxvirus 
family.  
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Family 
 
Subfamily 
 
Genus 
 
Type species 
 
Poxviridae 
 
Chordopoxvirinae 
 
Orthopoxvirus 
Parapoxvirus 
Avipoxvirus 
Capripoxvirus 
Leporipoxvirus 
Suipoxvirus 
Molluscipoxvirus 
Yatapoxvirus 
 
Vaccinia virus, Variola virus 
Orf virus 
Fowlpox virus 
Sheeppox virus 
Myxoma virus 
Swinepox virus 
Molluscum contagiosum virus 
Yaba monkey tumor virus 
  
Entomopoxvirinae 
 
Alphaentomopoxvirus 
Betaentomopoxvirus 
Gammaentomopoxvirus 
 
Melolontha melolontha entomopoxvirus 
Amsacta moorei entomopoxvirus 
Chironomus luridus entomopoxvirus 
 
Table 1.1 Classification of Poxviruses (Data of Virus Taxonomy, 2000) 
 
The laboratory prototype of orthopoxviruses used in this study is vaccinia virus (VacV), 
which has been employed to eliminate the smallpox epidemic of the 18th and 19th 
centuries (see next paragraph).  
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1.1.2 Smallpox disease 
Smallpox, also called variola, is one of the most devastating diseases known, affects 
only humans, and is caused by variola virus (VarV). The name “variola” is derived from 
a term “variolation”, which was a practice of inhaling material from the dried pox scabs 
or inoculating this material directly beneath the skin to stimulate the immune system 
against smallpox. There are two clinical forms of smallpox: variola major, concerning 
more than 90% cases and with the case-fatality rate varied from 5 to 40%, and variola 
minor, a milder form of smallpox with a mortality rate of about 0.1-2%. Outbreaks of 
variola minor were observed independently of variola major outbreaks and located 
mostly in South America and South Africa (Shchelkunov et al., 2005). However, 
biological distinctions between diverse forms of variola still lack a complete 
explanation.  
Transmission of VarV follows inhalation or other close contact with infected persons or 
their belongings, such as blankets (Damon, 2007). Infectious forms of the virus occur in 
the pustules formed during the incubation period, as illustrated on Fig. 1.1.1. During the 
first hour of the incubation period virus infects pulmonary macropahges, then spreads 
from the lungs to local lymph nodes where it multiplies, and is borne by blood. The 
virus also replicates in the spleen, bone marrow and lymph tissue. Finally, leucocytes 
with multiplied virus appear in dermal and mucosal vessels, leading to characteristic 
skin and mucosal symptoms (de los Rios and Jimenez-Gomez, 2007). 
Infection begins with high fever (38-400C) and chills, often accompanied by malaise, 
headache, lumbar pain, and less frequently by nausea, vomiting, abdominal pain and 
delirium. The rash arises within 4 days of infection and begins with small red spots on 
the tongue and in the mouth. These spots evolve to sores that break open and spread the 
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virus into the mouth and throat, and soon after to the skin beginning on the face and 
extending to arms, legs and entire body within 24 hours. By the third day of the rash it 
becomes raised bumps, filled with a thick, opaque fluid containing infectious virions. 
During the next 5 days the bumps evolve to round pustules, which then begin to form 
crusts and scabs. The scabs begin to fall off, releasing infectious virions and leaving the 
marks on the skin. The patient remains contagious until the last scab falls off (de los 
Rios and Jimenez-Gomez, 2007). 
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Figure 1.1.1 A poster showing the stages of rash during smallpox infection. Multilingual 
versions of the poster were prepared and distributed in 1970, during smallpox eradication 
programme (From Fenner et al., 1988) 
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1.1.2.1 Smallpox in human history  
Smallpox has had a massive impact on human history for more than 2000 years. The 
virus causing smallpox probably originated in either Egypt or India. Examination of the 
Egyptian mummies, as well as analysis of the ancient Indian Sanskrit describing the 
smallpox-like disease suggest that smallpox existed on those lands as early as 1000-
1400 B.C. (Hopkins, 2002). By 1000 A.D. smallpox spread in Europe, North Africa and 
East Asia, but did not become a major problem until the 17th century (Carmichael and 
Silverstein, 1987). During the 17th and 18th centuries smallpox was introduced by 
Europeans into North and South America, Australia and South Africa, becoming a 
worldwide issue.  
Until recently, smallpox was the most infectious and deadly epidemic disease of 
humans, with a mortality rate exceeding 30%. In the previous century alone smallpox 
killed more than 300 million people around the world and most likely would have been 
killing millions until now if not for the recognition that vaccination with cowpox or 
vaccinia virus protects from smallpox infection, which has been observed and published 
by Edward Jenner in 1798. The live vaccine was applied intradermally by scarifying the 
skin on the arm. The virus replicated at the site of scarification stimulating both 
antibody-mediated and T cell-mediated protective immunity against smallpox and other 
orthopoxviruses such as monkeypox (Dimmock et al., 2007). Smallpox was completely 
eradicated in 1977 through the international vaccination campaigns carried out by the 
World Health Organization (WHO). The remaining stocks of VarV have been destroyed 
with the exception of two reservoirs in United States and Russia (WHO, 1999) under 
the supervision of WHO. Smallpox became a history, and the only epidemic disease 
known that has been completely eradicated by vaccination. 
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1.1.2.2 Poxviruses still endanger 
Although variola virus does not occur naturally in the environment anymore, there is a 
concern that if unknown stocks of VarV exist, they can be used as a potential and very 
dangerous biological weapon in bioterrorism. There is also a possibility of genetically 
engineering orthopoxvirus strains such as monkeypox virus to create a smallpox-like 
disease. Since WHO stopped the routine vaccination against smallpox in 1980 due to 
the mass side effects and complications caused by vaccinia virus, the effects of a 
smallpox outbreak on our current population would be profound. 
In addition, other orthopoxvirus infections, such as monkeypox, have been reported in 
humans. A recent outbreak of the monkeypox disease occurred in the United States in 
2003, when 72 humans were diagnosed with monkeypox after contact with wild prairie 
dogs (Shchelkunov et al., 2005). Monkeypox virus can spread between humans and 
cause a serious, smallpox-like disease (Fig. 1.1.2).  
 
                                
Figure 1.1.2 Human monkeypox. The day 8 of the monkeypox infection on a 7-year-old girl 
(From Breman et al., 1980) 
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Considering the facts described above, further research in poxviruses is essential in 
terms of investigating new antiviral agents and improved vaccines. 
 
1.1.3  Vaccinia virus 
A remarkable poxvirus that is not host-species specific is vaccinia virus (VacV), a 
laboratory prototype of poxviruses, which, together with cowpox virus, has been used 
for immunisation against smallpox. Since VacV and VarV belong to the same 
Orthopoxvirus genus, they are closely related genetically, morphologically, and cover a 
similar host range. VacV is the most widely studied poxvirus and has greatly 
contributed to the expansion of general knowledge on infectious diseases and immunity; 
it was the first animal virus seen under the microscope, precisely titered, grown in tissue 
culture, physically purified, and chemically analyzed (Moss, 2007). Furthermore, VacV 
has been used as a live recombinant expression vector for protein synthesis in vivo and 
in vitro (Moss, 1996) providing a new tool in gene therapy, developing vaccines against 
various infectious diseases, and cancer therapy (Mastrangelo et al., 2000).  
 
1.1.3.1 The origin of VacV 
Although VacV biology has been widely studied and the virus was used for millions of 
vaccinations, its origin and natural host remain a mystery. Some scientists believe that 
VacV is a laboratory strain with no natural reservoir, and could be a result of a cowpox 
virus transformation during vaccination (Shchelkunov et al., 2005). Furthermore, 
Bedson and Dumbell (1964) were able to obtain recombinants of variola and cowpox 
viruses with properties similar to VacV, suggesting its origin. Another hypothesis 
proposes that VacV is a derivative of other animal viruses that have disappeared from 
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the environment such as horsepox virus (Shchelkunov et al., 2005). Vaccinia-like 
viruses were also isolated from buffaloes in India at the late 1960s- early 1970s, and 
most recently in 1992-96 (Kolhapure et al., 1997), and also from dairy cattle and 
humans in Brazil during the outbreak in 1990s (Damaso et al., 2000). Those isolates 
could be the derivatives of the vaccinia-like viruses originally existing in nature, but 
most likely they are mutated vaccine strains accidentally introduced into the 
environment during smallpox eradication and vaccination. Some of those naturally 
occurring strains became subspecies of VacV, such as buffalopox and rabbitpox virus 
(Virus Taxonomy, 2000). 
Summarizing, the origin of VacV needs further investigation including the analysis of 
genomic structures of VacV and related orthopoxviruses, which will probably solve that 
point of issue. 
 
1.1.3.2 Virion structure and entry 
The orthopoxvirus virions exist in four different forms, depending on the stage of 
maturity: immature virions (IV), mature virions (MV), wrapped virions (WV), and 
extracellular virions (EV). The last three forms are infectious and differ in the number 
of membranes and thus surface antigens (reviewed by Smith et al., 2002). The vaccinia 
virion is very large in comparison to other animal viruses. Reconstruction of the 
intracellular mature virion (MV) by cryo-electron tomography carried out recently by 
Cyrklaff and colleagues (2005) revealed its brick-shape with rounded edges and 
dimensions of approximately 360x270x250 nm (Fig. 1.1.3 A, B). Each MV is 
surrounded by a lipid membrane which is 5-6 nm thick and contains at least one, but 
most frequently two lateral bodies built up by a heterogeneous protein layer and 
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attached to the outer membrane. The central part of the virion possesses a dumbbell-
shaped core with the wall composed of two layers (Fig. 1.1.3 C, D; Fig. 1.1.4). The 
outer membrane of the core appears continuous, but pore-like structures were identified 
on the inner core membrane that may be involved in releasing the viral mRNA into the 
cytoplasm shortly after infection (Griffiths et al., 2001), indicating that VacV entirely 
uncoats the outer core membrane before getting into the cytoplasm.  
 
 
             
Figure 1.1.3 Images of the VacV mature virion (MV) reconstructed by cryo-electron 
tomography. (A, B) Two orthogonal views along perpendicular axes, highlighting the outer 
shape and size of the virion. (C, D) Translucent illustration of the virion showing the complex 
internal structure of the core. (From Cyrklaff et al., 2005) 
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Figure 1.1.4 Schematic diagram of the structure of orthopoxvirus mature virion (MV). 
Virion is brick-shaped and surrounded by two lipid membranes. Viral genome DNA and a 
number of proteins within the core are organized as a nucleosome. Lateral bodies are attached to 
the outer lipoprotein membrane, which is 12 nm thick. The outer membrane surface 
appears to consist of irregularly shaped tubules. (From Damon, 2007) 
 
The viral genome is situated in the core. In the tomographic reconstructions the contents 
of the core separate in two phases, one of which is denser, contains DNA, and was 
found to concentrate near the core membrane, while the lower density volume is free of 
DNA and is most likely occupied by enzymes and factors needed for synthesis of early 
viral mRNA (Cyrklaff et al., 2005).       
Investigations of the mechanism(s) used by VacV to enter cells are complicated by the 
existence of multiple infectious forms that differ from one another by their outer 
membrane. MVs have a single outer membrane while EVs possess an additional 
antigenically distinct outer membrane that must be disrupted prior to or during entry 
(Moss, 2007). MV enters the cell by fusion of the lipoprotein membrane with the 
plasma membrane or following endocytosis, while entry of the EV is still a matter of 
some debate. However, it is known that virus entry is facilitated by interaction of viral 
 13 
proteins with specific cell surface receptors, which can determine tropism (Sieczkarski 
and Whittaker, 2005; reviewed in Moss, 2006).  
The outer membrane of MV is covered with irregularly shaped, randomly located 
surface tubules (Fig. 1.1.4) in lengths of about 50-100 nm, consisting of a single, 58 
kDa polypeptide (Muller and Williamson, 1987). Surface tubules were shown to inhibit 
cellular protein synthesis both in vivo and when added to the rabbit reticulocyte lysate 
(Mbuy et al., 1982).  
 
1.1.3.3 Life cycle 
Unlike most other DNA viruses, poxviruses replicate exclusively in the cytoplasm of 
infected cells rather than in the nucleus, in structures called viral factories or virosomes, 
and can even replicate in enucleated cells (Prescott et al., 1971; Pennington and Follett, 
1974). A single virion contains a complete transcription system essential for the 
synthesis of viral mRNA which is capped, methylated and polyadenylated (Moss, 
2007). A great number of viral core-associated enzymes and factors have been 
identified including RNA polymerase, DNA helicase, topoisomerase, vaccinia early 
transcription factor (VETF), capping and methylating enzymes, and many more. VacV 
also encodes protein kinases and a protein phosphatase, suggesting the role of protein 
phosphorylation in the regulation of its life cycle (Traktman, 1996).   
The VacV life cycle starts after fusion with the cell membrane and releasing the core 
into the cytoplasm (Fig. 1.1.7). The early genes are transcribed and translated 
immediately, while the core translocates on microtubules to specific cytoplasmic 
compartments and forms a viral factory, where intermediate-to-late protein synthesis as 
well as viral DNA replication occur. The viral factory is also a place where the early 
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VacV proteins accumulate (Kovacs and Moss, 1996, Domi and Beaud, 2000; 
Katsafanas and Moss, 2007). As soon as the late genes are transcribed, virion assembly 
begins with the formation of distinct membrane structures. The newly synthesized viral 
particles containing structural proteins, enzymes and early transcription factors are 
wrapped by membranes derived from virus-modified trans-Golgi or endosomal 
cisternae, containing at least seven viral proteins (Moss, 2007), and released from the 
cell through exocytosis. Some enveloped virions remain attached to the cell surface and 
induce the growth of actin tails beneath virions on the plasma membrane to facilitate 
virus spread into neighbouring cells (Smith and Law, 2004). 
 
1.1.3.4 Virion assembly 
The assembly of vaccinia virions begins in viral factories that form close to the nucleus. 
The core of the immature virion (IV) originates from the crescent-shaped precursors, 
and subsequently condenses and differentiates to form a mature virion (MV). The 
difference in morphology between those two types of virions has been illustrated in 
Figure 1.1.5. MV is an infectious virion and can be released by cell lysis. However, 
these virions are not sufficient for the efficient virus spread, and the additional 
enveloped forms of the virions are required for this process. A number of MVs are 
wrapped by modified trans-Golgi (Schmelz et al., 1994) or endosomal (Tooze et al., 
1993; van Eijl et al., 2002) cisternae to form intracellular wrapped virions (WV), which 
then translocate to the cell surface through microtubules. WVs can remain on the cell 
surface as a Cell-associated Enveloped Virion (CEV), or be released from the cell 
through exocytosis, resulting in loss of the outer membrane and forming the 
extracellular mature virion (EV) (Moss and Ward, 2001; Smith et al., 2002).  
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Figure 1.1.5 Images of vaccinia virions in cells infected overnight, acquired by using a 
three-dimensional electron microscopy system. A. Immature virions (IV) with one selected 
and color coded with membrane in yellow and core in blue. B. Mature virions (MV) with 
characteristic dumbbell-shaped core. One virion selected and color coded with membrane in 
yellow and core in two shades of blue, separated by a palisade layer in red. (From Heuser, 2005)  
 
VacV can spread from cell-to-cell in several ways. Direct spread can be mediated by 
cell lysis, release of MV and re-infection of adjacent cells. In turn, CEV particles 
present on the cell surface can be driven into neighbouring cells by actin tails, which are 
formed in response to expression of the proteins encoded by A33R, A34R or A36R 
genes (Smith and Low, 2004). 
 
1.1.3.5 Genome organization                
Because poxviruses replicate in the cytoplasm of infected cells and hence are extremely 
self-sufficient, the mature virions contain the complete package of enzymes needed for 
synthesis of early viral mRNA. The nuclear material of VacV is a linear double-
stranded DNA molecule with the approximate length of 190 kb and encodes more than 
200 genes (Goebel et al., 1990; Lefkowitz et al., 2005). The vaccinia genome has A+T-
A. B. 
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rich, covalently closed hairpin ends that connect the two DNA strands (Baroudy et al., 
1982; Condit et al., 1996). As a result, when the DNA is fully denatured, a circular 
single-stranded molecule is generated. Furthermore, VacV genome contains quite large 
(approximately 10 kbp) inverted terminal repetitions (ITRs), which comprise identical 
but oppositely oriented sequences at both ends of the genome and exist in variable 
lengths (Garon et al., 1978). Next to the ends of the ITRs, short tandem repeated 
sequences occur (Wittek and Moss, 1980), which are thought to participate in 
recombination events (Traktman, 1996). The ITRs include a highly conserved DNA 
sequence of less than 100 bp required for the resolution of the VacV hairpin terminus 
(DeLange and McFadden, 1987; Merchlinsky, 1990), and a number of open reading 
frames (ORFs). The structure of the VacV genome is illustrated in Figure 1.1.6. 
Vaccinia genes are very tightly packed in the genome; the gaps between coding 
sequences usually do not exceed 50 nt. Moreover, vaccinia genes do not contain introns, 
most likely as a consequence of the cytoplasmic site of replication, which makes 
analysis of the genomic sequences much simpler. There is no specific order of the genes 
location on the genome with respect to function, although Mackett and Archard (1979) 
illustrated that essential genes required for virus growth aggregate around the central 
part of the genome, which comprises around 60% of the total genome. Genes situated 
outside this region are generally not required for virus replication, but seem to be related 
to immune modulation and providing each poxvirus species unique and specific 
characteristics.  
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Figure 1.1.6 Schematic illustration of the VacV genome. A. A structure of the entire linear 
double-stranded DNA genome illustrates the hairpin ends and the location of inverted terminal 
repetitions comprising the tandem repeated sequences. B. The nucleotide sequences of the 
inverted and complementary forms of the terminal loops. (From Moss, 2007) 
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Figure 1.1.7 Replication cycle of vaccinia virus. A single virion containing DNA, enzymes 
and transcription factors attaches to a cell (1) and fuses with the cell membrane (2). Virion 
releases the core, and synthesizes early mRNA that is translated into various proteins (3). After 
uncoating (4) the DNA is replicated to form concatemeric molecules (5). Intermediate genes are 
transcribed and the mRNA is translated and to form late transcription factors (6). The late genes 
are transcribed, and the mRNA is translated and forms structural proteins, enzymes and early 
transcription factors (7). Virion assembly begins with the formation of the crescent-shaped 
precursors (8). The concatemeric DNA intermediates resolve into unit genomes, which are 
packed in immature virions (IV) (9). Maturation leads to the formation of infectious intracellular 
mature virions (MV) (10). MVs are enveloped by trans-Golgi membranes and the wrapped 
virions (WV) are transported to the cell surface on microtubules (11, 12). After fusion with the 
cell membrane extracellular enveloped virions (EV) are released from the cell, followed by actin 
tail formation beneath the EV (13). (From Moss, 2007)  
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1.1.3.6 DNA replication 
As mentioned before, the vaccinia virus genome is a linear double-stranded DNA 
molecule with the approximate length of 190 kb that is unusual in having covalently 
closed ends, which means that the molecule does not have free 5’ or 3’ termini. 
Consequently, denaturation of DNA results in the formation of a circular single-
stranded molecule. VacV DNA is extremely AT-rich (67%), especially on the termini, 
and is not methylated. Although the detailed biochemistry of VacV replication is not yet 
established, the unique structure of the VacV genome and the presence of concatemer 
junctions suggest a similar model of replication to the rolling hairpin model proposed 
for a single-stranded parvovirus DNA (Tattersall and Ward, 1976). Replication of VacV 
DNA does not only provide progeny genomes, but also is an obligatory step leading to 
the activation of viral intermediate gene transcription (Vos and Stunnenberg, 1988; 
Keck et al., 1990). In turn, it is thought that optimal DNA replication requires the 
synthesis of viral and/or cellular proteins that are made at intermediate and late times 
after infection.   
Vaccinia DNA replication begins one to two hours after infection with the introduction 
of a nick (cleavage at the phosphodiester bond between two nucleotides) near one or 
both ends of the termini, presumably within 200 bp of the end of the molecule (Du and 
Traktman, 1996). Strand cleavage provides a free 3’-OH end, which acts as a primer 
terminus for the viral DNA polymerase (Fig. 1.1.8). Strand extension proceeds towards 
the hairpin telomere, leading to the formation of a dimeric tail-to-tail concatemer, which 
is then resolved to monomer progeny genomes and packed into newly synthesized 
virions.   
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Figure 1.1.8 Schematic model for poxviral DNA replication. F and S indicate the fast and 
slow electrophoretic mobilities of DNA fragments containing complementary and inverted 
hairpin sequences. Newly synthesized DNA shown as dashed lines, with arrowhead at the 3’-
OH termini. Complementary sequences are labeled with upper and lower case. “Res” indicates 
the resolution sites within the concatemer junction. (From Moss, 2007)  
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In spite of the fact that poxviruses are relatively self-sufficient and encode proteins 
responsible for DNA replication and mRNA transcription, like all viruses they remain 
completely dependent on the host-cell translational machinery to produce viral proteins. 
Consequently, they have to compete with the host-cell in utilising the protein synthesis 
factors. Virus influence affects all host-cell translational processes including initiation, 
elongation, termination, and signaling pathways, but the majority of the viral strategies 
are focused on translation initiation (Gale et al., 2000). 
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1.2 Translation initiation in eukaryotes 
Translation is a multistep and multifactorial process leading to the synthesis of proteins, 
the molecules highly important for every living organism. Such an important process 
needs to be precisely monitored and regulated, and can enable the rapid manipulation of 
protein production without involving new mRNA synthesis, processing, or export. 
Although translational rates can be controlled at each of the three levels (initiation, 
elongation, termination) the majority of the regulation affects the initiation step, when 
the ribosome is recruited to the mRNA (Mathews et al., 2007). This fact seems to be 
logical and agrees with the biological principle which says that it is easier and more 
efficient to govern the process at its outset than to interrupt it in midstream and have to 
struggle with the activated apparatus and the accumulation of intermediates.  
The regulation of translational rates (the frequency of mRNA translation) plays a key 
role in many fundamental biological processes including cell growth, development and 
response to stress agents. Modulation of initiation can influence both the overall rate of 
protein synthesis as well as the relative rates of synthesis of different proteins. Control 
of the overall rate of translation is potentially important for cell growth during G1 phase 
of the cell cycle, while the concentrations of the growing number of specific proteins 
involved in cell proliferation and differentiation control are now considered to be 
modulated, at least in part, at the translational level (Mathews et al., 2007).  
Usually, translation in eukaryotes is cap-dependent and starts with recognition of the 5’ 
end of the mRNA and association of initiation factors. However, translation of some 
cellular mRNAs does not involve the cap and occurs through internal ribosome entry 
mechanism, which involves the internal association of ribosome subunits at or near the 
initiation codon without requiring entry from 5’ end of the mRNA. Internal ribosome 
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entry sites (IRES) were first discovered in viral mRNAs (Jang et al., 1988; Pelletier and 
Sonenberg, 1988), and the first cellular IRES was documented a few years later 
(Macejak and Sarnow, 1991).  
The key elements involved in cap-dependent translation initiation are eukaryotic 
initiation factors (eIFs), the 80S ribosome and a messenger ribonucleic acid (mRNA).  
 
1.2.1 The structure of eukaryotic mRNA  
The mRNA is an RNA molecule that carries codes from the DNA in the nucleus to the 
region of protein synthesis in the cytoplasm. The translational efficiency of eukaryotic 
mRNA is limited by the rate of translation initiation, which is in turn determined by 
structural characteristics of mRNA that affect recruitment of ribosomes, scanning to the 
initiation codon, and recognition of initiation codon. Eukaryotic mRNA associates 
dynamically with proteins mediating nuclear export, subcellular localization, stability, 
and translation initiation or suppression. Broadly, the mRNA molecule is divided into a 
coding sequence that is flanked by non-coding regions located in the 5’ or 3’ 
untranslated regions (UTRs) that determine stability and translational efficiency. The 
majority of mRNAs transcribed in the nucleus contain a 5’-terminal m7G[5’]ppp[5’]N 
cap (where m7G represents 7-methylguanylate, p represents phosphate group and N is 
any nucleotide), and a 3’poly(A) tail.  
 
1.2.1.1  Cap structure  
All eukaryotic mRNAs and small nuclear ribonucleic acids (snRNAs) that are 
transcribed in the nucleus are modified at their 5’ ends by binding a 7-methylguanosine 
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to the first transcribed nucleotide. 7-methylguanosine is linked by the 5’-5’-triphosphate 
bridge to the first nucleoside (Muthukrishnan et al., 1975) (Fig. 1.1.9). This 
modification is essential for efficient gene expression and viability for all living 
organisms from yeasts to humans, and is often referred to as “capping”, and the 
enzymes catalyzing that process are referred to as “capping enzymes”(Cowling, 2010). 
The guanosine is methylated on the 7 position directly by a methyl transferase to 
produce the 7-methylguanosine cap, abbreviated as m7G.  
 
 
 
Figure 1.1.9 Structures of the cap at the 5’ end of eukaryotic mRNA. The guanosine is 
methylated on position 7 by the methyl transferase and connected to the 5’ end of the mRNA 
via the unusual 5’-to-5’ triphosphate linkage. (From Molecular biology of the cell, 2002) 
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The 7-methylguanosine is required for translation of the majority of the mRNAs, with 
the exception of a group of mRNA translated by IRES (Spriggs et al., 2008). The 
presence of m7G is critical for mRNA recognition by eIF4F complex and the ribosome 
in the initiation stage of protein synthesis. The cap was also reported to stabilize mRNA 
against exonucleases, to promote transcription, splicing, polyadenylation, and nuclear 
export of RNA. Capping occurs in the cell nucleus and is a highly regulated process 
controlled by several cellular factors (reviewed by Cowling, 2010). 
Some viruses, including vaccinia virus, encode a polypeptide containing all three 
enzymes required for capping (triphosphatase, guanylyltransferase, methyltransferase) 
which allows the efficient capping and cap methylation of the viral mRNAs (Shuman, 
2002).  
 
1.2.1.2  Poly(A) Tail  
mRNA is modified at the 3’ end by addition of the poly(A) tail in a process called 
polyadenylation (Shatkin and Manley, 2000). The poly(A) tail consists of multiple 
adenosine phosphates which only have adenine bases, and ranges from 50 bases long in 
yeasts to 300 bases in higher eukaryotes (Pestova et al., 2007). However, most histone 
mRNAs and some viral RNAs (reovirus, rotavirus) do not contain this structure 
(Marzluff, 1992; Poncet et al., 1993). The poly(A) tail plays an important role in 
translation efficiency, promoting the recruitment of 43S preinitiation complexes to the 
mRNA (Tarun and Sachs, 1995), and in mRNA stability, protecting the mRNA from 
enzymatic degradation in the cytoplasm (Guhaniyogi and Brewer, 2001). Poly(A)- 
mediated translation initiation and the cap/poly(A) synergy require poly(A)-binding 
protein (PABP) (Tarun and Sachs, 1995) and its interaction with eIF4G (Tarun et al., 
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1997), leading to the formation of the “closed loop configuration” of the mRNA 
molecule which stabilizes the translation initiation complexes on the mRNA and 
facilitates the scanning process. Moreover, Munroe and Jacobson (1990) implicated the 
role of poly(A)-tail and PABP in enhancing the 60S ribosomal subunit recruitment.  
Both the cap and poly(A) tail are important but not essential for translation, as mRNAs 
lacking any of these structures are still translated only less efficiently (Gingras et al., 
1999). 
 
1.2.2 Mechanism of cap-dependent translation initiation 
Following transcription, post-transcriptional modification and nucleo-cytoplasmic 
export, eukaryotic mRNA is competent for translation. The ribosome does not bind to 
mRNA directly, but involves a series of protein:protein and protein:RNA interactions 
resulting in the formation of an initiation factor:ribosome complex (Morley, 2001). 
Generally, translation initiation of eukaryotic mRNA occurs by a scanning mechanism, 
which starts with the recognition of the 5’ terminus of the mRNA and the cap structure, 
and scanning of the ribosome towards the initiation codon (Kozak, 1989). 
To do this, the methionine initiation transfer-RNA (Met-tRNAi) and initiation factor 2 
(eIF2) associate with the 40S ribosomal subunit to form a 43S pre-initiation complex 
(Fig. 1.1.10). The complex then binds to mRNA through interactions with the 
translation initiation factor complex eIF4F, forming the 48S initiation complex and 
migrates to the AUG starting codon. The large (60S) ribosomal subunit joins the 48S 
initiation complex forming the final 80S initiation complex which begins translation of 
the coding sequences (Pain, 1996).  
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Figure 1.1.10 Mechanism of translation initiation. A ternary complex is formed by binding 
the initiation factor eIF2 together with GTP to the Met-tRNAf. A ternary complex associates 
with a 40S ribosomal subunit carrying eIF3 to form a 43S pre-initiation complex, which then 
binds to mRNA at the 5’ terminal m7GTP cap, and migrates along mRNA towards the AUG 
codon. The mRNA binding to this complex involves participation of the eIF4E, eIF4G, eIF4A, 
and the helicase-stimulatory factor eIF4B. In the final step, Met-tRNAf interacts with the AUG 
codon, facilitated by eIF2 and eIF4B to form the 48S initiation complex. Then the 60S 
ribosomal subunit binds to the mRNA together with eIF5 using the energy from the hydrolysis 
of two GTP molecules to two GDP molecules. The final 80S initiation complex is formed by 
joining the larger (60S) ribosomal subunit to the initiation complex.  (From Lopez-Lastra et al., 
2005) 
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1.2.3 eIF4F initiation complex 
A key step in translation initiation is association of the pre-initiation complex with an 
mRNA mediated by initiation factors eIF4. Within the eukaryotic translation initiation 
factors (eIFs), the eIF4F complex plays a critical role in regulating the translation of 
capped messages (Sonenberg and Hinnebusch, 2009). The eIF4F complex together with 
associated proteins are localized to the 5’ end of mRNA and unwind mRNA secondary 
structure, allowing interaction of the 43S initiation complex with the AUG start codon 
(Fig. 1.1.11). However, the exact mechanism leading to the assembly of eIF4F on the 
mRNA cap structure is still a matter of some debate (Morley, 1994; Pain, 1996; Gingras 
et al., 1999).  
eIF4F consists of three subunits: eIF4G, a large scaffolding protein on which the 
complex is built; eIF4E, a small cap-binding protein; and eIF4A, an RNA helicase that 
facilitates ribosomal scanning. Each of those subunits plays a unique and crucial role in 
initiating cap-dependent translation. Regulation of eIF4G and eIF4E activities 
significantly affects translational rates, therefore it has been a focus of many research 
groups recently.  
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Figure 1.1.11 Mechanism of 48S initiation complex formation. In this schematic closed-loop 
model of translation initiation the eIF4F complex interacts with both the 5’end of mRNA and 
the poly(A) tail (through PABP), and recruits the 40S ribosomal subunit through binding with 
eIF3. (From Lopez-Lastra et al,. 2005) 
 
1.2.3.1  eIF4G  
There are two isoforms of eIF4G in mammals: eIF4GI and eIF4GII, which are 46% 
identical, have molecular masses of 171 kDa and 176 kDa, respectively, and exhibit 
similar biochemical activities (Gingras et al., 1999). Human eIF4G was initially isolated 
as part of a large protein complex, identified later as eIF4F, that could restore protein 
synthesis in cell extracts derived from poliovirus-infected HeLa cells (Prevot et al., 
2003). eIF4G interacts with many different cellular and viral proteins and plays an 
important role in gathering initiation factors to begin the effective process of protein 
synthesis.  
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1.2.3.1.1 eIF4G structure 
eIF4G is a large scaffold protein on which the eIF4F complex is built. It possesses 
binding sites for the remaining eIF4F components: eIF4E and eIF4A, and also other key 
translation initiation factors such as eIF3 complex and poly(A)-binding protein (PABP) 
(Fig. 1.1.12). Furthermore, binding sites for MAP-kinase-interacting kinase-1 and -2 
(MNK1/2) were identified on the C-terminal region of eIF4GI and eIF4GII (Pyronnet et 
al., 1999). It has been shown that complexes between these proteins exhibit enhanced 
mRNA cap-binding and RNA helicase activities.  
Three domains of eIF4G have been identified that are comparable in size: the N-
terminal fragment, characterized by its cleavage by picornaviral proteases; the middle 
domain that is critical for assembly of the translation machinery; and the C-terminal part 
which appears to function as a translation modulator (Prevot et al., 2003). 
 
 
Figure 1.1.12 Schematic illustration of eIF4G binding sites for PABP1, eIF4E, eIF4A, eIF3 and 
MNK1. Amino acid location of each binding site is indicated in brackets. (Data of Hinton et al., 
2007) 
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1.2.3.1.1.1 eIF4G–PABP interaction 
The eIF4G-PABP interaction enhances the formation of 48S and 80S complexes and 
ribosome recycling through mRNA circularization, thus is important for the 
contribution of the poly(A)-tail in translation initiation at the 5’ end (Tarun and Sachs, 
1995) (see paragraph 1.2.1.2). Moreover, Kahvejian et al. (2005) showed that PABP 
enhances translation and stimulates ribosome recruitment to the mRNA, both 40S and 
60S subunits, and that an interaction between PABP and eIF4G is essential for this 
enhancement.  
 
1.2.3.1.1.2 eIF4G – eIF4E interaction 
The best characterized binding site on eIF4G is that for eIF4E, which is placed within 
the N-terminal half of the gene (Fig. 1.1.12) at the position 572-578 in human eIF4GI 
(Gingras et al., 1999). This eIF4G fragment binds to the dorsal, convex surface of 
eIF4E behind the cap-binding slot by interacting with a number of evolutionarily 
conserved residues through hydrogen bonds, salt bridges, and van der Waals contacts 
(Marcotrigiano et al., 1999). The role of eIF4E is to recognize and associate with the 7-
Methyl-Gppp cap, and association with eIF4G stimulates this binding (Haghighat and 
Sonenberg, 1997). Interaction between eIF4E and eIF4G is regulated by eIF4E-binding 
proteins (4E-BPs), which block the eIF4G-binding site on eIF4E (Ptushkina et al., 
1999). Furthermore, it has been suggested that PABP-binding to eIF4G may stimulate 
eIF4E-cap interaction (von Der Haar et al., 2000). 
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1.2.3.1.1.3 eIF4A, eIF3 and Mnk1/2- binding sites 
The carboxy-terminal part of the eIF4G molecule contains eIF4A- and eIF3- and 
MNK1/2- binding sites. There are two independent binding sites for eIF4A, one is 
located in the middle portion of eIF4G, which also possesses the RNA- and eIF3- 
binding sites (Lamphear et al., 1995), and the other is located in the COOH-terminal 
part of eIF4G, which also binds the eIF4E kinases Mnk1 and Mnk 2 (Pyronnet et al., 
1999). Although there are two binding sites, eIF4G only binds one eIF4A molecule 
(Rhoads, 2009). eIF4A is a 46-kDa polypeptide that exhibits RNA-dependent ATPase 
and RNA helicase activities (Gingras et al., 1999), which is thought to unwind 
secondary structure in the 5′-untranslated region of the mRNA. The helicase activity of 
eIF4A is noticeably stimulated by two RNA-binding initiation factors, eIF4B and eIF4H 
(Rozen et al., 1990). The eIF3-eIF4G1 interaction is thought to form a link between the 
40S subunit and mRNA. Hinton et al. (2007) demonstrated that eIF4G lacking either the 
eIF4A-binding sites or eIF3-binding site was still able to interact with eIF4E, but 
resulted in significant decrease of translational rates. The eIF4G-Mnk1/2 interaction is 
important for eIF4E phosphorylation (see section 1.2.3.2.2.3). 
 
1.2.3.2  eIF4E  
The smallest subunit of the eIF4F complex was discovered in 1978 as a 24 kDa cap 
binding protein termed cap binding protein I (CBPI), later renamed eIF4E, and was the 
first eIF4F component identified; the other components were isolated during eIF4E 
purification by affinity chromatography (Sonenberg et al., 1978; Tahara et al., 1981; 
McKendrick et al., 1999). eIF4E exists in both free form and as a part of an eIF4F 
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complex, and was shown to form nuclear bodies in addition to its cytoplasmic 
localization (Rousseau et al., 1996).  
 
1.2.3.2.1 Structure of eIF4E 
The three-dimensional structure of eIF4E illustrates a cupped hand-shaped molecule, 
which consists of one α/β domain. The secondary structure includes three long and one 
short α helices and an 8-stranded, antiparallel β sheet (Marcotrigiano et al., 1997). The 
cap recognition occurs via interaction between two highly conserved tryptophan 
residues on the concave surface, whereas the majority of the interacting partners, such 
as eIF4G and eIF4E-binding proteins (4E-BPs), bind via the convex face of eIF4E 
involving tryptophan 73 (Goodfellow and Roberts, 2008).  
Interaction between eIF4E and eIF4G is a key step in cap-dependent translation 
initiation. This interaction enables eIF4G to bring eIF4F complex and ribosome to 
mRNA and start protein synthesis. Both eIF4G and 4E-BP1, the translational repressor, 
compete with each other for the binding site on eIF4E. Moreover, association of one of 
those proteins with eIF4E results in conformational changes in eIF4E, and leads to 
enhanced association of eIF4E with the cap (Volpon et al., 2006). The nature of the 
structural changes during cap-binding has not been fully understood, although 
evaluations of CD difference spectra noticed with human cap-bound and apo-eIF4E 
(free eIF4E) suggested that a region of approximately 40 amino acids undergoes large-
scale structural rearrangements (Cohen et al., 2001).   
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1.2.3.2.2 Function of eIF4E 
eIF4E was discovered as a protein promoting translation initiation, and the majority of 
the study on its structure, function, and regulation has been evaluated with this in mind. 
eIF4E is an essential factor for cap-dependent translation that mediates 5’ 7-Methyl-
Gppp cap recognition by the eIF4F complex and recruitment of mRNA to the ribosome, 
which results in formation of the 43S pre-initiation complex followed by scanning of 
the mRNA. In addition, eIF4E is thought to be the first factor interacting with the 
mRNA to initiate translation. It is well known that eIF4E stimulates translation of 
capped mRNA, although mRNAs differ in their dependence on eIF4E (reviewed by 
Goodfellow and Roberts, 2008; Rhoads, 2009). Moreover, Svitkin et al. (1996) 
demonstrated that depletion of eIF4E (together with associated proteins) from the cell 
extracts significantly reduced translation of capped mRNA.  
Apart from its function in cap recognition, eIF4E plays also a crucial role in nuclear 
transport. The majority (up to 68%) of the total cellular eIF4E is localized in the 
nucleus, in distinct sites termed nuclear bodies, where it is involved in the export of the 
mRNAs (Iborra et al., 2001; Strudwick and Borden, 2002). eIF4E enters the nucleus by 
associating with the eIF4E-binding protein known as 4E-transporter or 4E-T (Dostie et 
al., 2000). Once in the nucleus, eIF4E interacts with several proteins which regulate 
cap-binding and mRNA export. One of such proteins is PML (promyelocytic leukaemia 
protein) which associates with eIF4E via its RING domain. Nuclear eIF4E was found to 
co-localize with PML in complexes termed PML nuclear bodies (Lai and Borden, 
2000). Changes in those complexes appear to be a result of stress such as viral infection 
(Regadand Chelbi-Alix, 2001) hence it is thought that PML regulates mRNA transport 
mediated by eIF4E in response to stress (Culjkovic et al., 2007). 
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Surprisingly, overexpression of eIF4E does not cause an overall increase in translational 
rates, but leads to deregulation of cellular growth and induces cell transformation 
(Mader and Sonenberg, 1995; de Benedetti and Harris, 1999). Conversely, increased 
expression of translational repressor 4E-BP1 can reverse the transformed phenotype and 
induce apoptotic cell death (Li et al., 2002; Proud, 2005). High levels of eIF4E have 
been detected in a number of cancers and malignant transformation (de Benedetti and 
Graff, 2004), however, the role of eIF4E in tumor progression still needs to be 
determined. It was suggested that overexpressed eIF4E observed in malignant 
transformation promotes the synthesis of growth stimulatory and antiapoptotic proteins 
(Clemens, 2004; Mamane et al., 2004). Another hypothesis says that overexpression of 
eIF4E may promote the export and selective translation of some mRNAs encoding 
proteins involved in cell proliferation and tumorigenesis (Topisirovic et al., 2003; 
Goodfellow and Roberts, 2008).  
 
1.2.3.2.3 eIF4E-Binding Proteins 
eIF4E was originally discovered as a single polypeptide bound to the 7-Methyl-Gppp 
cap, but since it was found in complexes with eIF4G it was renamed as a subunit of 
eIF4F. However, the number of eIF4E-binding proteins has grown recently and many of 
the newly discovered roles of eIF4E are mediated by its interaction with those new 
binding partners.  
The specific and high affinity interaction between eIF4E and eIF4G leads to recruitment 
of eIF4F complex to mRNA, which allows the activation of eIF4A-driven unwinding 
machinery. The association of eIF4G with cap-bound protein enables initiation and 
stimulates cap-dependent translation. In contrast, binding of 4E-BP1, the translational 
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repressor, to eIF4E disrupts eIF4F formation and thereby inhibits cap-dependent 
translation, whereas cap-independent translation may actually be enhanced by the 4E-
BPs (Svitkin et al., 2005). 
The 4E-BPs are small (approximately 10-12 kDa), acidic, heat-stable proteins, 
discovered in 1994 by using Far-Western hybridization technique (Pause et al., 1994), 
which enabled the isolation of cDNAs encoding two small (~12kDa) proteins 
associating with eIF4E and sharing 56% identity. These proteins, named 4E-BP1 and 
4E-BP2 were shown to inhibit cap-dependent translation both in vivo and in vitro. In 
addition, Pause et al. (1994) demonstrated that binding of 4E-BPs to eIF4E does not 
alter the affinity of eIF4E for the cap structure. Instead, it prevents the association 
between eIF4E and eIF4G and thus the assembly of eIF4F complexes (Haghighat et al., 
1995). Both eIF4G and 4E-BPs possess a small amino acid motif (YXXXXLφ, where X 
is any amino acid, and φ is an aliphatic residue Leu, Met or Phe) which interacts with 
eIF4E (Mader et al., 1995). Deletion or mutation of this sequence was shown to abolish 
interaction with eIF4E. Four years after the discovery of 4E-BP1 and 4E-BP2 proteins, 
Paulin et al. (1998) reported a new member of the 4E-BP family termed 4E-BP3 which 
shares approximately 58% identity with 4E-BP1/2. However, 4E-BP1 is the most 
widely studied, and is thought to be a prototype of the 4E-BPs family. 
Another eIF4E-binding protein that disrupts eIF4F is Maskin, which is thought to 
repress translation of cyclin B1 and c-Mos mRNA in Xenopus oocytes through the 
interaction with the RNA-binding protein CPEB [CPE-binding protein] and eIF4E (de 
Moor and Richter, 1999; Cao and Richter, 2002; Pascreau et al., 2005). CPEB interacts 
with the cytoplasmic polyadenylation element (CPE), a small sequence in the 3' UTR of 
mRNAs, and mediates cytoplasmic polyadenylation. Despite rather weak association of 
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Maskin with eIF4E, Maskin does disrupt the eIF4G-eIF4E interaction. Therefore, the 
CPEB–Maskin–eIF4E complex inhibits the translation of CPE-containing mRNAs 
specifically (Stebbins-Boaz et al., 1999). As soon as frog oocytes are induced to 
complete meiosis, CPEB stimulates growth of poly(A) tail. The newly elongated 
poly(A) tail is then bound through PABP, which in turn associates with eIF4G. PABP-
bound eIF4G displaces Maskin from eIF4E, thereby inducing translation (Cao and 
Richter, 2002).  
Selected proteins interacting with eIF4E are also involved in embryogenesis. In 
Drosophila melanogaster the product of the fs (2)cup gene (Cup), a nucleocytoplasmic 
shuttling protein, was found to directly associate with eIF4E which promotes retention 
of the Cup protein in the cytoplasm (Zappavigna et al., 2004). Cup is required for the 
proper accumulation and localization of eIF4E within the cytoplasm of developing 
oocytes. It was demonstrated that the Cup–eIF4E complex plays a crucial role in ovary-
specific developmental programs. Furthermore, the role of eIF4E-binding proteins in 
mammalian neurogenesis has recently been revealed. Jung et al. (2006) demonstrated 
that neuroguidin (Ngd) binds to eIF4E and inhibits translation of CPE-containing 
mRNAs. Ngd occurs in axons and dendrites of the mammalian nervous system and 
contains three eIF4E-binding motifs.  
Another eIF4E-binding protein discovered ten years ago is eIF4E transporter (4E-T), 
which was shown to mediate the nuclear import of eIF4E via the importin αβ pathway 
(Dostie et al., 2000). 4E-T is thought to function to inhibit translation and promote 
recruitment of P-body through a third unrelated pathway specific for mammalian cells. 
4E-T binds to eIF4E through the same site on eIF4E that associates with eIF4G and 4E-
BP1 (Dostie et al., 2000). Furthermore, overexpression of 4E-T was shown to inhibit 
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cap-dependent, but not cap-independent translation (Ferraiuolo et al., 2005), which may 
involve at least two mechanisms. First, binding of 4E-T prevents eIF4E from binding to 
eIF4G, which would negatively affect translation initiation (Dostie et al., 2000). 
Second, interaction between eIF4E and 4E-T results in accumulation of eIF4E in P-
bodies (Farraiuolo et al., 2005), separating the associated mRNA from the translation 
apparatus. Noteworthy, depletion of 4E-T by RNA interference results in loss of P-
bodies and stabilization of at least some RNAs (Farraiuolo et al., 2005).  
In the case of viruses, VPg proteins of plant potyviruses and human caliciviruses also 
interact with eIF4E, which reduces eIF4E affinity for the cap and inhibits host 
translation (Leonard et al., 2000; Goodfellow et al., 2005).  
 
1.2.3.2.4 eIF4E regulation 
Since eIF4E plays an important role in cap recognition and association of the initiation 
complex with mRNA, it is a key target for the regulation of protein synthesis. eIF4E 
activity is regulated by at least three different mechanisms: (1) modulation of its 
abundance, (2) phosphorylation, and (3) binding of translational repressor proteins 
(Gingras et al., 1999). 
 
1.2.3.2.4.1 Regulation of eIF4E abundance and turnover  
The mechanisms regulating eIF4E gene expression are not completely understood, but 
transcriptional activation appears to be an important part of this regulation. Expression 
of eIF4E has been shown to be correlated with c-Myc expression during the cell cycle 
(Rosenwald et al., 1993). In addition, in cells overexpressing c-Myc an increased level 
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of eIF4E mRNA has been observed, and transcription of the eIF4E gene was responsive 
to activation of a Myc-estrogen fusion protein. Furthermore, two functional Myc-
binding sites (E boxes) have been characterized in the eIF4E promoter, and both of 
them are required for promoter activity (Jones et al., 1996). 
The c-Myc protein is a member of the nuclear oncoproteins and functions as a 
transcriptional factor that activates a great number of genes. Moreover, its function in 
regulating cell proliferation and growth has been described (Adhikary and Eilers, 2005). 
Since eIF4E itself is a key regulator of cell growth and proliferation, it appears to be an 
important downstream target of c-Myc. Recent findings suggest that the role of Myc 
during cell growth and proliferation is related to an increase in eIF4F activity. C-Myc 
mRNA is complex and effectively translated during eIF4F stimulation, forming a 
feedforward relationship and providing a possible molecular mechanism of cell 
transformation by Myc (Lin et al., 2009). Therefore, developing therapeutics that inhibit 
eIF4F and/or Myc could be a potential treatment for a wide range of human cancers. 
 
1.2.3.2.4.2 Regulation by phosphorylation 
eIF4E is phosphorylated on Ser209 in response to extracellular stimuli such as growth 
factors, hormones and mitogens (Joshi et al., 1995). Phosphorylation of eIF4E is 
regulated by extracellular signal-regulated kinases (ERKs) and mitogen-activated 
protein kinases (p38/MAPK). The ERK signaling cascade is stimulated by growth 
factors, hormones, cytokines or mitogen treatment. A putative role for the ERK pathway 
in eIF4E phosphorylation was suggested after demonstrating an increased 
phosphorylation of eIF4E in ras- or src-transformed cells (Frederickson et al., 1991; 
Rinker-Schaeffer et al., 1992). However, Flynn and Proud (1996) demonstrated that 
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ERK cannot phosphorylate eIF4E in vitro, which suggested indirect role of ERK in 
eIF4E phosphorylation. The p38/MAPK pathway is activated by various types of 
cellular stress such as heat shock and exposure to arsenite or anisomycin. Stimulation of 
this pathway was shown to enhance eIF4E phosphorylation (Morley and McKendrick, 
1997; Wang et al., 1998). It was later discovered that both ERK and p38/MAPK kinases 
regulate the eIF4E phosphorylation indirectly through phosphorylation of Mnks 
(Mnk1/2) – the kinases interacting with the scaffold protein eIF4G and directly 
phosphorylating eIF4E on Ser209 (Waskiewicz et al., 1997; Wang et al., 1998; 
Pyronnet et al., 1999). Free Mnk1/2 does not phosphorylate eIF4E efficiently, but does 
so through interaction with eIF4G. The C-terminal region of eIF4G contains a binding 
site for both Mnk1 and Mnk2, whereas no such a binding site was determined on eIF4E 
(Pyronnet et al., 1999), which suggests that eIF4E is regulated by phosphorylation only 
as a part of eIF4F complex, by eIF4G placing Mnk1/2 and eIF4E in proximity to one 
another.  
The biological significance of eIF4E phosphorylation is not completely understood. 
Phosphorylation of eIF4E has been reported to enhance its binding affinity for the cap 
and mRNA (Minich et al., 1994), which may lead to the increased translational rates 
observed after eIF4E phosphorylation (Bonneau and Sonenberg, 1987; Morley et al., 
1993; Dyer et al., 2003), and formation of more stable eIF4F complex (Bu et al., 1993). 
The most recent studies demonstrate that eIF4E phosphorylation decreases its affinity 
for the cap (Scheper et al., 2004). However, while some reports show a strong 
correlation between eIF4E phosphorylation and translational stimulation, other studies 
illustrate no effect of eIF4E phosphorylation on translation (McKendrick et al., 2001; 
Morley and Naegele, 2002), or even its negative effect on protein synthesis (Knauf et 
al., 2001).  
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Overall, it is not clear how eIF4E phosphorylation controls the function of eIF4E. 
Although phosphorylation of eIF4E is not critical for high levels of translation, the most 
recent studies demonstrate that it does control cell transformation (Furic et al., 2010) 
and viral mRNA translation (Walsh et al., 2008). 
 
1.2.3.2.4.3 Regulation by translational inhibitors 
The third mechanism regulating eIF4E is through its interaction with a family of 
inhibitory binding proteins, 4E-BPs. 4E-BPs act in their hypophosphorylated form as 
competitive inhibitors of eIF4G binding to eIF4E (Gingras et al., 2004; Proud, 2004). 
Interaction of 4E-BP1 with eIF4E inhibits cap-dependent translation both in vivo and in 
vitro. In contrast, activation of the PI3K/Akt/mTOR pathway causes phosphorylation of 
the 4E-BPs at multiple sites, decreases its affinity for eIF4E and thus releases the cap-
binding protein which is then incorporated into the eIF4F complex by interaction with 
N-terminal region of eIF4G (see Fig. 1.2.1). Interaction between 4E-BP1 and eIF4E 
does not appear to alter the affinity of eIF4E for the cap since eIF4E-4E-BP1 complexes 
were found to associate with the cap (Pause et al., 1994).  
The phosphorylation of 4E-BP1 is regulated by a wide range of extracellular stimuli 
including growth factors, hormones, cytokines, mitogens, and G-protein coupled 
receptor ligands (Gingras et al., 1999). During early adenovirus and VacV infection 4E-
BP1 also becomes hyperphosphorylated, which results in an increase of translation rates 
(Gingras and Sonenberg, 1997; Walsh et al., 2008). An increase in 4E-BP1 
phosphorylation is correlated with a decrease of binding affinity to eIF4E. 
Phosphorylation of 4E-BP1 occurs at multiple sites and is regulated by mTORC1 to 
control the release of eIF4E which then interacts with eIF4G promoting eIF4F 
 42 
formation (Gingras et al., 1999). Furthermore, recent studies have shown that 
phosphorylation of 4E-BP1 stimulates its ubiquitination, which leads to protein 
degradation (Elia et al., 2008). In contrast, physiological stresses that inhibit translation 
and cause dephosphorylation of 4E-BP1, such as DNA damage, amino-acid starvation 
or the activation of p53 might actually stabilize 4E-BP1. Tilleray et al. (2006) reported 
that induction of p53 leads to accumulation of hypophosphorylated 4E-BP1, and a 
similar effect has been observed in cells treated with the proapoptotic cytokine TRAIL 
(Elia et al., 2008). 
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1.2.4 Signaling pathways regulating protein synthesis 
Translation rates are chiefly regulated at the initiation stage, and precisely controlled in 
response to extracellular stimuli, environmental stress, hormone/growth factor signals, 
and availability of nutrients and amino acids (Raught and Gingras, 2007). Since protein 
synthesis consumes a high proportion of cellular metabolic energy, the status of energy 
of the cell can also modulate translation factors. The aforementioned agents regulate the 
translational apparatus via phosphorylation of translation factors and related proteins, 
which may affect the basic activity of translation factors or their ability to bind other 
components (other factors, ribosome, RNA). These changes are mostly controlled by 
signaling pathways regulating the activities of kinases and effector proteins. These 
pathways include: 
 
I. The phosphatidylinositide 3-kinase (PI3K) pathway 
II. The mammalian target of rapamycin (mTOR) pathway 
III. The ERK and p38 MAP kinase pathways (Wang and Proud, 2007) 
 
In this study, we are interested mostly in the first two pathways, the PI 3-kinase (PI3K) 
and the mTOR pathway. 
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1.2.4.1 The PI 3K/Akt/mTORC1 pathway 
The PI3K pathway plays a key role in the transduction of signals from extracellular 
stimuli such as hormones, growth factors, mitogens, and cytokines to regulate cell 
growth, proliferation and survival. The PI3Ks are lipid kinases generating second 
messengers by phosphorylation of the phosphatidyl group at the 3’ position of the 
inositol ring to form phosphatidylinositol phosphate (PIP), phosphatidylinositol 
biphosphate (PIP2) or phosphatidylinositol triphosphate (PIP3) (Fig. 1.2.1) (Vivanco 
and Sawyers, 2002; Engelman et al., 2006). Phosphatidylinositol (PI) is a component of 
eukaryotic cell membranes and is unique among phospholipids because it can be 
phosphorylated at multiple free hydroxyls. A number of phosphorylated derivatives of 
PI, termed phosphoinositides, have been identified in eukaryotic cells from yeast to 
mammals, and are thought to be involved in regulation of many cellular processes such 
as proliferation, cytoskeletal organization, survival, glucose transport, and platelet 
function. The enzymes that phosphorylate PI and its derivatives are termed 
phosphoinositide kinases. Although PI represents only a small group among total 
cellular phospholipids, it plays a significant role in signal transduction as a precursor of 
several second-messenger molecules (Fruman et al., 1998).  
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Figure 1.2.1 Chemical structures of phosphatidylinositol (A), phosphatidylinositol-3,4-
biphosphate (PIP2) (B), and phosphatidylinositol-3,4,5-triphospahte (PIP3) (C). 
Phosphatidylinositol (PI) is a glycerophospholipid that contains a glycerol backbone, two non-
polar fatty acid tails, and a phosphate group substituted with an inositol polar head group. The 
inositol can be phosphorylated to form phosphatidylinositol phosphate (PIP), 
phosphatidylinositol biphosphate (PIP2) or phosphatidylinositol triphosphate (PIP3). 
(www.medlibrary.org/medwiki/Phosphatidylinositol) 
 
PI3Ks consist of three classes of kinases based on their primary structure and substrate 
specificity. Class I PI3Ks can be divided into class IA and class IB, depending on the 
receptors to which they link. Class IA consists of the catalytic subunit (p110, 
comprising three isoforms α, β, δ) and an adaptor/regulatory subunit p85 containing two 
SH2 domains, which are essential for their activation by tyrosine kinase receptors. Class 
IB PI3Kγ has a p101 subunit, which is required for maximal Gβγ-stimulated formation 
of PIP3 (Stephens et al., 1997; Maier et al., 1999). Catalytic subunits form heterodimers 
with various regulatory subunits and can use PI 3,4-bis-phosphate (PIP2) as a substrate 
to generate the second messenger PI 3,4,5-tri-phosphate PIP3.  
 A C B 
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Glycerol  
Inositol ring 
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Class II PI3Ks are large (170-210 kDa) proteins that share 45-50% similarity with class 
I PI3Ks (Fruman et al., 1998). Class II consists of three subunits named PI3KC2α, 
PI3KC2β and PI3KC2γ, which contain a C-terminal region with homology to C2 
domains1. These enzymes can be activated by chemokines, cytokines, insulin, epidermal 
growth factor (EGF) or platelet-derived growth factor (PDGF) (Turner et al., 1998; 
Brown et al., 1999; Arcaro et al., 2000; Ktori et al., 2003), and preferably 
phosphorylate PI and PI-4-P. The mechanism regulating the activity of class II PI3Ks 
and their function have not been fully explored, although it was reported that PI3KC2β 
might be involved in lysophosphatidic acid-induced cell migration of cancer cells 
(Maffucci et al., 2005). Class III PI3Ks phosphorylate only PI and consist of the Vps34 
enzyme. These proteins may play a role in the regulation of mTORC1 by amino acids 
(Nobukuni et al., 2005). 
The PI3K pathway starts with the PI 3-kinase. Activation of PI3K leads to activation of 
Akt (PKB) through its phosphorylation (at T308 and S473) which, in turn, 
phosphorylates a number of substrates including TSC-2, an upstream regulator of 
mTORC1 (Wand and Proud, 2007) (Fig. 1.2.2). Akt phosphorylation is mediated by 
mammalian target of rapamycin complex 2 (mTORC2) and phosphoinositide-dependent 
protein kinase 1 (PDK1) acting as downstream effectors for PI3K pathway (Alessi et 
al., 1996; Sarbassov et al., 2005). Akt consists of three isoforms (α, β, γ) composed of 
N-terminal central catalytic domain and C-terminal hydrophobic domain. Both Akt and 
PDK1 are recruited to the plasma membrane through interactions with PIP3, where 
PDK1 activates Akt by phosphorylating threonine 308. Activated Akt is an essential 
mediator for the regulation of proliferation and growth by PI3K. 
                                                 
1
 A C2 domain (Protein kinase C homology domain 2) is a Ca2+-binding motif of approximately 130 
residues in length. C2 domain is involved in targeting proteins to the cell membrane, and can bind a 
variety of different ligands and substrates including phospholipids, inositol phosphatases, and intracellular 
proteins (Nalefski and Falke, 1996). 
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Figure 1.2.2 The PI3K/Akt/mTOR pathway and its pharmacological inhibitors. PI3K is 
activated through cytokines, chemokines, insulin or growth factors, and then phosphorylates its 
downstream substrates. PDK1 and Akt are recruited to the cell membrane where PDK1 
phosphorylates Akt on Thr308 and Ser473. Akt then can activate mTORC1 directly or 
indirectly by phosphorylation and inactivation of TSC2, which normally inhibits mTORC1 
when dephosphorylated. mTORC1 activates p70S6 kinase-1, which directly phosphorylates 
ribosomal protein S6 and leads to increased protein translation. mTORC1 also phosphorylates 
4E-BP1, causing its dissociation from eIF4E, and freeing eIF4E to participate in formation of 
the translation initiation complex by binding to eIF4G, which is also phosphorylated by 
mTORC1. mTORC1 indirectly (through p70S6K) stimulates phosphorylation of mTORC2, 
which then inhibits Akt.  T-bars represent suppression. Inhibitors marked in red. 
 
Akt phosphorylates a number of factors such as proapoptotic protein Bad, caspase-9, 
glycogen synthase kinase 3β, and FKHR, which leads to the suppression of such 
processes as cell growth, survival, and proliferation (Datta et al., 1997; Cardone et al., 
1998; Pap and Cooper, 1998), and also regulates the activity of transcription factors 
stimulating the expression of several cell death genes. For instance, phosphorylation of 
Torin1 
Rapamycin 
   Torin1 
LY294002 
Wortmannin 
PI3K 
AKT 
mTORC1 
PDK1 
mTORC2 
TSC2 
P70S6K 
S6 
4E-BP1 
eIF-4E eIF-4G 
 48 
Bad causes its dissociation from Bcl-Xl and its sequestration by 14-3-3 proteins, thus 
preventing it from translocation to the mitochondria, an event necessary for its 
proapoptotic function (Kennedy et al., 1999; Yang et al., 2001). As part of the 
proapoptotic role, activated death receptors have been shown to attenuate survival 
signaling events, thus potentiating cell death (Yousefi et al., 2003). 
Furthermore, PI3K is thought to play a major role in cancer pathogenesis. The most 
important proteins involved in proliferation and tumorigenesis are p110α and its 
regulatory subunit p85 belonging to class IA PI3Ks. The activity of PI3K is 
counteracted by the phosphatase PTEN (phosphatase and tensin homolog deleted on 
chromosome 10), which acts as a tumor suppressor. PTEN and p85 were shown to be 
mutationally inactivated in a wide range of malignant human cancers, but mostly in 
prostate and endometrial cancers, melanomas, and glioblastomas, thereby constitutively 
activating PI3K (Vivanco and Sawyers, 2002; Bader et al., 2005). Hyperactivation of 
Akt isoforms α, β, and γ by PIP3 or other kinases, such as PDK1 or PDK2, has been 
reported in many human cancers. Noteworthy, mutated PI3 kinases are thought to be 
ideal drug targets, thus specific inhibitors of these mutants could have a significant 
therapeutic effect (reviewed by Bader et al., 2005).  
Precise regulation of the PI3K/Akt pathway is essential to coordinate the balance 
between protein synthesis and protein degradation in response to nutrient availability.  
 
1.2.4.1.1 Inhibitors of the PI3 kinase  
The PI 3-kinase has two widely used specific inhibitors, LY294002 and wortmannin, 
which have been crucial in establishing the roles of PI3K in cellular processes. 
LY294002 and wortmannin are structurally unrelated and they both target the p110 
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catalytic subunit of PI3K effectively blocking this kinase. Unfortunately, the poor 
solubility and high toxicity have limited their clinical use. However, LY294002 and 
wortmannin provide a powerful preclinical tool to study the cellular consequences of 
PI3K inhibition. 
LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-I-benzopyran-4-one) is a synthetic 
compound that was derived from the naturally occurring bioflavonoid quercetin (Vlahos 
et al., 1994). LY294002 competitively inhibits the ATP-binding site of PI3K, but does 
not inhibit several other ATP-requiring enzymes. This drug has been used in studies of 
cardiovascular, neuronal, immune, and diabetes-related cell function for more than a 
decade, and it is more widely used in cell biology than wortmannin due to its higher 
stability in solution. An IC502 for this inhibitor of approximately 1µM has been 
measured for a class IA PI3K, and 19 µM for class II (Vlahos et al., 1994; Walker et al., 
2000). As such, LY294002 is widely used in many studies, including our own, over 
ranges of 20-50 µM to ensure complete inhibition of both Class I and Class II PI3Ks. 
   
Figure 1.2.3 Chemical structure of LY294002. (www.medlibrary.org/medwiki/LY294002) 
 
Wortmannin is a natural small molecule product isolated in 1957 from the fungus 
Penicillium wortmanii, and reacts covalently with a residue in the active site of PI3K 
inactivating it irreversibly (Powis et al., 1994; Walker et al., 2000). Wortmannin was 
                                                 
2
 IC50 – half maximal inhibitory concentration 
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shown to act as a noncompetitive PI3K inhibitor with respect to ATP, and has low IC50 
lying between 1-10 nM for class I PI3K which makes it more potent inhibitor than 
LY294002. In contrast to LY294002, wortmannin was shown to cause large 
conformational rearrangement in the active site of PI3K (Walker et al., 2000).  
 
 
Figure 1.2.4 Chemical structure of wortmannin (www.medlibrary.org/medwiki/wortmannin) 
Wortmannin inhibits all PI3K isoforms and has shown antitumor activity against a variety of 
human cancers (Schultz et al., 1995; Lemke et al., 1999; Teranishi et al., 2009) but due to the 
fact that it is a biologically unstable molecule, wortmannin seems not to be a good drug 
candidate. However, the use of wortmannin analogs such as PX-866 has recently been reported 
to have a potential therapeutic role in human glioblastoma (Koul et al., 2010). Because of its 
instability, wortmannin is often used at a very broad range of concentrations, often depending 
upon how long the treatment time of the experiment is. 
 
1.2.4.2 mTOR  
Another downstream target of PI3K/Akt is mammalian target of rapamycin (mTOR), a 
kinase that plays a central role in the regulation of cell growth and size, proliferation, 
nutrient responses, survival, and protein synthesis (Hay and Sonenberg, 2004). mTOR is 
evolutionarily conserved serine/threonine kinase, which in humans is encoded by the 
FRAP1 gene. mTOR was discovered as the molecular target of rapamycin, an 
antifungal agent used clinically as an immunosuppressant and more recently as an 
anticancer drug (Heitman et al., 1991; Kunz et al., 1993; Fasolo and Sessa, 2008). 
Rapamycin binds to a small, ubiquitously expressed protein FKBP12 (FK506-Binding 
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Protein, molecular mass of 12 kDa), which then binds and inhibits mTOR in a poorly 
understood mechanism (Gingras et al., 2007). Recent research indicates that 
deregulation of the mTOR pathway occurs in a majority of human cancers (Chiang and 
Abraham, 2004; Guertin and Sabatini, 2007; Engelman, 2009), suggesting that 
rapamycin analogs may be potent therapeutic agents.  
A single TOR molecule is a high molecular-weight protein containing several distinct 
and conserved structural domains. The N-terminus possesses 20 tandem HEAT 
(Huntington, EF3, A subunit of PP2A, TOR1) repeats that are involved in protein-
protein interactions (Andrade and Bork, 1995). The C-terminal half of mTOR contains a 
kinase domain that shares sequence similarity with the catalytic domain of PI3K, and 
also the FATC (FRAP, ATM, TRAP, C-terminal) domain that is essential for mTOR 
activity (Peterson et al., 2000; Takahashi et al., 2000). mTOR interacts with several 
different proteins including raptor and rictor, and forms two different types of 
complexes: mTORC1 and mTORC2. 
The downstream signaling of mTOR requires the associated factors: regulatory 
associated protein of mTOR (raptor), and G protein β-subunit-like protein (GβL) (Hara 
et al., 2002; Kim et al., 2003). These three components constitute the mTORC1 
complex, which interacts with downstream substrates through raptor. Raptor associates 
with both N- and C-terminal domains of mTOR, while GβL binds specifically to the 
carboxyl end of this factor. Noteworthy, treatment with rapamycin disrupts only 
association with raptor, while it does not affect GβL binding to mTOR (Kim et al., 
2003). In mammals, mTORC1 regulates the activity of several translation factors 
(eIF4G, eIF4B), translation inhibitors (4E-BP), and ribosomal S6 kinases. mTORC1 
regulates the availability of initiation factor eIF4E through the phosphorylation of the 
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4E-binding protein (4E-BP) leading to an increase in protein synthesis. mTORC1 also 
activates, either directly or indirectly, p70 S6 kinase (p70S6K), which in turn 
phosphorylates ribosomal protein S6 (Gingras et al., 2007). 
In the case of mTORC2, while it also contains GβL, raptor is replaced by a large 
adaptor protein named rapamycin-independent companion of mTOR (rictor) 
(Sarbassov et al., 2004). mTORC2, in contrast to mTORC1, is resistant to rapamycin 
treatment and does not activate either S6K1 or 4E-BP1. Instead, it was shown to 
phosphorylate and activate PKB/Akt on Ser473 by a mechanism similar to activation of 
S6K1 by mTORC1 (Fig. 1.2.1) (Sarbassov et al., 2005).  
Signaling towards mTORC1 can be activated by various agents including insulin, 
growth factors, and amino acids. The mechanism of mTORC2 regulation was not 
known until recently, when Julien et al. (2010) discovered that phosphorylation of rictor 
requires mTORC1 activity. Rictor has been shown to be phosphorylated directly by 
p70S6K in vivo and in vitro, in a rapamycin-insensitive manner. Because mTORC2 was 
shown to phosphorylate Akt, it appears to form part of a feedback loop between mTOR 
and Akt.  
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1.3 Manipulation of cellular translational apparatus by viruses 
As mentioned before, all viruses remain dependent on the host-cell translation 
machinery to synthesize viral proteins, for the reason that protein synthesis requires 
specific proteins that cannot be encoded within viral genomes. As a result, viruses 
developed various tricks and strategies to take control of translation factors, optimize 
viral mRNA translation, and avoid host-cell antiviral responses, and consequently 
viruses compete with the cell at the translational level (Schneider and Mohr, 2003). 
Some of such recently discovered strategies are discussed later in Section 4.  
Viruses can be broadly divided into two classes, RNA and DNA viruses. The strategies 
used by each class of viruses are briefly characterized below. 
 
1.3.1 RNA viruses 
RNA viruses can contain either positive- or negative-sense genome, the latter of which 
must be transcribed to form positive sense mRNA which is then translated into proteins 
using host cell ribosomes. Unlike DNA viruses, and despite the need for using the host 
cell ribosomes for protein synthesis, many RNA viruses produce mRNA which lacks 
either the 7-Methyl cap or the poly(A) tail. The lack of these structures, particularly the 
5’mRNA cap, results in the necessity to develop novel mechanisms to ensure translation 
of viral mRNA.  
 
1.3.1.1 The closed-loop model of translation initiation 
As mentioned before, experimental evidence suggests that mRNA circularization is 
required for efficient cellular protein synthesis. However, a number of viruses, such as 
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rotaviruses, generate mRNA that lacks a 3’poly(A) tail. Rotavirus is a member of 
Reoviridae and contains 11 double-stranded RNA segments. Each segment is 
transcribed into mRNA that possess a 5’cap structure but lacks a 3’poly(A) tail. Instead, 
the 3’end contains a tetranucleotide motif which is recognized by the virus encoded 
NSP3 protein (Piron et al., 1998; Vende et al., 2000). NSP3 binds specifically to the 
conserved viral 3’end and to the scaffold protein eIF4G. In addition, eIF4G displays 
higher affinity for NSP3 than for PABP and as a consequence the interaction between 
eIF4G and PABP is disrupted in rotavirus-infected cells (Groft and Burley, 2002), 
which results in reduced efficiency of host mRNA translation and circularization-
mediated enhancement of viral protein synthesis. Another virus lacking 3’poly(A) tail is 
Dengue virus, a mosquito-borne member of the family Flaviviridae. In this case PABP 
was found to interact with the 5’UTR of the viral mRNA to bring about its 
circularization (Polacek et al., 2009). 
 
1.3.1.2 IRES 
One of the mechanisms used by some RNA and DNA viruses to initiate protein 
synthesis is use of an IRES (Internal Ribosome Entry Site), which is a sequence of 
nucleotides that allows initiation of the translation process in the middle of mRNA, on 
highly structured regions located within the 5’UTRs (Pelletier and Sonenberg, 1988), 
without involving 5’mRNA cap. The entry of ribosomes at an internal site of mRNA 
was first found in picornaviruses (poliovirus) (Pelletier and Sonenberg, 1988) and 
encephalomyocarditis virus (EMCV) (Jang et al., 1988), and occurs in a growing 
number of viral mRNAs including those of hepatitis C virus (HCV) (Tsukiyama-Kohara 
et al., 1992; Wang et al., 1993), flaviviruses (Lemon and Honda, 1997), and 
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retroviruses (Balvay et al., 2007). IRES has even been proposed for some herpesviruses 
mRNAs (Low et al., 2001). It was also suggested that some mammalian mRNAs also 
have IRES (reviewed by Carter et al., 2000). 
Surprisingly, there is no general mechanism used by these viruses. In HCV-infected 
cells IRES directly binds to 40S ribosomal subunit, while picornavirus IRESes do not 
attract 40S directly, but rather through high-affinity eIF4G-binding site (Hellen and 
Sarnow, 2001). Viral IRESes have been divided into four groups (Kieft, 2008; Hellen, 
2009) based on their secondary structure, requirement for eIFs, the location of the start 
codon relative to the site of the 40S ribosomal subunit recruitment, and the ability to 
operate in rabbit reticulocyte lysate with or without supplementation (Kieft, 2008). 
There is a number of different mechanisms of initiation used by viral IRES elements, 
however, no viral proteins have been found to be essential for IRES function, although 
the protease 2A encoded by poliovirus is thought to play a stimulatory role (Hambidge 
and Sarnow, 1992).  
In contrast to cap-dependent translation, translation initiation mediated by IRES 
elements is independent of the cap, and is therefore independent of eIF4F integrity. As 
such, these viruses often inactivate eIF4F by cleaving eIF4G or PABP, or 
dephosphorylating 4E-BP1. 
 
1.3.2 DNA viruses 
In contrast to many RNA viruses that inactivate eIF4F function, an increasing number 
of DNA viruses are being found to stimulate the assembly of translation initiation 
complexes to maximize viral protein production. These include herpes simplex virus 
(HSV), human cytomegalovirus (HCMV), VacV, and African swine fever virus (ASFV) 
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(Kudchodkar et al., 2004; Walsh and Mohr, 2004; O'Shea et al., 2005; Walsh et al., 
2005; Walsh et al., 2008; Castello et al., 2009). In all of these cases viruses activate 
mTOR to phosphorylate 4E-BP1 and stimulate eIF4F assembly. In the case of human 
papillomavirus (HPV), little is known about its effects on eIF4F, however, it has been 
shown that HPV de-regulates eIF4E and 4E-BP1 through mTOR activation, which may 
contribute to cell transformation (Oh et al., 2006). Another example of eIF4F 
manipulation is adenovirus-encoded 100k protein, which binds to the C-terminus of 
eIF4G and evicts Mnk, leading to dephosphorylation of eIF4E (Cuesta et al., 2000; 
Cuesta et al., 2004). 100k protein also binds to the viral mRNA to promote its 
translation by the process of “shunting” in which ribosomes physically bypass parts of 
the 5’ untranslated region to reach the initiation codon (Yueh and Schneider, 1996; Xi et 
al., 2004). In addition, a number of other viral factors have been shown to interact with 
eIF4F and regulate its function during infection (discussed in Section 4). 
In contrast to other DNA viruses, only the Poxviridae and Asfarviridae, with its only 
member ASFV, replicate exclusively in the cytoplasm of infected cells. Recent studies 
have shown that besides stimulating eIF4F assembly both VacV and ASFV cause a 
unique redistribution of host translation factors to viral replication compartments 
(Katsafanas and Moss, 2007; Walsh et al., 2008; Castello et al., 2009). How this 
impressive rearrangement of the host translation system is accomplished remains 
unknown, and is part of the aim of this study.  
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1.4  Aims of thesis 
 
Previous studies by a number of researchers showed that poxviruses stimulate eIF4F 
formation and commandeer components of this host translation initiation complex by 
redistributing and concentrating them within viral factories by an unknown mechanism. 
This thesis aimed to analyze the signaling pathways activated by vaccinia virus and 
leading to eIF4F complex assembly in infected cells. We intended to evaluate the effect 
of VacV on PI3K/Akt/mTOR pathway, which is the key pathway regulating protein 
synthesis in cells, but had not been studied in VacV-infected cells. Investigation of its 
changes would provide valuable information not only about vaccinia virus strategies, 
but also the cellular signaling and translational machinery in general. 
Finally, we aimed to identify possible viral/cellular protein(s) involved in redistribution 
of translation factors during VacV infection. In order to do this it was essential to screen 
components of the eIF4F complex in VacV-infected cells to search for such protein(s). 
The next step would be to clone and express that protein(s) in cells to determine its 
function and importance in VacV replication. As a last point we planned to find the 
regions of the protein(s) responsible for its function.  
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Section 2.0 
Material and Methods 
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2.1 Equipment  
Applied Biosystems 2720 Thermal Cycler 
Centrifuge Beckman Avanti J-25I 
Container with printed label, 30 ml (greiner bio-one) 
Gene Pulser II Electroporator (Bio-Rad Laboratories) 
Hotplate stirrer (SB162, Stuart) 
Laminar flow cabinet (Lamin Air, Model 1.2, Holten) 
Leica DFC 500 microscope 
Microcentrifuge Sigma 1-15 PK 
Microcentrifuge Galaxy 14D, VWR 
Microprocessor ph meter (pH210, HANNA instruments) 
Mini see-saw rocker (SSM4, Stuart) 
Micropipettes 1-10 µl, 10-100 µl, 20-200 µl, 100-1000 µl (VWR) 
Pipettes 1 ml, 2 ml, 5 ml (costar, USA) 
Pipettes 10 ml, 25 ml (greiner bio-one) 
Power Supply (PowerPac™ HV, catalogue no. 164-5056, BIO-RAD) 
Speed Gel SG 200 gel dryer (Savant, Farmingdale, NY) 
Steri-cycle CO2 Incubator (Thermo Electron Corporation) 
Tips, natural bevelled (TipOne, Starlab) 
Vortex Mixer (PV-1, Grant Bio) 
Vacuum Millipore  
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2.2 Antibodies  
Table 2.1 Primary antibodies used in immunocytochemical studies 
Antibody Host Supplier, #catalogue no. Dilution 
Akt Rabbit Cell Signalling #9272 1/1000 
Phospho-Akt Ser473 Rabbit Cell Signalling #9271 1/1000 
Phospho-Akt Thr308 Rabbit Cell Signalling #9275 1/1000 
Phospho-Erk Rabbit Cell Signalling #9101 1/1000 
mTOR Rabbit Cell Signalling #2972) 1/1000 
p70 S6 Kinase Rabbit Cell Signalling #9202 1/1000 
4E-BP1 Rabbit Cell Signalling #9452 1/1000 
Caspase 3 Rabbit polyclonal Cell Signaling #9662 1/1000 
Cleaved Caspase 3 Rabbit polyclonal Cell Signaling #9661 1/1000 
Parp Rabbit polyclonal Cell Signaling #9542 1/1000 
Cleaved Parp Rabbit polyclonal Cell Signaling #9541 1/1000 
PABP Rabbit polyclonal Cell Signaling #4992 1/1000 
PABP Rabbit monoclonal Gift (Simon Morley) 1/3000 
Phospho-eIF4G Rabbit polyclonal Cell Signaling #2441 1/1000 
eIF-4E Mouse monoclonal BD Labs #610269 1/1000 
P-eIF2α Rabbit polyclonal Cell Signaling #9721 1/1000 
eIF-4G Rabbit polyclonal Gift (Ian Mohr) 1/5000 
Vaccinia virus Rabbit Virostat # 8101 1/1000 
I3 Rabbit Gift (J. Krijnse-Locker) 1/2000 
FLAG Rabbit Sigma-Aldrich 1/1000 
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2.3 Water  
Ultrapure water was used in the preparation of all media and solutions. Water was first 
pretreated using activated carbon and pre-filtration, and then purified by a reverse 
osmosis system (Milipore Milli-RO 10 Plus, Elgastat UHP) with a standard of 12-18 
MΩ/cm resistance. 
 
2.4 Sterilization 
Water, glassware, lids and all thermostable solutions were sterilised by autoclaving at 
121o C for 20 minutes under pressure of 1 bar. Thermolabile solutions and drugs were 
filtered through a 0.45 µm sterile filter (Milipore, Millex-hv, SLHV033RB). Low 
protein-binding filters were used for all protein-containing solutions. 
 
 
2.5 Cell culture 
2.5.1 Medium 
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
supplemented with 2 mM L-glutamine (Invitrogen, UK), 1 mM sodium pyruvate 
(Invitrogen, UK), 50 units of penicillin, and 50 µg per ml of streptomycin (both 
Invitrogen, UK). Medium with 5 % fetal bovine serum (FBS) (Sigma) was used for 
culturing cells, whereas 0.2 % FBS supplementation was added to the medium for 
starving NHDFs.  
 
2.5.2 Cell lines 
The utilized cell lines were (1) primary normal human diploid fibroblasts (NHDFs) 
(Clonetics, Walkersville, Maryland, United States), (2) HEK-293 cells, and (3) BSC40 
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cells (which are monkey epithelial kidney cells), both kindly provided by Dr. I. Mohr, 
New York University. 
 
Table 2.2 Cell lines used in the study 
Cell line Cell type Basal medium Source 
NHDF 
Normal human 
diploid fibroblasts 
DMEM 
 
Clonetics 
 
HEK-293 
Transformed 
human embryonic 
kidney cells 
DMEM Dr. I. Mohr 
BSC40 
Monkey epithelial 
kidney cells 
DMEM Dr. I. Mohr 
  
NHDFs were used to carry out the majority of the experiments as we were interested in 
the effects of viral infection on normal human cells. NHDFs express low levels of 
translation factors that are noticeably activated during infection. We also used serum 
starvation to study both actively cycling and resting states of NHDFs. 
HEK-293 is a hypotriploid human cell line established from primary human embryonic 
kidney cells, which were transformed with human adenovirus 5 DNA (Graham et al., 
1977). On account of the presence of increased quantities of translational factors, 
characteristic for transformed cell lines, HEK-293 cells were used in this study to 
perform the majority of the binding assays.  
BSC40 is a high-temperature tolerant derivative of BS-C-1 established by Brockman 
and Nathans (1974), which supports the growth of vaccinia virus for titering. 
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2.5.3 Cell passaging 
Cells were grown in a CO2 incubator at 37o C and 5 % CO2 until confluent. A 10 cm2 
dish of cells was then quickly washed with PBS and treated with 1 ml of trypsin. After 
an incubation of five to ten minutes at 37o C cells were resuspended in the appropriate 
amount of medium and mixed well. NHDFs were split 1:3, 293 cells were split 1:10 and 
seeded into new tissue culturing containers. 
 
2.5.4 Cell starvation 
For serum starvation, confluent cultures of NHDFs were washed three times in PBS 
then cultured in DMEM containing 0.2 % FBS for 5 days, when more than 98 % of the 
cells are in the G1 phase of the cell cycle. Starvation of NHDFs was used to simulate the 
resting state of cells.  
 
2.5.5 Cell harvesting 
For the preparation of whole cell extracts from cultures seeded in 6-well plates or on 35 
mm2 dishes, cells were lysed in 250 µl of working sample buffer to solubilize total 
cellular proteins. Working sample buffer was prepared from the stock of 2 x Laemmli 
buffer. 
 
                  1 x working buffer                                                2 x  Laemmli buffer       
                  50 % 2x Laemmli                                                 12.5 % 1M Tris, pH 6.8                       
                   45 % UHP water                                                     20 % SDS (20 %)                  
               5 % β-Mercaptoethanol                                            40 % Glycerol (50 %) 
   4 µl 8 % bromophenol blue per ml buffer                               27.5 % UHP water    
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The working sample buffer contains a negatively charged detergent sodium 
dodecylsulfate as well as β-Mercaptoethanol being the reducing agent. The tensid SDS 
binds to the proteins hydrophobic regions and leads to an unfolding of the polypeptide 
chains. Other subunits are also released from the protein. Anionic SDS interacts 
proportionally to the protein’s molecular weight and confers its negative charge. β-
Mercaptoethanol is added to analyse the polypeptide’s linear form. This reducing agent 
cleaves the disulfide bond between two thiol groups. The samples were boiled after 
harvesting for three minutes to destroy remaining secondary and tertiary structures. All 
proteins are now showing an ellipsoid structure and are generally not separated by their 
conformation but by their size. After heating the samples, they were cooled, vortexed, 
centrifuged and stored at -20° C until further usage. 
                            
2.5.6 Cell freezing 
To allow long term storage of cell stocks, cells were frozen and cryo-preserved in liquid 
nitrogen at temperature below -180o C. Once frozen properly, such stocks should last 
indefinitely. 
 Cells to be frozen were harvested in the log phase of growth (i.e. actively 
growing and approximately 60-70 % confluent) by centrifugation at 1200 rpm 
for 5 min. 
 Pelleted cells were carefully re-suspended in freezing medium (FBS containing 
10 % DMSO) (Sigma) and transferred into cryovials (Greiner). 
 Cryovials were immediately placed in isopropanol freezing container, as DMSO 
is toxic to cells at room temperature, and set at -80o C for 24 h. 
  Cryovials were then transferred into liquid nitrogen containers, where they were 
stored until required. 
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2.5.7 Cell thawing 
Immediately prior to removal of a cryovial from the liquid nitrogen stores for thawing, a 
sterile universal tube containing growth medium was prepared for the rapid transfer and 
dilution of thawed cells to reduce their exposure time to DMSO freezing solution.  
 The cryovial was quickly thawed at 37o C water bath.  
 When thawed, the DMSO-cell suspension was quickly transferred to the media-
containing universal. 
 The suspension was centrifuged at 1200 rpm for 5 min, the DMSO-containing 
supernatant removed, and the pellet re-suspended in fresh growth medium. 
 Thawed cells were placed on 10 cm2 dish and allowed to attach overnight. 
 After 24 h the cells were re-fed with fresh growth medium to remove any 
residual traces of DMSO. 
 
2.6 Cell fixation 
Cells were washed 1x with cold PBS. The fixing solution was made by diluting the 
Formaldehyde Solution 37 % (Sigma) in PBS in a ratio of 1:10, and 2 ml of the solution 
was added to cells for 10 min. Cells were then washed 3x in cold PBS and stored in 2 
ml of PBS at 4o C. 
 
2.7 Virus 
Vaccinia virus Western Reserve (VacV WR) was a kind gift of Dr. Stewart Shuman, 
Memorial Sloan-Kettering, New York, and was propagated and titered on permissive 
BSC40 cells as described below. 
 
 
 66 
2.7.1 Growing viral stocks 
Virus was grown in confluent 10 cm2 dishes using BSC40s, the cell line that supports 
the growth of VacV (Brockman and Nathans, 1974). 
 One day before infection BSC40 cells grown in 5 % FBS were seeded on 10 cm2 
dishes by splitting 1:2 each confluent 10 cm2 dish. The next day medium was 
changed to 2 % FBS, which supports virus growth.  
  The stock tube of VacV was trypsinized for 30 min at 37o C in an equal volume 
of 0.25 % trypsin (diluted 1:10 in PBS). Trypsinization reaction was then 
neutralized by adding an equal or larger volume of medium containing 2 % FBS. 
 Cells were infected at moi 0.05 and virus was grown at 37o C for 2-3 days (the 
virus is highly cell associated so growing stocks at lower temperature doesn’t 
have any advantage). Medium was replaced with an equal volume of serum-free 
DMEM, and cells were scraped very carefully, to avoid splashing the virus 
around. Cells together with serum-free medium were collected in a 50 ml Falcon 
tube and placed at -80o C.  
 To harvest the virus, cells were freeze/thawed by placing the tube in a 37o C 
waterbath, a total of three times. Medium containing the virus was then 
aliquoted in 1ml aliquots and stored at -80o C. 
 
2.7.2 Titering virus 
Virus was titered using confluent BSC40 cells grown in DMEM 5 % FBS in 6-well 
plates. 
 The day before titering, BSC40 cells were seeded at 5x105 cells per well of a 6-
well plate. 
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 The virus was thawed and trypsinized with an equal volume of 0.25 % trypsin; 
mixed well by pipetting up and down and incubated for 30 min at 37o C. 
Trypsinization reaction was then neutralized by adding 500 ul DMEM 2 % FBS. 
 Serial dilutions of virus in DMEM 2 % FBS were made, and 500 ul of each 
dilution was then added to cells containing 1.5 ml 2 % FBS DMEM, and mixed 
gently. 
 Cells were placed at 37o C, and on day 3 plates were fixed by aspirating medium 
and adding 10 % TCA (Trichloroacetic acid) (Sigma) for 10 min. Staining the 
plates was performed by aspirating 10 % TCA and adding Crystal Violet stain 
(Merck) for 15 min, followed by rotating plates on orbital rotator. Plates were 
then washed using tap-water and left to dry. 
 
2.8 SDS-PAGE   
(Sodium dodecylsulfate polyacrylamide gel electrophoresis) 
To fractionate the samples, an acrylamide percentage was chosen depending on the size 
of the proteins to examine. To look at proteins with a high MW like eIF4G a 10 % gel 
was used while the different phosphorylation states of 4E-BP1 were much better 
resolved in a 17.5 % gel. The increasing percentage of acrylamide made it harder for 
large proteins with a low electrophoretic mobility to pass through the gel while small 
proteins were separated more clearly. 
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Table 2.3 Ingredients for SDS-PAGE resolving gel  
 
 
Table 2.4 Ingredients for SDS-PAGE stacking gel (5 ml) 
Water (ml) 3.175 
1M Tris pH 6.8 (ml) 625 
30% Acrylamide (ml) 850 
2% Bis-Acrylamide (ml) 350 
20% SDS (µl) 25 
10% APS (µl) 25 
TEMED (µl) 12.5 
 
 
All ingredients (40 % Acrylamide, 2 % Bis-Acrylamide and TEMED from Merck; Tris, 
SDS and APS from Sigma) were mixed according to Tables 2.3 and 2.4, and the 
resolving gel was poured between two vertical glass plates. The vertical construction 
minimizes oxygen absorption which limits the polymerization. Approximately 500 µl of 
water-saturated iso-butanol (Sigma) was added on top to overlay the resolving gel and 
prevent further oxygen uptake. After one hour alcohol was washed out, the stacking gel 
was poured on top, the comb inserted and once everything was set, gels were transferred 
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to the electrophoresis chamber. The chambers were filled with 1x electrode buffer (0.25 
M Tris, 2.5 M Glycine [Sigma], 1 % SDS), and bubbles that could influence the electric 
current were removed with the help of syringes filled with buffer. The marker was 
prepared in working sample buffer using 3 µl of Precision Plus Protein Dual Colour 
Standards (Bio-Rad) per lane. After loading 5 to 14 µl of the sample the gel was run at 
150 volts to resolve the proteins. 
 
2.9 Western blotting (Immunoblotting) 
The western blot or protein immunoblot is used for highly sensitive detection as well as 
quantification of immobilized proteins. The SDS-PAGE separated proteins are 
transferred to a nitrocellulose membrane via wet electroblotting, immobilized and 
immunochemically detected. For that the gel was carefully fixed between a piece of 
chromatography paper and a nitrocellulose membrane. The sandwich made of the 
chromatography paper, the gel, the nitrocellulose membrane, second piece of 
chromatography paper, and two sponges on each side was stabilized between two 
plastic scaffolds and then transferred to a chamber filled with 1x transfer buffer mixed 
with 20 % methanol (Merck). The methanol in the buffer helps removing SDS from 
protein-detergent complexes and increases the affinity between proteins and the 
membrane.  
 
5 X wet western transfer buffer                               1 X transfer buffer: 
           124 mM Tris                                      20 % 5x wet western transfer buffer 
         960 mM Glycine                                               20 % methanol 
             0.05 % SDS                                                 60 % UHP water 
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An electric current induced by 57 volts for one hour transferred the proteins out of the 
gel onto the membrane. Big proteins such as eIF4G needed three hours of transfer. 
Afterwards the membrane was washed in 1 X TBS-T (tris-buffered saline with Tween 
20) (1.5 M NaCl, 0.5 M Tris, 0.1 % Tween 20, pH adjusted to 7.4 using concentrated 
HCl) to remove remaining SDS. 
 
To detect proteins, the membrane was blocked in 1x TBS-T with 3 % dried skimmed 
milk powder with less then 1 % fat (Marvel, Premier International Foods, UK) or 3 % 
bovine serum albumin (BSA) (Sigma). The blocking prevented non-specific binding of 
antibodies used for detection of the target protein to the membrane. After washing, the 
membrane was incubated with primary antibodies at 4° C over night. The next day the 
membrane was washed 3 times for five minutes with 1 x TBS-T to remove the 
remaining primary antibodies and incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies in 1 x TBS-T with 3 % dried skimmed milk powder or 
3 % BSA for one hour. The horseradish peroxidase catalysed the oxidation of luminol 
when activated by hydrogen peroxide. The product of this reaction is very unstable and 
decomposes immediately. It emits blue light that leads to a dark region which 
corresponds to the protein bands of interest when exposed to X-ray film. The brightness 
of the light is proportional to the amount of protein present. After washing the 
membrane 3 times for five minutes it was subjected to chemiluminescence western 
blotting substrate according to the manufacturer’s instructions (Pierce ECL, Thermo 
Scientific), fixed between cling films, exposed to x-ray film, and developed in the dark 
room using Kodak developer/fixer solutions. 
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2.10 Metabolic labelling  
Radioactive medium was made by using the following components: 
       1 ml Methionine/Cysteine-free DMEM (Sigma) 
       10 µl L-Glutamine (Gibco) 
       10 µl Pen-Strep (Gibco) 
       10 µl NaPyruvate (Gibco) 
       25 µl HEPES, pH 8 (sterile, TC grade)        
All ingredients were mixed by gently swirling, and warmed up at 37o C. 35S-Methionine 
(Perkin Elmer) was thawed and 7 µl (0.017 mCi) was added per 1ml of medium (or 20 
µl in the case of immunoprecipitation assay), and gently mixed. Old medium was 
aspirated off from cells, and radioactive medium was added with the amount of 1ml per 
35 mm dish. If the cells were infected, the pipette used for applying the medium was 
carefully placed in 1 % virkon several times, to inactivate the virus before placing the 
pipette into radioactive waste. The dish was then carefully placed in the designated 
container for labeling, together with the opened 35 mm dish containing activated 
charcoal, and incubated at 37o C in cell culture incubator for 1 h. After labeling, the dish 
was carefully removed and transferred to the safety cabinet. Radioactive medium was 
removed by pipette, mixed with virkon to inactivate the virus, and placed into liquid 
disposal container for 35S waste. Cells were lysed in appropriate lysis buffer (Laemmli 
buffer to make total cell extracts, NP40 buffer for immunoprecipitation assay). All 
tubes, pipettes and used dishes were placed in the solid waste disposal area for 35S 
waste. 
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2.11 Gel fixation and drying 
Resolved SDS-PAGE gels containing samples that had been labelled with 35S-
methionine/-cysteine were placed in destain solution (Table 2.5) for 20 min at room 
temperature. The gel was dried on cardboard at 80o C for two hours under vacuum with 
a Speed Gel SG 200 gel dryer to remove the water in the gel. The dried gel was then 
exposed to x-ray film at -80° C for the appropriate exposure time and developed using 
Kodak developer/fixer solutions. 
 
Table 2.5 Ingredients of destain solution 
  
 
 
 
 
                                 
2.12 Immunoprecipitation 
Anti-eIF4G and anti-PABP immunoprecipitation from metabolically labeled cell 
extracts was performed as follows. After labeling, soluble cell extracts were prepared in 
NP-40 lysis buffer (NLB) and centrifuged at 10000xg for 10 min at 4o C. Extracts were 
treated with a cocktail of nucleases (RNAse A, RNase T1 and Micrococcal Nuclease) 
then precleared with 5 µl normal rabbit serum and incubated with 2 µl primary antibody 
for 1 h. Then samples were added to Protein A Sepharose beads (GE Healthcare) and 
incubated for another hour at 4o C. Beads were washed 3 times in NP-40 buffer and 
boiled in Laemmli buffer. 
 
Destain solution 
25 % Methanol 
10 % Acetic Acid 
65 % UHP water 
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NP-40 lysis buffer (10 ml) 
                                         500 µl of 1 M HEPES/KOH pH 7.4 containing 40 mM EDTA 
                                         400 µl of 2.5 M NaCl (Sigma) 
                                         80 µl of 0.25 M Na3VO4 (Calbiochem) 
                                         250 µl of 1 M Glycerophosphate (Calbiochem) 
                                         125 µl of 2 % NP-40  
                                         10 µl of 1.5 M MgCl2 (Sigma) 
                                          8.56 ml Water 
                                          1 protease inhibitor cocktail tablet (CompleteR Mini-tablets,   
                                          Roche) 
 
2.13 7-methyl GTP sepharose 4B chromatography 
107 cells were washed in PBS then lysed in 600 µl NLB, treated with RNAse A and 
precleared with 80 µl packed-bed volume (pbv) BSA-blocked sepharose 4B 
(Amersham) for 1 h. Input samples were taken from precleared extracts and the 
remaining sample was incubated with 50 µl pbv BSA-blocked 7-Methyl GTP-
Sepharose (Amersham) for 1 h then washed in NP-40 lysis buffer, and boiled in 
Laemmli buffer. 
 
2.14 ssDNA-binding assay 
3 x 107 cells were washed in PBS then lysed in NLB and centrifuged at 10000 xg for 10 
min at 4o C. Extracts were treated with RNAse A (50 µg) for 20 min at room 
temperature, then treated with RNAse Inhibitor (Sigma-Aldrich). Extracts were 
precleared for 1 h with 20 µl p.b.v. anti-biotin antibody conjugated sepharose 4B 
(Sigma-Aldrich). Precleared extracts were then programmed with 7.5 µg 
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phosphothioate-stabilized 5’-biotin conjugated ssDNA (sequence: 
ataattaataacaccatagaccaccgcccgaaggg) (Sigma) and 20 µl p.b.v. anti-biotin antibody-
conjugated sepharose 4B for 2 h at 4o C. Resin was recovered and washed extensively in 
NLB before boiling in Laemmli buffer. 
 
2.15 Transfections 
Cells were seeded in antibiotic-free medium and transfected using Fugene HD 
Transfection Reagent (Roche) according to the manufacturer’s instructions. 
 
2.16 Immunofluorescence 
Cells were seeded on glass-bottom 35 mm dishes (Lennox). On day 2 cells were 
transfected with 0.5 µg pGFP-I3L. On day 3 cells were infected overnight (16-20 h) at 
the indicated moi. Cells were then fixed in 3.7 % formaldehyde/PBS for 20 min, washed 
extensively with PBS and permeabilized in 0.1 % Triton for 20 min. After washing, 
dishes were blocked in a mixture of 3 % BSA and 1 % Donkey Serum in TBS for 40 
min, then probed for 1h with anti-eIF4G antiserum (1:3000) in 3 % BSA and 1 % 
Donkey Serum in TBS-0.1 % Tween (TBS-T). Dishes were washed three times with 
TBS-T then probed for 40 min with TRITC (rhodamine isothiocyanate derivative)-
conjugated cross-adsorbed donkey anti-rabbit secondary (Jackson ImmunoResearch) 
(1:1000) in 3 % BSA and 1 % Donkey Serum in TBS-T. Samples were washed three 
times with TBS-T, DNA was stained with Hoescht for 5 min and washed again in TBS-
T. Images were captured on a Leica DFC 500 microscope. 
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2.17 Coomassie staining 
After resolution of samples by SDS-PAGE, gels were sequentially soaked in coomassie 
stain overnight. 
Coomassie stain:            50 % MeOH  
                                       10 % Acetic acid (Merck) 
                                        0.25 % Coomassie Brilliant blue (Biochemica) 
 
The following day gels were washed in destain solution (see Table 2.5) for 90 min, 
frequently changing the solution at first, and stored in destain solution. 
 
2.18 Silver Staining and Mass Spectrometry Analysis 
After resolution of samples by SDS-PAGE, gels were sequentially soaked for 10 min 
each time in 50 % Methanol (Merck), 5 % Methanol, 30 µM DTT, 0.1 % (w/v) AgNO3 
(Sigma), then visualized with 3 % (w/v) Na2CO3.  Bands were excised from silver 
stained gels and destained using a 1:1 mixture of 30 mM potassium ferricyanide/100 
mM sodium thiosulfate solution. In-gel digestion using sequence grade trypsin 
(Promega) at a concentration of 12.5 ng/µl trypsin in 10 mM ammonium bicarbonate 
containing 10 % (vol/vol) acetonitrile was carried out overnight at 37o C. Tryptic 
peptides generated were extracted and analyzed by LC-MS/MS using an LTQ ion trap 
mass spectrometer (Thermo Fisher Scientific). The data generated was searched using 
BioWorks 3.3.1 (Thermo Fisher Scientific) against a subset of human and viral proteins 
from the SwissProt database. 
 
 
 
 76 
2.19 Isoelectric focusing  
Isoelectric focusing (IEF) is an electrophoretic method of protein separation based on 
their isoelectric point (pI). The pI is the pH at which the protein has no net charge and 
does not move in an electric field. The net charge is the sum of all positive and negative 
charges of the protein. Proteins carry positive, negative or zero net electrical charge, 
depending on the pH of their surroundings. IEF gels create a pH gradient to separate the 
proteins according to their unique pI (Garfin, 2003). This description of the procedure 
was kindly given to us by Dr. Simon Morley (University of Sussex), and is based on the 
vertical slab version of IEF published by Savinova and Jagus (1997). 
Firstly, a 50 ml stock of incomplete gel mix was made, filtered using a 0.22 µl filter 
(large syringe and pressure, not vacuum) and stored at 4o C. 
Table 2.6 The components of the incomplete gel mixture. 
  42.8 ml pure water 24.13 ml H2O 
4.86 g acrylamide 12.17 ml 40 % Acrylamide 
274.3 mg bis-acrylamide 13.7 ml 2 % Bis-acrylamide 
1.71 g CHAPS 1.71 g of CHAPS 
 
 
2.19.1 Making and pouring the gel 
The gel was mixed as outlined in table 2.7 leaving out the APS and TEMED. The 
mixture was gently heated at 37o C waterbath to dissolve the urea. Once urea was 
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dissolved, the APS and TEMED was added, and the gel was poured right to the top of 
plates, combs added and gels were allowed to set. 
 
Table 2.7 The components of the gel used for IEF. 
1 Gel (6 ml) 2 Gels (12 ml) 
3.5 ml Incomplete gel mix 7 ml incomplete gel mix 
3.24 g urea 6.48 g urea 
0.45 ml ampholines* 0.9 ml ampholines 
20 µl 10 % APS 40 µl 10 % APS 
10 µl TEMED 10 µl TEMED 
                    * pH range 3-10.       
 
 
2.19.2 Sample buffer and sample preparation 
7x sample buffer was made as described in table 2.8. 1 ml aliquots were stored at -20o C 
to be reused when needed.  
Table 2.8 The components of the 5 ml stock 
Components Volume 
21 % (v/v) ampholines (same as for gels)  1.05 ml 
14 % (v/v) ß-mercaptoethanol 0.7 ml 
35 % (w/v) CHAPS 1.75 g 
H2O             3.0 ml 
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For sample preparation 1x sample buffer was made as described below. 
    1x sample buffer:          143 µl of 7 x sample buffer 
                                           0.54 g urea (gives 9 M final) 
                                           550 µl MilliQ water 
Running buffers were prepared as described below (Tab. 2.9).  
 
Table 2.9 The components of the running buffer        
Cathode (outer chamber)   0.05 M Histidine (= 3.88g/500ml) 
Anode (inner chamber)       0.01 M Glutamic Acid (= 0.073g/500ml) 
 
500 ml of each buffer was freshly made. The buffers were chilled as the high voltage 
used during IEF can increase buffer temperature and warp the gels. 
 
 
2.19.3 Running the gels 
Once gel was set, the combs were removed and wells were washed out thoroughly with 
water. 20-25 µl of 1x sample buffer was added to each well. The wells were then 
carefully overlayed with 10 µl 6 M urea followed by glutamic acid. The inner chamber 
of the IEF apparatus was filled with 0.01 M glutamic aid and the outer chamber was 
filled with 250 ml 0.05 M histidine. The apparatus was placed in a plastic container and 
surrounded with ice to maintain a low temperature. The gels were then prefocused for a 
total of 1 h on reverse polarity at the following voltage: 
- 20 min at 200 V 
- 20 min at 300 V 
- 20 min at 400 V 
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After prefocusing the wells were washed out thoroughly with water. Before the end of 
the prefocus stage the samples were prepared by boiling and allowing cooling. A 1:1 
dilution of sample with 1x IEF sample buffer was prepared. The samples were then 
vortexed immediately and 25 µl of sample was loaded into each well. The sample was 
overlayed with urea and glutamic acid as for prefocusing and IEF was performed by 
increasing voltages in 50 V increments every 20 min starting at 500 up to 750 V, each 
one for 20 min, then run at 1000 V for another 20 min. Again, as for prefocus, IEF was 
run on reverse polarity. After electrophoresis the gel was transferred to nitrocellulose 
and probed with antieIF4E antiserum as described for Western Blotting. 
 
 
2.20 Cloning procedure and plasmids 
2.20.1 Purification of I3 from VacV-infected cells 
Since VacV genes do not have introns, genomic DNA can be used for cloning. To 
prepare template for cloning, DNA was first isolated from uninfected or VacV-infected 
BSC40 cells, as described by Roper (2004). Cells were harvested by scraping in PBS, 
centrifuged, and lysed in buffer 1 (40 µM Tris-EDTA [pH 9], 1.5 M NaCl, H2O) and 
buffer 2 (40 µM Tris-EDTA [pH 9], 7.5 % SDS, H2O). Cells were then incubated with 
proteinase K to remove proteins from the DNA. Finally, proteinase K was heat-
inactivated to avoid degradation of DNA polymerases used in PCR reaction, and DNA 
was purified by a phenol-chloroform extraction.  
 
The I3L gene was then amplified from VacV genomic DNA by PCR using specific 
primers as described below. 
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2.20.2 PCR reaction 
Primers were dissolved in TE buffer to make a 100 pMol/µl stock, from which the 
working primer stock of 10 pMol/µl was prepared. The target sequence was amplified 
in a 50 µl reaction using the KOD XL DNA polymerase kit (Novagen) and the PCR 
conditions as indicated in table 2.10. The PCR was performed using 2720 Thermal 
Cycler (Applied Biosystems). The amplified PCR product was gel purified using 
Qiagen kit and following the manufacturer’s instructions. All necessary ingredients 
were supplied with the kit. 
 
Table 2.10 PCR conditions used in this study                                
Step of PCR reaction Temperature [oC]  Time [sec] 
 
 
Cycles 
Initial denaturation 94 300 1 
Denaturation 94 15 35 
Annealing 60.3 30 35 
Elongation 72 60 35 
 
 
2.20.3 Restriction enzyme digestion of plasmid DNA 
2 µl of each isolated product sample was run out on a 1 % agarose gel to check for 
degradation. 1 µl of the product, together with the same amount of the plasmid 
backbone, was then digested using 0.2 µl of the specific restriction enzymes. The 10 µl 
digestion reaction was carried out for 1 h at 37o C. The backbone was then SAP (Shrimp 
Alkaline Phosphatase) treated for 20 min at 37o C. SAP was inactivated by heating the 
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reaction to 65o C for 10 min. 1 µl of each digestion reaction (backbone and PCR 
digestion) was then run on 1 % agarose gel to check the sizes. 
 
2.20.4 Ligation of target DNA into a suitable vector 
Ligation of the target DNA into a plasmid backbone (in a ratio 1:1) was carried out in a 
10 µl reaction including T4 DNA ligase (1 µl), ligase buffer 10x (1 µl), and usually 1 µl 
of both target DNA and backbone plasmid. Three different types of plasmids were used 
in this study: the mammalian expression vectors pCI-neo and pGFP-N, and the bacterial 
expression plasmid pET-15b containing the lac operon. Ligation reaction was carried 
out at 16o C for 1 h. To provide the control, an additional reaction containing backbone 
plasmid but no insert DNA was included. 
 
2.20.5 Transformation of bacteria 
1 µl of the ligation reaction was transformed into appropriate bacteria, DH5α or 
BL21(DE3) (both Invitrogen), following the manufacturer’s instructions. Bacteria were 
thawed on ice very slowly, mixed with the ligation reaction and heat-shocked by 
placing the transformation into the 37o C/42o C waterbath for approximately 30 sec, then 
returned on ice for 2 min. Cells were then cultured in 1 ml SOC at 37o C in a shaking 
incubator for 1 hour to recover and begin expressing resistance marker gene. 20 µl and 
200 µl of the transformation reaction was then plated on LB Agar (Sigma) containing 
the appropriate antibiotic. Bacterial culture was then spread on the plate using sterile 
glass beads, and plates were incubated overnight at 37o C. The next day single colonies 
were isolated and inoculated in 3 ml LB broth (Sigma) containing the appropriate 
antibiotic. The cultures were incubated overnight at 37o C in a shaking incubator, and 
the next day minipreps were made from the bacterial pellet.  
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2.20.6 DNA miniprep of plasmid DNA 
Overnight bacterial cultures were centrifuged at 17000 xg and the minipreps were made 
using the QIAprep System (Qiagen) and following the manufacturer’s instructions. 
Three basic steps of the procedure include: 
 Preparation and clearing of a bacterial lysate 
 Adsorption of DNA onto the QIAprep membrane 
 Washing and elution of plasmid DNA 
 DNA was eluted in 30-50 µl Buffer EB (10 mM Tris-Cl, pH 8.5). Plasmid DNA 
purified by this system does not require phenol extraction or ethanol precipitation, and 
can be used directly for restriction enzyme digestion and sequencing. 
 
2.20.7 Plasmid DNA restriction enzyme digestion and sequencing 
To confirm the orientation of the inserted DNA in the plasmid, restriction digestion was 
then carried out using the enzyme from the original cloning and one enzyme outside the 
insert. The digestion reaction was then run on 1 % agarose to check the orientation of 
the insert. 
In order to fully confirm the orientation of the inserted DNA in the plasmid and exclude 
mutations, the samples were sent to be sequenced. 
 
2.20.8  Plasmids, restriction enzymes and primers used in this study 
2.20.8.1 Generation of His-tagged I3L 
To generate His-tagged I3L the following primers were used, containing EcoR1 and 
Sal1 restriction sites for cloning. The His sequence is italicized.  
Forward: GCAACT GAATTC CGCCGCC ATG cat cat cat cat cat cat 
AGTAAGGTAATCAAGAAG 
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Reverse: GCAACT GTCGAC TCTAGT TCA TAC ATT GAA TAT TGG CTT TTC 
 
2.20.8.2 Generation of FLAG-tagged I3L 
To generate FLAG-tagged I3L the following primers were used, containing EcoR1 and 
Sal1 restriction sites for cloning. The FLAG sequence is italicized.  
Forward: GCAACT GAATTC CGCCGCC ATG AGTAAGGTAATCAAGAAG 
Reverse: GCAACT GTCGAC TCTAGT TCA ctt gtc gtc atc gtc ttt gta gtc TAC ATT 
GAA TAT TGG CTT TTC 
 
2.20.8.3 Generation of GFP-tagged I3L 
To generate pGFP-I3L the following primers were used, containing EcoR1 and Kpn1 
restriction sites, to amplify I3L from viral DNA. 
Forward: GCAACT GA ATT CTC GCC GCC ATG AGT AAG GTA ATC AAG AAG 
Reverse: GGC CCG CGG TAC CGT TAC ATT GAA TAT TGG CTT TTC 
The amplified PCR product was gel purified and digested then ligated into the EcoR1-
Kpn1 cloning site of the mammalian expression plasmid, pGFP-N (Clontech). 
 
2.20.8.4 Generation of FLAG-tagged actin 
FLAG-Actin was amplified from cDNA prepared from RNA isolated from human cells. 
The following primers, containing EcoR1 and Sal1 restriction sites, were used to 
amplify the gene and ligate it into the EcoR1-Sal1 cloning site of pCI-Neo. The FLAG 
sequence is italicized. 
Forward: GCAACT GAATTC CGCCGCCATGTGCGACGAAGACGAGACC 
Reverse:GCAACTGTCGACTCTAGTTCActtgtcgtcatcgtctttgtagtcGAAGCATTTGCG
GTGGAC 
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Ligations were transformed into DH5α cells and individual colonies were isolated. 
Recovered plasmids were analyzed by restriction digestion then sequenced to ensure 
cloning fidelity. 
 
2.20.8.5 Generation of I3L fragments 
To generate purified his-tagged full length I3 and fragments thereof the I3L gene was 
PCR amplified using the following primers containing Not1 and Nde1 cloning sites: 
Full Length I3: 
Forward: GCAACTCATATGAGTAAGGTAATCAAGAAG 
Reverse: GCAACTGCGGCCGCGACTAGTTCATACATTGAATATTGGCTTTTC 
I3-F1: 
Forward: GCAACTCATATGAGTAAGGTAATCAAGAAG 
Reverse: GCAACT GCGGCCGC GACTAGT TCA atc aat gat tag ttt ctt gag 
I3-F2: 
Forward: GCAACTCATATGAGTAAGGTAATCAAGAAG 
Reverse: GCAACT GCGGCCGC GACTAGT TCAaac ata ttc tac cat ggc tcc 
I3-F3: 
Forward: GCAACTCATATGAGTAAGGTAATCAAGAAG 
Reverse: GCAACT GCGGCCGCGACTAGTTCAatacaacataggactagccgc 
I3-F4: 
Forward: GCAACTCATATGAGTAAGGTAATCAAGAAG 
Reverse: GCAACT GCGGCCGC GACTAGT TCA aca att agc gta ttg aga agc 
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I3-F5: 
Forward: GCAACTCATATGtct atc tct ata aaa ctt act g 
Reverse: GCAACTGCGGCCGCGACTAGTTCATACATTGAATATTGGCTTTTC 
 
PCR products were digested with Not1 and Nde1 and ligated into Not1/Nde1 cloning 
sites in the bacterial expression plasmid, pET-15b. Ligations were transformed into 
DH5α cells and individual colonies were isolated. Recovered plasmids were analyzed 
by restriction digestion then sequenced to ensure cloning fidelity. Plasmids were then 
transformed into BL-21(DE3) cells (Invitrogen).  
 
2.21 Protein purification 
Overnight starter cultures were used to inoculate 250 ml cultures (LB broth containing 
ampicillin) grown at room temperature until O.D. = 600 (approximately 5 h) then 
induced with 0.05 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 60 min. IPTG 
is a non-metabolisable metabolite of lactose that triggers transcription of the lac operon. 
Cells were harvested by centrifugation at 6000 xg for 15 min at 4o C. The specific 
purification procedure was carried out for each protein as described below, and all 
proteins were then dialysed overnight, with buffer changes 2 h before and after the 
overnight dialysis. The components of dialysis buffer were as follows: 
 
Dialysis buffer components:     20 mM HEPES-KOH pH 7.4 
                                                  100 mM KCl 
                                                   5 % Glycerol  
                                                   UHP water 
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2.21.1 Purification of His-tagged I3 proteins 
His-tagged I3 proteins were purified at room temperature using His-Talon columns 
(Clontech). Cell pellet was resuspended in xTractor buffer containing Benzonase (1 µl 
per 2 ml of buffer) and Protease Inhibitor Coctail, EDTA-free (Roche) (1 tablet per 15 
ml of buffer) and lysed by sonication using a Branson probe 102C (5 pulses of 10 sec 
on, 10 sec off; performed on ice), then centrifuged at 27000 xg for 15 min (Beckman 
Avanti J-25I, JA17 rotor) at 4o C to separate soluble from insoluble proteins. 
Supernatant was collected and applied on the cartridge, which was previously 
equilibrated according to the manufacturer’s instructions. Using a syringe attached to 
the Luer Lock Adapter, the sample was passed through the column, the resin was 
washed with the Wash Buffer provided with the kit, and eluted by applying 5 column 
volumes of Elution Buffer. The 1 ml fractions of the purified protein were collected and 
analyzed by performing a Bradford assay (Bio-Rad Protein Assay, Bio-Rad 
Laboratories) (Bradford, 1976). Fractions were snap-frozen in a dry ice-EtOH bath, and 
stored at -80o C. 
 
2.21.2 Purification of GST-tagged eIF4G fragments 
GST-tagged eIF4G fragments (kind gift of Dr. Robert Schneider, NYU Langone 
Medical Center) were purified from BL21(DE3) cells at 4o C by using the B-Per GST 
Fusion Protein Spin Purification Kit (Pierce). Cell pellet was resuspended in cold PBS 
containing Benzonase (1 µl per 2 ml of PBS) and Protease Inhibitor Coctail, EDTA-free 
(Roche) (1 tablet per 15 ml of PBS), lysed by sonication using a Branson probe 102C (5 
pulses of 10 sec on, 10 sec off; performed on ice), and centrifuged at 27000 xg for 15 
min (Beckman Avanti J-25I, JA17 rotor) to separate soluble from insoluble proteins. 
Supernatant was collected and incubated with 1ml Immobilized Glutathione (provided 
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with the kit) at 4o C for 1 h, then centrifuged at 1200 xg (Sigma 1-15 PK) for 5 min at 4o 
C. The supernatant was removed and the gel slurry was resuspended with 0.25 ml Wash 
Buffer, transferred to a column provided with the kit, and centrifuged at 1200 xg for 2 
min at 4o C. Washing step was repeated once more, and the resin was then eluted using 
the Elution Buffer, according to the manufacturer’s instructions. The 1 ml fractions of 
the purified protein were collected and analyzed by performing a Bradford assay (Bio-
Rad Protein Assay, Bio-Rad Laboratories) (Bradford, 1976). Fractions were snap-frozen 
in a dry ice-EtOH bath, and stored at -80o C. 
 
2.21.3 Batch-purification of eIF4E 
Untagged human eIF4E was batch-purified from BL21(DE3) cells at 4o C. Cell pellet 
was resuspended in cold PBS containing Protease Inhibitor Cocktail, EDTA-free 
(Roche) (1 tablet per 15 ml of PBS), lysed by sonication using a Branson probe 102C (5 
pulses of 10 sec on, 10 sec off; performed on ice), and centrifuged at 27000 xg for 15 
min (Beckman Avanti J-25I, JA17 rotor) to separate soluble from insoluble proteins. 
Supernatant was collected and snap-frozen in a dry ice-EtOH bath, and stored at -80o C. 
When needed, lysates were thawed on ice, treated with benzonase and batch-purified by 
incubation with 7-Methyl GTP Sepharose 4B for 1h at 4o C. The resin was then washed 
several times to remove unbound debris. 
 
2.22 Generation of VacV mutant 
Deletion of the I3L gene was carried out using a novel application of the VAC-BAC/λ 
system in which the complete VacV genome is cloned in a bacterial artificial 
chromosome (BAC), and rescued by fowlpox virus, a distantly related poxvirus (Domi 
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and Moss, 2002). A two-step procedure was used to replace the I3L ORF of the VAC-
BAC plasmid with the ampicillin (Amp) resistance gene by homologous recombination 
in E.coli DH10B cells. In the first step I3L ORF was replaced with the Amp ORF. In 
the second step VAC-BAC ∆I3L plasmid was transfected into fowlpox virus-infected 
cells that are not permissive for fowlpox virus. 
 
2.22.1 Deletion of I3L ORF 
2.22.1.1 Primers and PCR 
To amplify the ampicillin ORF from the pET plasmid by PCR the following primers 
containing approximately 18 bp of the 5’ and 3’ end of the amp gene and 50 bp of 
homologous sequences flanking the region where I3L overlaps the I2L and I4L ORFs 
were used: 
Forward: AAAGTGAAAATATATATC ATTATATTACAAAGTACAA 
TTATTTAGGTTTATCTTGA AGACGAAAGGGCC 
Reverse: TCCGGAGACCCCATAAAT ACACCAAATATAGCGGC 
GTACAACTTATCCATGAG ATTATCAAAAAGG 
 
To confirm that ampicillin ORF replaced I3L ORF the following primers containing the 
I3L flanking sequences were used: 
Forward: CAAAGTACAATTATTTAGG 
Reverse: AATACACCAAATATAGCGG 
The conditions used for the PCR reactions are described in table 2.6 
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2.22.1.2 Preparation of electrocompetent VAC-BAC cells 
E.coli cells strain DH10B harboring VAC-BAC/λ plasmid (gift of A. Domi and B. 
Moss) needed to be specially treated in order to perform the efficient transformation 
through electroporation.  
 
2.22.1.2.1 Activation of the recombination system 
To induce expression of λ recombination genes in E.coli DH10B/VAC-BAC/λ, the 
protocol recommended by Domi and Moss (2005) was used. 50 ml of LB medium 
containing tetracycline (25 µg/ml) and chloramphenicol (34 µg/ml) was inoculated with 
500 µl of an overnight culture of E.coli DH10B/VAC-BAC/λ and incubated at 32o C 
until OD600 was approximately 0.6. Then, the culture was induced at 42o C for 45 min. 
The cells were chilled on ice for about 10 min. 
 
2.22.1.2.2 Cell wash 
After activation of the recombination system, 15 ml cell aliquots were collected by 
centrifugation at 4o C, 2200 xg for 10 min (Beckman Avanti J-25I, JA14 rotor). After 
discarding supernatant the pellet was washed 3 times with ice-cold 10 % glycerol in 
UHP water, and resuspended in 50 µl of the same solution. Electrocompetent cells were 
then snap-frozen in a dry ice-EtOH bath, and stored at -80o C 
 
2.22.1.3 Transformation of DH10B cells 
Electrocompetent E.coli DH10B cells harboring VAC-BAC/λ plasmid were thawed on 
wet-ice, and 50 µl of the cells was mixed with 1 ng of the PCR amplified DNA (Amp 
ORF containing the flanking sequences), then gently transferred into the pre-chilled on 
ice electroporation (EP) cuvettes (Gene Pulser Cuvette, 0.1 cm electrode, Bio-Rad 
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Laboratories). EP cuvettes were kept on ice for 5min then dried and placed in the 
electroporator. Transformations were performed using a Gene Pulser II Electroporator 
(Bio-Rad Laboratories). The following EP parameters were used: 
 
         EP parameters:       200 Ω 
                                        2.0 kV 
                                        25 µF 
                                        10-12 MSec 
Immediately after electroporation cells were diluted in 1 ml of SOC medium (Sigma), 
mixed gently by pipetting up and down and transferred to the 30 ml tube. Cells were 
incubated at 37o C shaking incubator for 1 h. Then, 200 µl cultures were plated on LB 
Agar plates containing Amp and chloramphenicol and incubated at 37o C overnight for 
selection of efficiently transformed cells.  
 
2.22.1.4 BAC purification  
In order to recover VAC-BAC/λ plasmid from DH10B cells, the BAC purification was 
performed using the QIAGEN Large-Construct Kit, which is based on the QIAGEN 
Anion-Exchange Resin.  
The single colonies of the wildtype DH10B/VAC-BAC/λ  cells and the recombinant 
DH10B/VAC-BAC∆I3L/λ  were used to inoculate a starter culture of 3 ml LB medium 
containing selective antibiotics (Amp and chloramphenicol). Cultures were incubated at 
37o C for 6-8 h with vigorous shaking (225 rpm). Then, 0.5 ml of the starter culture was 
inoculated into 500 ml selective LB medium, and grown at 37o C for 16 h with vigorous 
shaking. Cells were harvested by centrifugation at 6000 xg for 15 min at 4o C (Beckman 
Avanti J-25I, JA17 rotor), and purified according to the manufacturer’s instructions. 
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Basically, the protocol starts with modified alkaline lysis and integrated ATP-dependent 
exonuclease digestion, which ensures selective removal of contaminating genomic 
DNA. Following digestion, BAC was then bound to QIAGEN Resin under appropriate 
low-salt and pH conditions. RNA, proteins, dyes, and low-molecular-weight impurities 
were removed by a medium-salt wash. BAC was eluted in high-salt buffer and then 
concentrated and desalted by isopropanol precipitation. DNA was then diluted in TE 
buffer, measured on Nanodrop and stored at 4o C. 
 
2.22.2 Rescue of infectious virus 
To recover the recombinant virus BSC40 cells were infected with 0.1 PFU per cell of 
the helper fowlpox virus (FPV) to provide the transcription system, as infection cannot 
be initiated with viral DNA alone. At 2 hpi cells were transfected with 1 µg of the 
VAC-BAC or VAC-BAC-∆I3L plasmid using Fugene HD Transfection Reagent 
(Roche) according to the manufacturer’s instructions. Transfected cells were incubated 
at 37o C until the plaques could be seen (5-7 days). Cells were then fixed in 
formaldehyde as outlined before. 
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3.1 Kinetics of infection in a variety of cell lines 
Three different cell types were used in this study:  
           (1) normal human diploid fibroblasts (NHDFs);  
           (2) human embryonic kidney 293 cells (HEK-293);  
           (3) transformed monkey kidney cells (BSC40s).  
 
The kinetics of VacV infection needed to be established in each cell type in order to 
perform further experiments.  
Cells were cultured on 35 mm dishes and mock-infected or infected with VacV with 
multiplicity of infection (moi) 5. After indicated time post infection (8, 16 or 25 hours) 
cells were metabolically labeled with [35S]methionine-cysteine for 1 h, and lysed in 
Laemmli buffer. Cell extracts were fractionated by SDS-PAGE and gels were dried and 
exposed to x-ray film at -80o C. First, comparison of transformed lines (HEK-293 and 
BSC40s) indicated similar kinetics in each cell line (Fig. 3.1.1). At 8 hours post 
infection (hpi) significant inhibition of cellular protein synthesis was observed, while 
more complete host shut-off and robust translation of late viral proteins was evident by 
16 hpi in both cell lines. By 25 hpi the patterns of protein synthesis were unchanged but 
had declined in intensity, demonstrating that late phases of infection were reached by 16 
hpi in these cells. 
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Figure 3.1.1 Autoradiograph illustrating the time-course of VacV protein synthesis in two 
transformed cell lines used in this study. Cells were metabolically labeled with [35S]methionine-
cysteine for 1 h prior to sampling. Molecular weight markers are indicated to the left. (M = 
mock) 
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The previous experiments were performed in transformed cells. However, to simulate 
the metabolic state of cells in the body more closely, we often use normal human 
diploid fibroblasts (NHDFs) and serum-starvation to growth-arrest these cells. This 
allows us to observe activation of signaling pathways and translation complexes that 
might be induced during viral infection, but also affects the kinetics of infection (Walsh 
et al., 2008). 
As such, cycling and serum-starved NHDFs were mock-infected or VacV-infected at 
moi 5. Extracts of cells metabolically labeled with [35S]methionine-cysteine were made 
at 16 and 25 hpi, and analyzed as described above. In cycling NHDFs, late stage 
infection, as determined by host shut-off and viral protein synthesis patterns, were 
reached by 16hpi, similar to transformed lines.  In contrast to cycling cells, in serum-
starved NHDFs the highest level of viral protein synthesis was detected at 24-25 hpi 
(Fig. 3.1.2 a), while at 16 h host shut-off was incomplete and some intermediate protein 
synthesis remained detectable (marked by asterix). This indicates that reducing the cells 
metabolism by starvation extends the replication cycle of VacV. As can be seen in Fig. 
3.1.2 b, western blotting showed that in serum-starved cells viral protein production 
reached the intermediate phase by 16 hpi with complete accumulation of the 
intermediate protein I3 (Fig. 3.1.2 c). However, while some structural proteins were 
produced, they continued to increase in abundance by 25 hpi, while others were only 
detected in 25 h but not 16 h samples.  
The majority of further research was carried out using starved NHDFs infected for 16 or 
24-25 hours, to analyze the middle or late phase of infection.  
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Figure 3.1.2 (a) Comparison of the kinetic of VacV infection in cycling and serum-starved 
NHDFs. Intermediate protein synthesis still detectable in serum-starved but not cycling cells at 
late stages of infection (16 hpi) are marked with asterix. Molecular weight markers are indicated 
to the left.  
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Figure 3.1.2 (b, c) Immunoblots illustrating the accumulation of total VacV proteins (b) and the 
intermediate protein I3 in serum-starved NHDFs (c) Molecular weight markers are indicated to 
the left. (M = mock, V16 = VacV-infected for 16 h, V25 = VacV-infected for 25 h) 
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3.2 Analysis of signaling and translation during vaccinia virus infection 
3.2.1 Manipulation of the cellular PI3K pathway by vaccinia virus 
It has recently been shown that VacV activates mTORC1 to phosphorylate 4E-BP1 
(Walsh et al., 2008). However, whether VacV activates mTORC1 directly or induces 
upstream signaling remained unknown so far. In this study we aimed to investigate the 
mechanism used by VacV to manipulate the PI3K/Akt/mTOR pathway that leads to the 
activation of mTORC1 and inhibition of the translational repressor 4E-BP1. To assign a 
role for the PI3 kinase in VacV translational strategies, the phosphorylation of its 
downstream effectors in the presence of specific inhibitors that block PI3K and 
mTORC1 (LY294002 and rapamycin, respectively) (Fig. 3.2.1) was evaluated.  
Serum-starved normal human diploid fibroblasts (NHDFs) were pre-treated for 1 hour 
with equal volumes of the following inhibitors: dimethyl sulfoxide (DMSO) solvent 
control, 40 µM3 LY294002 (LY), and 2 µM4 rapamycin. Cells were then uninfected or 
infected with 10 PFU VacV, and phosphorylation of selected proteins was measured at 
16 hpi by immunoblotting of whole cell extracts using specific antisera against 
phosphorylated forms of Akt (P-Akt) and ERK (P-ERK), or total forms of Akt (T-Akt), 
p70S6K and 4E-BP.  
Interestingly, VacV caused increased phosphorylation of Akt in infected cells, while 
LY294002 completely blocked this process (Fig. 3.2.2). In addition, inhibitors did not 
affect the total level of Akt. The fold change (F.C.) in Akt phosphorylation was 
quantified by densitometry and averaged, and then presented relative to uninfected 
                                                 
3
 High concentration (40µM) of LY294002 was used because high doses of this drug were shown to 
inhibit both class I and class II of PI3 kinases, while low doses (2µM) inhibit only class I (Vlahos, 1994). 
4
 High concentration (2µM) of rapamycin was used to make sure mTORC1 activity is completely 
inhibited.   Concentrations are normally between 100-200 nM. 
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levels, arbitrarily set at 1. LY294002 also inhibited phosphorylation of mTOR 
downstream substrates: p70S6 kinase (p70S6K) and 4E-BP1, which are activated and 
phosphorylated in VacV-infected cells (Fig. 3.2.3). Similar effects of LY294002 were 
observed in uninfected, serum-starved NHDFs (not shown). Multiple phosphorylation 
of 4E-BP1 and p70S6K was detected by mobility shift analysis with high-percentage 
SDS-PAGE gels (hyper- and hypophosphorylated forms are indicated). The mTORC1 
inhibitor, rapamycin, blocked VacV-induced phosphorylation of p70S6K and 4E-BP1, 
as reported previously (Walsh et al., 2008), but did not reduce Akt phosphorylation 
which lies upstream of mTORC1 (Fig. 3.2.3).  
The abundance of eIF4E, used as a loading control, remained unaltered and inhibitors 
did not significantly affect phosphorylation of ERK, a kinase outside of the PI3K 
pathway which phosphorylates the eIF4E kinase MNK1, and is known to be activated 
by VacV. This indicates the specificity of PI3K and mTOR inhibitors. The fold change 
(F.C.) in ERK phosphorylation was quantified by densitometry and averaged, and then 
presented relative to uninfected levels, arbitrarily set at 1 (Fig. 3.2.4).  
These results reveal the importance of the host PI3 kinase in VacV-induced downstream 
signaling to mTORC1 and its substrates, 4E-BP1 and p70S6K. Therefore, we further 
examined the impact of PI3K inhibition on the formation of eIF4F complexes.  
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Figure 3.2.1 Simplistic PI3K pathway including key factors involved and points at which 
inhibitors function. T-bars represent suppression. Circled P’s represent phosphorylation events.  
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Figure 3.2.2 (a) Western blot analysis of AKT phosphorylation in mock (M) and VacV-infected 
cells (VACV) in a presence of indicated inhibitors. (F.C.= fold change measured by 
densitometry; LY = LY294002; Rapa = rapamycin)  
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Figure 3.2.2 (b) Densitometry analysis of AKT phosphorylation in mock and VacV-infected 
cells in the presence of indicated inhibitors. (M = mock; V = VacV-infected; LY = LY294002, 
Rapa = rapamycin) 
P-AKT F.C.       1          3.3         -         3.6  
   M                   VACV 
 P-AKT 
T-AKT 
 
DMSO      DMSO        LY           RAPA 
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Figure 3.2.3 Immunoblot illustrating the LY294002 and rapamycin effects on mTOR’s 
substrates phosphorylation in mock (M) and VacV-infected cells. (LY = LY294002, Rapa = 
rapamycin) 
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Figure 3.2.4 (a) Immunoblot illustrating phosphorylation of ERK in mock (M) and VacV-
infected cells in the presence of indicated inhibitors. (F.C. = fold change measured by 
densitometry; LY = LY294002; Rapa = rapamycin) 
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Figure 3.2.4 (b) Densitometry analysis of ERK phosphorylation in mock and VacV-infected 
cells in the presence of indicated inhibitors. (M = mock; V = VacV-infected; LY = LY294002, 
Rapa = rapamycin) 
P-ERK F.C.           1        22.7        20.1      23.9  
   M                   VACV 
DMSO      DMSO        LY           RAPA 
P-ERK 
eIF4E 
 104 
3.2.2 The effect of LY294002 and rapamycin on eIF4F complex formation in 
VacV-infected cells 
3.2.2.1 The levels and binding of eIF4G, eIF4E and 4E-BP1 
To examine the effect of LY294002 and rapamycin on the formation of eIF4F complex 
during VacV-infection, 7-methylguanosine cap binding assays were carried out. Serum-
starved NHDFs were uninfected or infected with 10 PFU VacV in the presence of 
DMSO, 40 µM LY294002 or 2 µM rapamycin, and 16 hpi the soluble cell extract was 
made. eIF4E was recovered from the lysate by 7-methylguanosine GTP batch 
chromatography, as described in Section 2.2.8, and samples were fractionated by SDS-
page and probed with antisera towards eIF4E, eIF4G and 4E-BP1 to establish the 
composition of eIF4E-bound complexes in each sample. 
In mock-infected cells both eIF4G and 4E-BP1 naturally bound to individual eIF4E 
molecules and were recovered on cap resin. VacV significantly increased the amount of 
eIF4G in eIF4E-bound complexes and blocked the binding of 4E-BP1, as expected and 
reported previously (Walsh et al., 2008). However, inhibition of PI3K resulted in a 
strong recruitment of 4E-BP1 to eIF4E and inhibition of eIF4G binding (Fig. 3.2.5 a). In 
addition, rapamycin only slightly affected binding of eIF4G, but did prevent 4E-BP1 
phosphorylation by VacV, which can be observed in input samples as well. The levels 
of eIF4E remained constant. The fold change (F.C.) in eIF4G and 4E-BP1 binding was 
quantified by densitometry and averaged, and then presented relative to uninfected 
levels, arbitrarily set at 1 (Fig. 3.2.5 b, c).  
These results demonstrated that by 16 hpi of serum-starved NHDFs, VacV increased 
levels of eIF4F in a PI3K-dependent manner. 
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Figure 3.2.5 (a) Immunoblot illustrating eIF4F complex formation in mock (M) and VacV-
infected cells in the presence of indicated inhibitors. (LY = LY294002, Rapa = rapamycin)  
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Figure 3.2.5 (b) Densitometry analysis of eIF4G binding to eIF4E in mock and VacV-infected 
cells in the presence of indicated inhibitors. (M = mock; V = VacV-infected; LY = LY294002, 
Rapa = rapamycin) 
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Figure 3.2.5 (c) Densitometry analysis of 4E-BP1 binding to eIF4E in mock and VacV-infected 
cells in the presence of indicated inhibitors. (M = mock; V = VacV-infected; LY = LY294002, 
Rapa = rapamycin) 
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3.2.2.2 The effects of inhibitors on the abundance of 4E-BP1 in VacV-infected 
NHDFs 
VacV infection has been shown to decrease the abundance of 4E-BP1 in a rapamycin-
sensitive manner (Walsh et al., 2008). We therefore examined effects of PI3K inhibition 
on 4E-BP1 abundance in infected cells.  
The total levels of 4E-BP1 in the samples described in the previous section were 
analyzed by immunoblotting using low-percentage (7.5 %) gel and with anti-4E-BP1 
antiserum. Low percentage gel was used to prevent the resolution of multiple 
phosphorylated 4E-BP1 isoforms, and monitor the steady-state levels of 4E-BP1. This 
experiment demonstrated that in fact rapamycin blocked 4E-BP1 degradation in VacV-
infected cells; however, LY294002 dramatically increased the abundance of this 
repressor bringing it to a higher level than observed in mock-infected cells (Fig. 3.2.6 
a). The fold change (F.C.) of 4E-BP1 levels was quantified by densitometry and 
averaged, and then presented relative to uninfected levels, arbitrarily set at 1 (Fig. 3.2.6 
b). 
 
 
 
 
 
 
 
 
 
 
 108 
 
Figure 3.2.6 (a) Immunoblot illustrating the total 4E-BP1 levels in mock (M) and VacV-
infected cells in the presence of indicated inhibitors. (F.C. = fold change measured by 
densitometry; LY = LY294002, Rapa = rapamycin) 
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Figure 3.2.6 (b) Densitometry analysis of 4E-BP1 accumulation in VacV-infected cells in the 
presence of indicated inhibitors. (M = mock; V = VacV-infected; LY = LY294002, Rapa = 
rapamycin) 
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3.2.2.3 The effect of PI3K and mTORC1 inhibitors on eIF4E phosphorylation in 
VacV-infected cells 
Since the PI3K inhibitor was found to significantly affect eIF4G association with eIF4E, 
the effect of LY294002 on eIF4E phosphorylation was examined. eIF4E is 
phosphorylated as part of eIF4F complex by eIF4G-associated kinase Mnk1/2, and this 
process is mediated by the MAPK/Erk signaling pathway (Wang et al., 1998; Scheper et 
al., 2001). Although the role of eIF4E phosphorylation in cellular translation has not 
been fully explored, it appears to play an important role in VacV protein synthesis. 
Walsh et al. (2008) demonstrated that inhibition of Mnk1 by CGP57380 significantly 
decreased VacV replication. Here, we examined if inhibition of PI3 kinase by 
LY294002 also impairs eIF4E phosphorylation.  
Serum-starved NHDFs were pre-treated with LY294002 or rapamycin for 1 hour, then 
mock or VacV-infected at moi 10, and lysed in Laemmli buffer at 16 hpi. The lysates 
were resolved by isoelectric focusing to separate the phosphorylated and 
unphosphorylated forms of eIF4E and analyzed by immunoblotting using anti-eIF4E 
antiserum. As shown in Fig. 3.2.7, VacV infection enhanced phosphorylation of eIF4E, 
whereas LY294002 significantly reduced this event due to the collapse of eIF4F 
complexes in which eIF4E phosphorylation occurs. Rapamycin did not significantly 
affect eIF4E phosphorylation. 
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Figure 3.2.7 Immunoblot illustrating eIF4E phosphorylation in mock (M) and VacV-infected 
cells in the presence of indicated inhibitors. Migration of phosphorylated (P-eIF4E) and 
hypophosphrylated (eIF4E) eIF4E is indicated to the left. (LY = LY294002, Rapa = rapamycin) 
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3.2.2.4 The effect of the PI3K and mTORC1 inhibitors on eIF4G phosphorylation 
in VacV-infected cells 
To investigate if other factors might be involved in eIF4F disruption caused by 
LY294002 in VacV-infected cells, the phosphorylation of eIF4G was examined. eIF4G 
is thought to be phosphorylated by a number of kinases including mTORC1 (Raught et 
al., 2000; Ling et al., 2005). Cell extracts were analyzed by western blotting using 
antisera against the total (T-eIF4G) or phosphorylated (P-eIF4G) forms of eIF4G. The 
results demonstrated that while the total levels of eIF4G remained constant, VacV 
evidently increased the accumulation of phosphorylated eIF4G (Fig. 3.2.8). Treating the 
cells with mTORC1 inhibitor prevented this stimulation maintaining phosphorylation at 
basal uninfected levels, whereas inhibition of PI3 kinase resulted in only modestly 
decreased eIF4G phosphorylation compared to uninfected levels. As such, dramatic loss 
of eIF4G phosphorylation did not occur specifically in LY294002-treated samples and 
is unlikely to contribute to the collapse of eIF4F. 
 
 
 
Figure 3.2.8 Immunoblot illustrating eIF4G phosphorylation in mock and VacV-infected cells 
in the presence of indicated inhibitors. (LY = LY294002, Rapa = rapamycin) 
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3.2.3 The effect of LY294002 and rapamycin on cellular stress response in VacV-
infected cells 
As mentioned before (section 1.2.2), initiation factor eIF2 catalyses Met-tRNAf  binding 
to the 40S ribosomal subunit during the formation of the ternary complex. eIF2 consists 
of three subunits: α, β, and γ. Phosphorylation of the smallest (α) subunit can be caused 
by physiological stresses such as heat shock or virus infection, and leads to disruption in 
overall protein synthesis or cell death by apoptosis (Clemens, 2001). Therefore, 
increased phosphorylation of eIF2α is considered one of the indicators of cellular stress 
and/or apoptosis. Another such an indicator is thought to be cleavage of eIF4G, which is 
an early event in apoptosis and results in the production of modified eIF4F complex 
containing eIF4E, eIF4A, and the central fragment of eIF4G instead of the full length 
(Morley, 2001).  
In the previous experiments no changes in eIF4G abundance were observed, suggesting 
that LY294002 was not inducing a cellular stress response. To further determine 
whether or not the observed LY294002 effect involves the cellular stress responses, the 
phosphorylation of eIF2α was examined. Serum-starved NHDFs were infected with 10 
PFU VacV per cell in the presence of DMSO, LY294002 or rapamycin. At 16 hpi cells 
were lysed in Laemmli buffer and analyzed by immunoblotting using antisera against 
the phosphorylated forms of eIF2alpha (P- eIF2α). The results, illustrated in Fig. 3.2.9, 
did not show noticeable changes in the total eIF2α phosphorylation, demonstrating that 
the observed effects of LY294002 and rapamycin seem not to be a result of cellular 
stress responses.  
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Figure 3.2.9 Immunoblot illustrating eIF2α phosphorylation in mock (M) and VacV-infected 
cells in the presence of indicated inhibitors. (LY = LY294002, RAPA = rapamycin) 
 
 
Furthermore, looking at cells morphology in a phase contrast microscope confirmed that 
cells were indeed infected characterized by long cellular protrusions and cell-cell 
detachment. However, LY294002-treated cultures actually exhibited a reduced 
cytopathic effect compared to cells treated with DMSO (Fig. 3.2.10). This suggested 
that LY294002 protected infected cells from morphological changes caused by the 
virus, and that VacV could not carry out its normal replication cycle in cells where PI3 
kinase was inhibited. In contrast, rapamycin did not protect the cells.  
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Figure 3.2.10 Phase contrast microscopy photographs of mock and VacV-infected serum-
starved NHDFs treated with LY294002 or rapamycin. 
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3.2.4 The effect of LY294002 and rapamycin on VacV protein synthesis 
Next, the effect of PI3K and mTORC1 inhibitors on total vaccinia virus protein 
synthesis was examined. Serum-starved NHDFs were mock- or VacV-infected in the 
presence of inhibitors, and at 16 hpi metabolically labeled with [35S] 
methionine/cysteine for 1 hour. Then cells were lysed in Laemmli buffer and 
fractionated by SDS-PAGE; the gels were dried and exposed to X-ray film at -80o C or 
analyzed by immnoblotting using antiserum against vaccinia virus. As observed in 
Figure 3.2.11, the inhibition of PI3K had a huge effect on the protein synthesis in 
infected cells. The translational rates were significantly suppressed even at high input 
doses of the virus, suggesting that viral proteins could not be efficiently produced in the 
presence of LY294002, while rapamycin did not affect protein synthesis. 
Immunoblotting of the same samples using antiserum against VacV confirmed the 
inhibition of protein production by LY294002.  
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Figure 3.2.11 The effect of LY294002 and rapamycin on VacV translational rates. Growth-
arrested NHDFs were mock or VacV-infected in the presence of DMSO, LY294002 or 
rapamycin. Cells were metabolically labeled with [35S]methionine-cysteine, then samples were 
resolved by SDS-PAGE and exposed to x-ray film (on the left) or analyzed by immunoblotting 
(on the right).  
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3.2.5 The LY294002 effect on the production of infectious virus 
We then examined the production of infectious virus in cells treated with inhibitors. 
6x105 NHDFs were infected with 10 PFU VacV per cell in the presence of DMSO, 
rapamycin or LY294002, and at 18 hpi the virus was harvested by repeated freeze/thaw 
cycles to disrupt cellular membranes and release the virus. Infectious virus was 
measured by diluting the lysates and infecting BSC40 cells. The virus titer was 
quantified by plaque assay and illustrated on the graph (Fig. 3.2.12). LY294002 clearly 
reduced the production of infectious virus up to 48-fold, which again confirmed the 
importance of PI3 kinase in VacV replication. Similar to the previous results, rapamycin 
did not affect VacV life cycle significantly, reducing viral titers by only 3-fold. The 
assay was repeated several times giving comparable results each time. 
 
 
Figure 3.2.12 Titration of infectious virus production in the presence of DMSO, LY294002 
(LY) or rapamycin (Rapa). 
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3.2.6 Investigation of apoptosis in LY294002-treated cells infected with VacV 
After publishing the results described above (Zaborowska and Walsh, 2009), a 
subsequent paper showed apoptotic effects of LY294002 in mouse A31 cell line 
infected with vaccinia or cowpox virus (Soares et al., 2009). As we had used serum-
starved human cells, we then examined whether apoptosis occurred in other cell types 
treated with this PI3K inhibitor. 
In our lab we had noticed before that the Akt inhibitor, Akt I, induces extensive 
apoptosis in human cells. This served as a control for detection of apoptosis in cells 
treated with LY294002. Three different cell lines including normal human cells 
(NHDFs), transformed human cells (HEK-293) and transformed monkey cells 
(BSC40s) were pretreated with DMSO, LY294002 or Akt inhibitor (Akti) for one hour, 
and then mock-infected or infected with VacV. The next day cells morphology was 
analyzed by phase microscopy and photographed (Fig. 3.2.13 a-c). Examination of the 
images clearly shows that cells treated with Akt inhibitor underwent apoptosis in all 
mock- and VacV-infected lines. In contrast, the PI3K inhibitor protected cells from 
morphological changes that suggested apoptotic death. The results were equal in all 
three analyzed cell lines, normal and transformed human cells and transformed monkey 
cells, suggesting that apoptosis caused by LY294002 in VacV-infected cells described 
by Soares et al. (2009) is specific only for certain cell types such as those derived from 
mice. 
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Figure 3.2.13 (a) Phase contrast microscopy photographs of mock (M) and VacV-infected  (V) 
cycling NHDFs treated with DMSO, LY294002 and Akti. 
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Figure 3.2.13 (b) Phase contrast microscopy photographs of mock (M) and VacV-infected (V) 
HEK-293 cells treated with DMSO, LY294002 and Akti. 
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Figure 3.2.13 (c) Phase contrast microscopy photographs of mock (M) and VacV-infected (V) 
BSC40 cells treated with DMSO, LY294002 and Akti.  
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To examine the effect of the inhibitors, LY294002 and Akti on total VacV protein 
production, HEK-293 cells were pretreated with the inhibitors for 1 hour before 
infection with VacV. At 16 hpi cell lysates were fractionated on SDS-PAGE gel and 
probed for expression of viral genes by western blot analysis using antibodies against 
VacV proteins. As shown in Fig. 3.2.14, the VacV protein levels were reduced by 
LY294002, as observed in serum-starved NHDFs, while in the presence of Akti neither 
cellular nor viral proteins were detected suggesting that virus replication could not take 
place, most likely on account of the cells death. In addition, LY294002 blocked Akt 
phosphorylation demonstrating that the inhibitor was effective (Fig. 3.2.14).  
Finally, the influence of LY294002 and Akti on PARP, an indicator of apoptosis, was 
examined. PARP (Poly [ADP-ribose] polymerase) is one of the targets for caspase-3 
and caspase-7, the execution caspases that play essential roles in apoptosis. Once PARP 
and other substrates are cleaved by caspases, the cytoplasmic endonucleases are 
activated leading to degradation of nuclear material and cytoskeletal proteins (Elmore, 
2007).  
The samples described above were fractionated on SDS-PAGE gel and analyzed by 
immunoblotting against PARP and Caspase-7. As shown in figure 3.2.14, LY294002 
did not cause PARP cleavage or caspase-7 processing in mock- or VacV-infected cells; 
while inhibition of Akt clearly resulted in PARP cleavage and apoptotic death of both 
mock-infected and VacV-infected cells.  
These results demonstrated that inhibition of PI3K, as contrasted with the effects of 
Akti, does not cause apoptosis in a number of different cell types infected with vaccinia 
virus.  
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Figure 3.2.14 Immunoblots illustrating the effect of LY294002 and Akti on VacV protein levels 
(the upper part of image) and PARP cleavage and caspase-7 processing (lower part of image) in 
mock-infected (Mock) and VacV-infected (VV) HEK-293 cells.  
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3.2.7 The role of mTOR in VacV protein synthesis 
As demonstrated before (sections 3.2.2.1, 3.2.2.2), the effect of LY294002 on 4E-BP1 
and P-Akt was distinct from rapamycin; it caused a strong accumulation of 4E-BP1 and 
inhibited Akt phosphorylation in VacV-infected cells. This suggests that other unknown 
branches of the PI3K pathway may be involved in 4E-BP1 regulation and eIF4F 
formation. Notably, rapamycin only partially inhibits mTORC1 and does not affect 
mTORC2 complexes. In contrast to rapamycin, the recently discovered inhibitor Torin1 
potently inhibits both mTORC1 (including rapamycin-sensitive and rapamycin-
insensitive mTORC1) and mTORC2 complexes (Thoreen et al., 2009). We therefore 
tested its influence on VacV infection in primary human cells. Figure 3.2.15 shows that 
Torin1 (50nM) blocked the phosphorylation of Akt and caused 4E-BP1 accumulation in 
VacV-infected cells. This was also observed in cells treated with two distinct inhibitors 
of PI3K, LY294002 (40 µM) and wortmannin (10 µM5) (Walker et al., 2000). 
 
 
 
 
 
 
 
Figure 3.2.15 Immunoblot illustrating the effect of Torin1 on Akt phosphorylation and 4E-BP1 
phosphorylation and accumulation. 
 
                                                 
5
 10µM wortmannin is considered a high concentration that inhibits PI3K class I, II and III, while low 
concentrations (250 nM) inhibit only class I of PI3K (Vlahos, 1994). However, for longer experiments 
higher concentrations are also necessary as wortmannin is unstable. 
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As Torin1 reproduced the effects of PI3K inhibitors on 4E-BP1 dephosphorylation and 
accumulation, 7-methyl GTP sepharose chromatography assay was carried out to look 
at the influence of Torin1 on eIF4F complex formation. Serum-starved NHDFs were 
pretreated with DMSO or 50 nM Torin1 for 1 hour, then mock-infected or infected with 
10 PFU VacV per cell for 18 hours. Cap-binding eIF4E and levels of associated eIF4G 
were examined by western blotting. The results showed that, similarly to LY294002, 
Torin1 disrupted the eIF4F complex in both mock-infected and VacV-infected cells 
(Fig. 3.2.16).  
 
 
Figure 3.2.16 Immunoblot illustrating the effect of Torin1 on eIF4F complex formation in VacV-
infected (VV) serum-starved NHDFs.  
 
 
Examining rates of translation in VacV-infected serum-starved NHDFs at 18 hpi 
demonstrated that, although Torin1 reduced viral protein synthesis more efficiently than 
rapamycin, its effects were not as dramatic as might be expected, given the robust 
inhibition of eIF4F formation by Torin1 (Fig. 3.2.17 a).  
In addition, viral protein accumulation at 18 hpi was not affected by Torin1 to the same 
extent as by LY294002 or wortmannin (Fig. 3.2.17 b). Two different concentrations of 
the PI3K inhibitors were used in this experiment. Two distinct concentrations of 
wortmannin (10 µM and 30 µM) reduced VacV protein synthesis to similar levels, and 
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similar to this, high concentration of LY294002 (40 µM), which inhibits both class I 
and class II of the PI3K (Vlahos, 1994), also reduced VacV protein levels. In contrast, 
low concentrations of LY294002 (2 µM), which did not completely block Akt or 4E-
BP1 phosphorylation (not shown), were more similar to the effects of rapamycin. 
However, the effects of Torin1 were stronger compared to rapamycin demonstrating 
that eIF4F does play a role in the synthesis of VacV proteins, but that other functions of 
PI3K were also important in VacV replication. 
Similar effects were obtained when performing titration of infectious virus production 
in the presence of inhibitors. 6x105 NHDFs were infected with 10 PFU VacV per cell in 
the presence of DMSO, 2 µM rapamycin, 50 nM Torin1 or 40 µM LY294002, and at 18 
hpi the virus was harvested by repeated freeze/thaw cycles to disrupt cellular 
membranes and release the virus. Infectious virus was measured by diluting the lysates 
and infecting BSC40 cells. The virus titer was quantified by plaque assay and illustrated 
on the graph (Fig. 3.2.17 c), which clearly shows the increasing effect of each inhibitor 
on the production of infectious virus, in agreement with their effects on viral protein 
production.  
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Figure 3.2.17 (a) Autoradiograph showing the effect of rapamycin and Torin1 on the total 
VacV protein synthesis. Cells metabolically labeled with [35S]methionine-cysteine from 15-16 
hpi. Molecular weight markers are indicated to the left. 
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Figure 3.2.17 (b) Immunoblot comparison of the effect of Torin1, rapamycin, and PI3K 
inhibitors on the total VacV protein accumulation in serum-starved NHDFs at 18 hpi. Samples 
analyzed by western blotting using anti-VacV antiserum. (Rapa = rapamycin, Wort = 
wortmannin, LY = LY294002) 
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Figure 3.2.17 (c) Titration of infectious virus production in the presence of 1- DMSO, 2- 
rapamycin, 3- Torin1, and 4- LY294002. 
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3.3 Redistribution of translation factors during VacV infection  
In the beginning of our investigation on redistribution of host translation factors caused 
by VacV, we speculated that a specific viral protein or cellular protein induced by the 
virus might associate with eIF4F and cause its rearrangement in infected cells. 
Therefore, we screened components of the eIF4F complex in VacV-infected cells to 
search for such a protein. This was done initially using serum-starved NHDFs infected 
for 16 hours to perform immunoprecipitation assays at the mid-phase of infection. 
 
3.3.1 Identification of a viral protein associated with eIF4G in VacV-infected 
cells 
The screening of translation factors was performed by metabolically labeling uninfected 
and VacV-infected cells from 15-16 hpi, and then immunoprecipitation of complexes 
from cell extracts using specific antibodies against eIF4G and PABP. Afterwards the 
immune complexes were resolved by SDS-PAGE and fixed, dried gels were exposed to 
x-ray film. Analysis of the detected proteins actively translated during labeling time in 
VacV-infected cells showed a 34-kDa protein associated with eIF4G that was not 
present in mock-infected cells (Fig. 3.3.1 a). In addition, immunoprecipitating eIF4G 
from cells infected for 24 hours demonstrated that the signal intensity from this 
polypeptide decreased significantly (Fig. 3.3.1 b), suggesting that it was no longer 
synthesized or no longer associated with eIF4G at this point.       
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a.                                                                          b. 
                   
 
Figure 3.3.1 Autoradiographs of metabolically labeled starved NHDFs illustrating (a) an 
unknown 34-kDa protein associated with eIF4G at 16 hpi, and (b) its signal intensity at 16 and 
24 hpi (to the right) Molecular weight markers are indicated to the left. (M = mock, V = VacV-
infected, PI = pre-immune serum, 4G = anti-eIF4G IP, 16 = 16hpi, 24 = 24hpi) 
 
We further examined whether this protein was present in anti-PABP immune 
complexes. PABP is an abundant RNA-binding protein involved in different cellular 
processes including translational control, but in VacV-infected cells the majority of 
PABP is distributed to different areas of the cell distinct from eIF4G (Mangus et al., 
2003; Walsh et al., 2008). Immunoprecipitation of anti-eIF4G and anti-PABP immune 
complexes clearly demonstrated that the 34-kDa protein was only detected at significant 
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levels in anti-eIF4G immune complexes, and it did not visibly associate with anti-PABP 
immune complexes (Fig. 3.3.2).  
 
 
 
Figure 3.3.2 Autoradiograph illustrating metabolically labeled starved NHDFs and the specific 
association of the 34-kDa protein with eIF4G factor at 16 hpi (4G). (M = mock, V = VacV-
infected) 
 
Looking at eIF4E abundance by western blotting in immunoprecipitated eIF4G- and 
PABP-complexes in infected serum-starved NHDFs showed that this cap-binding 
protein was recovered with eIF4G in large amounts, but only very small amounts of 
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eIF4E were noticed in anti-PABP immune complexes, despite efficient antigen recovery 
(Fig. 3.3.3). This demonstrated that, of the total amount of this abundant multifunctional 
cellular protein, only small amounts of PABP were associated with eIF4F complexes in 
these cells. In the case of infected cells, PABP did not appear to associate with large 
amounts of either eIF4E or the 34-kDa protein found associated with eIF4G. Also, at 16 
h point where eIF4F assembly begins an increase in eIF4E recovery is seen in both 
eIF4G and PABP immune complexes from infected cells. 
. 
 
 
Figure 3.3.3 Immunoblot illustrating anti-eIF4G and anti-PABP complexes immunoprecipitated 
from infected serum-starved NHDFs. (M = mock, V = VacV-infected) 
 
To identify the unknown 34-kDa protein, BSC40 cells were mock-infected or infected 
for 16 h. Nuclease-treated soluble cell extracts were prepared and immunoprecipitated 
with anti-eIF4G antiserum. Immune-complexes were resolved by SDS-PAGE, and the 
gels were silver-stained as described in section 2.2.12. A specific band present only in 
infected samples and migrating at 34-kDa was detected (Fig. 3.3.4 a). The band was cut 
out and analyzed by mass spectrometry. During the analysis in various independent 
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experiments an average of 4-6 peptides were identified, all of which corresponded to the 
VacV-encoded ssDNA-binding phosphoprotein I3 (GI no. 66275869), with sequence 
coverage ranging from 18.2-23 %. A sample MS/MS spectrum is shown in figure 3.3.4 
b. 
I3 protein is encoded by the VacV I3L gene, and has previously been shown to be an 
early-to-intermediate stage protein (Rochester and Traktman, 1998), which explains our 
observation that it is actively synthesized and detected in eIF4G immune complexes at 
intermediate, but not late stages of infection (Fig. 3.3.1 b).  
 
 
Figure 3.3.4 (a) Protein identification: representative image from silver-stained gel, with an 
asterix indicating the 34-kDa protein in question. (M = mock, V = VacV-infected) 
 
 
 
 
 
 
 
 
   M             V 
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Figure 3.3.4 (b) Protein identification: a sample MS/MS spectra of a peptide from I3. 
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3.3.2 A non-immune based assay to examine I3 association 
To verify the interaction of I3 with eIF4G by an alternative, non-immune-based assay, 
cell extracts were analyzed by 7-Methyl GTP-sepharose chromatography. In this 
experiment we used HEK-293 cells to examine a different cell type and where the 
infection reaches late stage by 16 hpi. This would tell us if I3 remained associated with 
eIF4G at late stages of infection, when its synthesis by the virus decreases, as shown in 
Fig. 3.3.1. HEK-293 cells were mock-infected or infected at moi 5 for 16 h, and then 
cap-binding eIF4F complexes were recovered from RNAse-treated soluble cell extracts 
on 7-Methyl GTP-sepharose.  
Analysis of these complexes by western blotting clearly showed that I3 associated with 
eIF4F complexes purified from VacV-infected cells; furthermore, after addition of 3 
mM free 7-Methyl GTP - which competes with the cap-sepharose for binding to eIF4F 
complex - to the extracts, I3 binding together with the eIF4F components eIF4E and 
eIF4G was strongly inhibited (Fig 3.3.5). All images were from the same blots and 
exposures, cropped to remove replicate experiments. A slower-migrating non-specific 
band noticed in all cap-bound samples probed with anti-I3 antiserum is indicated with 
an asterix, and is not I3 protein.  
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Figure 3.3.5 Immunoblot illustrating cap-bound complexes in mock (M) and VacV-infected 
(VV) HEK-293 cells. (+/-) indicate the presence/absence of free 7-Methyl GTP. Asterix 
indicates non-specific band. 
 
3.3.3 Localization of I3 protein in infected cells 
It has been shown recently that cellular translational factors such as eIF4G and PABP 
are redistributed during VacV infection to viral factories by an unknown mechanism 
(Katsafanas and Moss, 2007; Walsh et al., 2008). Having identified I3 as a viral protein 
associating with eIF4G, the subcellular localization of I3 and eIF4G in VacV-infected 
cells was examined by immunofluorescence assay. To do this we GFP-tagged the I3L 
gene and transfected cells, then infected the cells and analyzed the subcellular 
localization of I3 together with its binding partner eIF4G.  
First of all, the I3L gene was PCR-amplified from VacV genomic DNA isolated from 
infected BSC40 cells using the primers containing EcoR1 and Kpn1 restriction sites (for 
details see section 2.2.13). DNA from uninfected cells was used as a control for 
specificity of the PCR reaction. The amplified PCR product was analyzed by agarose 
gel electrophoresis, which confirmed the presence of the amplified gene of expected 
size (Fig. 3.3.6). The PCR product was then purified, digested with EcoR1 and Kpn1 
   M          VV        VV    M          VV        VV 
7M-Cap Input 
eIF4G 
I3  
7M-GTP      -            -          +             -            -          + 
eIF4E 
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enzymes, then ligated into the EcoR1-Kpn1 cloning site of the mammalian expression 
plasmid pGFP-N which carried kanamycin resistance, to generate a C-terminally GFP-
tagged form of I3 protein. pGFP plasmid contains an enhanced GFP mutant which 
allows the expression of GFP to be visualized with UV light.  
 
 
Figure 3.3.6 Gel electrophoresis analysis of PCR-amplified pGFP-I3L. (M = mock, V = VacV-
infected) 
 
HEK-293 cells were transfected with empty plasmid or 0.5 µg pGFP-I3L. To confirm 
the functionality of the fusion protein, at 24 hours post transfection cells were lysed in 
NP-40 Lysis Buffer, treated with nuclease and analyzed by 7-Methyl GTP-sepharose 
chromatography. Western blotting of the samples demonstrated that GFP-I3 was 
recovered in cap-complexes together with eIF4G and eIF4E, although at low levels - 
most likely because of low efficiency of the transient transfection (Fig. 3.3.7).  
 
               M         V 
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Figure 3.3.7 Immunoblot illustrating 7-Methyl GTP-sepharose chromatography of HEK-
293 cells transfected with the control DNA (-) or pGFP-I3 (+). 
 
 
To perform the immunofluorescence assay, transfected cells were VacV-infected at moi 
5 for 16 hours. Cells were fixed in formaldehyde and probed with anti-eIF4G antiserum, 
which was detected with TRITC-conjugated anti-rabbit secondary. Cellular DNA in the 
nucleus and viral DNA in the factories were visualized using Hoescht, and cells were 
analyzed under a fluorescence microscope. As shown in figure 3.3.8, numerous viral 
factories formed nearby the nuclei, some of them larger than others and diffusely 
stained. eIF4G, normally dispersed in the nucleus and the cytoplasm of uninfected cells, 
relocalized to the viral replication compartments, as reported previously (Katsafanas 
and Moss, 2007; Walsh et al., 2008). Interestingly, GFP-tagged I3 colocalized with 
eIF4G within the same distinct areas of viral factories, as can be seen in merged image 
(Fig. 3.3.8). Colocalization could be observed in over 80 % of the cells that expressed 
the plasmid at low levels, whereas high expression levels resulted in saturation of cells 
with GFP-I3, and difficulties to distinguish colocalization. 
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Figure 3.3.8 Immunofluorescence images illustrating accumulation of eIF4G and GFP-I3 in 
viral factories in VacV-infected HEK-293 cells. 
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3.3.4 Investigation of I3-eIF4F interaction in uninfected cells 
The previous experiments showed that I3 associates with eIF4F complexes in infected 
cells. To examine the binding ability of I3 to eIF4F in the absence of other viral 
proteins, experiments with uninfected cells expressing I3L gene were carried out. 
 
3.3.4.1 Expression of his-I3 in HEK-293 cells 
To examine the ability of I3 to associate with eIF4F in uninfected cells, first of all I3L 
gene needed to be cloned and expressed in the cells. The I3L gene was PCR-amplified 
from VacV genomic DNA isolated from uninfected or infected BSC40 cells using the 
primers containing EcoR1 and Sal1 restriction sites, as well as N-terminal 6 x His 
sequence (for details see Section 2). The amplified PCR product was analyzed by 
agarose gel electrophoresis, which confirmed the presence of the amplified gene (Fig. 
3.3.9).  
 
 
Figure 3.3.9 Gel electrophoresis analysis of PCR-amplified his-I3L. (M = mock, V = VacV-
infected) 
                          M            V 
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The amplified gene was purified, digested with EcoR1 and Sal1, then ligated into the 
EcoR1-Sal1 cloning site of the mammalian expression plasmid pCl-Neo which carried 
ampicillin resistance, to generate N-terminally his-tagged form of I3 protein. After 
transformation of pCI-His-I3L in DH5alpha cells, eight separated colonies (labeled A-
H) were chosen to isolate the plasmids. DNA sequencing of those plasmids showed no 
mutations, and plasmid G was chosen to perform further experiments.   
Two sets of HEK-293 cells, which were 45 % and 90 % confluent, were transfected 
with empty plasmid or 200 ng pCl-His-I3L. To confirm the presence of the fusion 
protein, 24 and 48 hours post transfection (hpt) cells were lysed and analyzed by 
western blotting using mouse anti-his antiserum. Figure 3.3.10 illustrates the expression 
of his-I3L plasmid 24 hpt, and shows the increased expression in the sample containing 
double amount of the cells. The expression of the plasmid significantly decreased at 48 
hpt (data not shown), thus the analysis of transfected cells in further experiments was 
performed at 24 hpt.  
 
 
Figure 3.3.10 Immunoblot illustrating his-I3 expression in HEK-293 cells. (C = control sample 
transfected with empty plasmid) 
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3.3.4.2 His-I3 interaction with anti-eIF4G immune complexes in transfected cells 
The I3-eIF4G interaction in HEK-293 cells was tested by recovering anti-his immune 
complexes from cell extracts. As I3 is an ss-DNA binding protein, to examine if 
exogenous ssDNA molecules could enhance I3-eIF4G association in vitro, 7.5 µg 
ssDNA was added to the cell extracts.  
As shown in figure 3.3.11, his-tagged I3 was recovered efficiently from the cells 
expressing this protein, while no his-reactive bands were noticed in the control sample 
that did not contain I3. In contrast, eIF4G was recovered not only in the samples 
containing his-I3, but also in control samples lacking I3, suggesting the unspecific 
binding between anti-his antibody and eIF4G. For that reason we decided to repeat the 
cloning procedure and tag I3 with different sequences to avoid the unspecific binding.  
 
 
 
Figure 3.3.11 Immunoblot illustrating anti-his immune complexes immunoprecipitated from 
HEK-293 cells. 
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3.3.4.3 Expression of FLAG-I3 in uninfected cells 
The FLAG-tag sequence was fused to either C- or N-terminal of I3L during PCR 
amplification, and the cloning procedure of FLAG-tagged I3 was carried out as 
described in Section 3.2.8.1. HEK-293 cells have been chosen again to examine the 
expression of C- and N-FLAG-tagged I3. Analysis of transfected cell extracts by 
western blotting demonstrated that C-FLAG-tagged I3 expressed more efficiently than 
N-FLAG-I3 (not shown), thus the C-FLAG-I3 plasmid was used to perform further 
experiments.  
 
3.3.4.4 FLAG-I3 interaction with anti-eIF4G immune complexes in transfected 
cells 
The FLAG-I3 interaction with eIF4G in HEK-293 cells was tested by recovering anti-
FLAG immune complexes from uninfected cell extracts. As shown in figure 3.3.12, 
FLAG-tagged I3 has been efficiently recovered from the cells expressing this protein, 
although it was not detected in input samples. eIF4G was not recovered with FLAG-I3, 
most likely because of the low FLAG-I3 abundance in analyzed samples. However, 
eIF4G was not detected in the samples lacking FLAG-I3 (not shown), which indicates 
that no unspecific binding between anti-FLAG antibody and eIF4G protein occurs. 
 
 
 
Figure 3.3.12 Immunoblot illustrating anti-FLAG immune complexes immunoprecipitated from 
HEK-293 cells. 
I3 
FLAG-I3       -         +          -         +    
IP Input 
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3.3.4.5 Making stable cell lines  
Because of the low expression levels of I3 in transiently transfected cells, we decided to 
create stable HEK-293 cell line over-expressing high levels of FLAG-I3. Having stable 
cell line highly expressing FLAG-I3 would provide consistency in performing 
experiments using always the same cells, instead of performing transient transfection 
for each experiment. 
The following steps needed to be performed in order to establish a new stable cell line: 
 
 
 
 
 
 
 
 Screening for expressing clones 
Selection of cells expressing the construct 
            Transfection with the construct 
Expanding and developing cell lines 
Clonal expansion of single cells in 96-well plate 
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3.3.4.5.1 Cloning FLAG-tagged actin 
To provide the control for I3-expressing cells, stable cell lines over-expressing FLAG-
tagged actin and FLAG-tagged empty vector have been also established. Actin is the 
most abundant protein in eukaryotic cells and of similar size to I3 thus is thought to 
make a good control for over-expressing genes.  
C-FLAG-actin was amplified from cDNA prepared from RNA isolated from human 
cells, and cloned as described in Section 3.2.8.1.  
 
3.3.4.5.2 Selection of transfected cells 
HEK-293 cells were transfected with 200 ng FLAG-I3, FLAG-actin or FLAG-empty 
vector.  The following day cells expressing recombinant genes were selected by adding 
geneticin.  
Geneticin (G418) is an aminoglycoside antibiotic that inhibits prokaryotic and 
eukaryotic protein synthesis, thus is toxic for mammalian cells. G418 is commonly used 
as a selective agent for the bacterial neo and kan genes. The product of these genes, 
aminoglycoside 3’-phosphotransferase (neomycin phosphotransferase) inactivates 
G418, neomycin, and kanamycin by phosphorylation. Therefore, introduction of any of 
these genes into cells results in their resistance to G418.  
Recombinant genes used in this study have been ligated into pCI-neo plasmid which 
carries G418 resistance. The amount of G418 needed to eliminate the cells not 
expressing the constructs was titrated using HEK-293 cells (not shown). 
At 24 hpt of cells with 0.5 µg of plasmid, the standard media were replaced with media 
containing G418 in a concentration of 1.5 mg/ml to initially select the cells that have 
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stably incorporated the plasmid. Selection was carried out for seven days, within which 
most of the cells that did not express the incorporated plasmid efficiently died. This was 
in line with the low transfection efficiency we were achieving with transient transfection 
experiments. The remaining cells were seeded on 96-well plates using medium 
containing reduced concentration of G418, in order to grow the colonies from single 
cells. Plates were viewed to identify wells containing single cells, which were marked, 
and plates were incubated at 37o C. When confluent, clones from 12-14 wells were 
trypsinized. Half of the cells was seeded into 24-well plates to continue the culture, 
while the other half was re-seeded into 96-well plates. The next day, when the cells on 
96-well plate were confluent, they were lysed in Laemmli buffer and screened by 
western blotting using anti-FLAG or anti-I3 antiserum to examine the expression of 
recombinant genes (Fig. 3.3.13 a, b).  
 
 
 
Figure 3.3.13 (a) Immunoblot illustrating the expression of FLAG-actin in selected HEK-293 
cells. (1-13 indicate numerical order of the wells from which cells expressing FLAG-actin were 
lysed) 
 
 
 
Figure 3.3.13 (b) Immunoblot illustrating the expression of FLAG-I3 in selected HEK-293 
cells. (1-13 indicate numerical order of the wells from which cells expressing FLAG-I3 were 
lysed) 
  1       2         3         4        5        6        7         8        9        10    11       12      13  
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The clones with the highest expression of recombinant genes (no. 11 for FLAG-actin, 
no. 12 for FLAG-I3) were selected to perform further experiments. 
 
3.3.4.6 FLAG-I3 interaction with anti-eIF4G immune complexes 
A stable HEK-293 cell line over-expressing recombinant FLAG-tagged I3 was then 
used to examine I3 interaction with eIF4G by recovering anti-FLAG immune 
complexes from uninfected and infected cell extracts. Infecting the cells was performed 
in order to compare the efficiency of recovering I3 in the presence and absence of the 
other viral components. Immunoprecipitated complexes were analyzed by western 
blotting using anti-eIF4G and anti-FLAG/I3 antisera. 
As shown in figure 3.3.14, eIF4G clearly associated with I3 in uninfected cells 
overexpressing FLAG-I3, although a faint band of eIF4G was noticed in the sample 
lacking the recombinant I3 (first lane); however, the higher position of that band 
suggests that it could be unspecific. Surprisingly, VacV-infection reduced eIF4G 
binding, most likely as a result of a competition between viral and recombinant I3 for 
binding to eIF4G. Since virus produces much greater amounts of I3 during replication 
(see input samples), it competed away FLAG-I3 from eIF4G. 
Probing with anti-FLAG or anti-I3 antibodies revealed equal amounts of FLAG-I3 in 
both mock and infected samples. Moreover, no I3 has been detected in infected sample 
lacking FLAG-I3, indicating the specificity of recovering anti-FLAG immune 
complexes from cell extracts.  
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Figure 3.3.14 Immunoblot illustrating anti-FLAG immune complexes immunoprecipitated from 
HEK-293 cells. (M = mock, V = VacV-infected, empty = empty vector) 
 
Looking at the input samples demonstrated similar amounts of eIF4G accumulated in all 
samples. Interestingly, anti-I3 antibody detected both FLAG-tagged (upper band) and 
viral I3, showing the differences in expression of the recombinant and viral I3.  
 
3.3.4.7 Studies of FLAG-I3 binding to eIF4F by 7M GTP-sepharose 4B 
chromatography  
The stable HEK-293 cell line expressing recombinant FLAG-tagged I3 was then used to 
examine I3 association with cap complexes in uninfected cells. Soluble cell extracts 
were prepared from HEK-293 cells expressing empty-vector and FLAG-I3, and treated 
with RNAseA. 7-Methyl GTP-sepharose 4B chromatography assay was performed, and 
samples were analyzed by western blotting using antisera against eIF4G, eIF4E and 
FLAG. As shown in figure 3.3.15, I3 was clearly detectable on 7-Methyl GTP-
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sepharose, together with other components of the eIF4F complex. A non-specific band 
located just below I3 in input samples was also detected by anti-FLAG antiserum, but it 
was not detected in 7M-Cap samples. In contrast, I3 was not detected on sepharose resin 
alone, which was used as the control for the I3 binding (not shown). This experiment 
confirmed that other viral gene products are not required for the interaction of I3 with 
eIF4F. 
 
Figure 3.3.15 Immunoblot illustrating cap-bound complexes in HEK-293 cells expressing 
FLAG-I3. Migration of I3 detected with anti-FLAG antiserum is indicated with the arrow (<). A 
non-specific band detected by this antiserum in input samples is indicated by the asterix. 
 
 
3.3.5 Investigation of I3-eIF4F interaction in vitro 
To determine whether I3 interacts with eIF4G directly or whether it involves additional 
factors, we performed in vitro binding assays using purified I3 and eIF4G proteins. First 
of all, I3 was cloned and ligated into the bacterial expression plasmid pET-15b, which 
contains an N-terminal His-sequence tag, and then cloned into BL21 cells. Overnight 
seed cultures were used to inoculate 500 ml, which was induced to express His-I3 using 
IPTG for 1 h. The protein was then purified by running benzonase-treated cell lysates 
over His-TALON columns, followed by dialysis, and the presence of I3 was confirmed 
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by gel electrophoresis and western blotting. Due to low yields I3 could not be visualized 
well by coomassie staining (not shown). 
To examine the binding, 200 ng his-I3 was incubated for 1 hour with 7-Methyl GTP-
sepharose 4B alone or 7-Methyl GTP-sepharose 4B that had been preincubated with 
nuclease treated HEK-293 cell extracts containing eIF4F complexes. As an additional 
control, his-I3 was also incubated with sepharose 4B only, that had also been 
preincubated with HEK-293 cell extracts. After 1 h incubation all beads were 
extensively washed to remove unbound complexes, and samples were analyzed by 
western blotting. As shown in figure 3.3.16, recombinant I3 specifically associated with 
eIF4F purified from cell extracts, and did not interact with the control sepharose 4B 
beads. In addition, the association with 7-Methyl GTP-sepharose 4B did not occur in the 
absence of eIF4F, indicating the specificity of I3 binding to that complex. 
 
 
 
Figure 3.3.16 Immunoblot illustrating cap-bound complexes isolated from HEK-293 cell 
extracts and incubated with his-I3. (Cap = 7-Methyl GTP-sepharose 4B; 4B = sepharose 
4B) 
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3.3.6 Investigation of I3-eIF4G interaction by in vitro binding assays 
The previous experiments demonstrated that I3 interacts with eIF4F complexes in 
infected or uninfected cells, while purified his-I3 interacted with eIF4F from uninfected 
cell extracts. To examine whether I3 binds to eIF4G directly or whether it involves 
other factors that mediate indirect I3-eIF4G interaction, in vitro binding reactions were 
carried out. Three different fragments of GST-eIF4G were used in this experiment to 
define regions of binding, and because full length eIF4G is difficult to purify. 
Three GST-tagged fragments of eIF4G: N-(aa157-626), M-(aa627-1045) and C-
(aa1045-1560) terminal, were used in the assay (Cuesta et al., 2000). Schematic 
representation of the regions is shown in figure 3.3.17, which also indicates the binding 
domains for PABP, eIF4E and RNA. To perform the assay, each of the fragments was 
isolated from benzonase – treated BL21 cells, and purified with glutathione-sepharose 
4B. The presence of the proteins was then confirmed by performing gel electrophoresis 
and coomassie brilliant blue staining (not shown).  
 
 
 
 
Figure 3.3.17 Schematic representation of the GST-tagged N-, M- and C-terminal regions of 
eIF4G. (The corresponding amino acid numbers of each fragment are indicated in brackets). 
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3.3.6.1 In vitro binding reactions with eIF4G fragments 
To perform the binding assay purified proteins were incubated together with 
glutathione-sepharose which recovers GST-tagged complexes from the reaction buffer. 
200 ng his-I3 was incubated for 2 hours with either dialysis buffer alone, to provide a 
control for the samples containing eIF4G, or together with 1 µg of each GST-tagged 
eIF4G fragment. The resin-bound complexes were then washed and analyzed by 
western blotting.  
As illustrated in figure 3.3.18, each of the eIF4G fragments was evidently recovered 
from the reaction buffer with similar efficiency. However, while I3 was present at 
identical levels in input samples, it was found to bind specifically to the C-terminal 
fragment of eIF4G in Glutathione-sepharose samples.  
 
 
 
Figure 3.3.18 Immunoblot illustrating association of his-I3 with N-, M- and C-terminal 
fragments of eIF4G. Samples were probd with anti-GST (GST) or anti-His (His) antibodies. 
 
This result clearly demonstrates that viral I3 associates with eIF4G protein through 
direct interaction. Moreover, it indicates that the location of I3-binding site on eIF4G 
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differs not only from PABP- and eIF4E-binding domains which are located on the N-
terminal fragment of eIF4G, but also from binding domains for RNA situated largely in 
the M-fragment, demonstrating that I3 association did not involve the nucleic acid-
binding regions of eIF4G. 
 
3.3.7 In vitro binding reactions with I3 fragments 
3.3.7.1 Generation of I3-fragments 
To identify the region of I3 involved in its association with C-terminal fragment of 
eIF4G, binding reactions were performed using five different fragments of I3, that was 
serially deleted in its C-terminal region by approximately 50 amino acids each time 
(Fragments 1-4) or deleted in its N-terminus by 59 amino acids (Fragment 5) (Fig. 
3.3.19) during PCR amplification. The PCR products were confirmed by agarose gel 
electrophoresis (Fig. 3.3.20). The sizes of the newly amplified I3 fragments are 
indicated in table 3.3.1. Each fragment was purified, digested and his-tagged by ligation 
into pET-15b plasmid. The plasmids were then transformed into BL21 cells, and 
proteins purified as described in Section 3.2.7.1.  
 
 
Figure 3.3.19 Schematic representation of the full-length I3 and its corresponding fragments 
together with their amino acids.  
 
ssDNA N’ C’ 
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Table 3.3.1 The sizes (in base pairs [bp]) of full length (FL) I3 and its fragments (F1-F5) 
        _________________________________________________________________________ 
 
                              I3 fragment                                  Size [bp] 
       ___________________________________________________________________ 
                                
                                   FL                                             807 
  
                                   F1                                             648 
 
                                   F2                                             480 
 
                                   F3                                             330 
 
                                   F4                                             180 
 
                                   F5                                             636 
        
___________________________________________________________________ 
 
 
 
 
 
 
 
Figure 3.3.20 Gel electrophoresis image showing PCR-amplified I3 fragments F1-F5. 
 
 
 
 
 F5       F4      F3     F2      F1 
- 1000 bp 
- 500 bp 
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3.3.7.2 In vitro binding reactions 
To examine which fragment(s) of his-I3 interacts with eIF4G, glutathione-sepharose 
and GST-tagged C-terminal eIF4G (C-4G) were incubated together with dialysis buffer 
alone, to provide the control sample, or containing full-length or truncated his-I3. Two 
independent preparations of full-length I3 were used in this assay (#1 and #2). The 
results from sample analysis by western blotting, using anti-his and anti-GST antibodies 
to detect I3 fragments and C-4G, are illustrated in figure 3.3.21. As can be seen on the 
immunoblots, C-4G was efficiently recovered on glutathione-sepharose in each sample. 
Both full-length I3 fragments were also recovered with C-4G, although differences in 
their abundance were noticed, more clearly illustrated in the lighter exposure of the 
input samples (lower panel). Furthermore, one of the I3 fragments labeled F1 (aa1-216) 
also bound to C-4G. Despite its low abundance compared to other fragments and seen in 
input samples, F1 clearly bound to C-4G suggesting that I3 associates with eIF4G by its 
C-terminal 160-216 fragment (Fig. 3.3.22). However, binding was not restored in F5, 
which contains that 160-216 domain. Possible reasons for this finding are discussed in 
Section 4. 
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Figure 3.3.21 Immunoblot illustrating the binding reactions of I3 Fragments 1-5 with C-
terminal eIF4G. (#1, #2 – full-length (FL) I3 from two independent preparations; F1-F5 – I3 
fragments)  
 
 
Figure 3.3.22 Schematic representation of the full-length I3 and its corresponding fragments 
indicating I3 binding site for eIF4G and ssDNA.     
ssDNA s DNA C-4G N’ C’ 
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3.3.8 The role of mTORC1 in I3 binding to eIF4F  
As mentioned before, mTORC1 is a complex regulating eIF4G phosphorylation as well 
as the activity of the translational repressor 4E-BP1. Furthermore, mTORC1 controls 
eIF4F complex formation by indirect regulation of eIF4E availability through 4E-BP1. 
Thus, its role in mediating the binding of viral I3 to cellular eIF4G/eIF4F was examined 
by treating the cells with rapamycin, the mTORC1 inhibitor. Binding was studied by 7-
Methyl GTP-sepharose chromatography and immunoprecipitation assays. 
 
3.3.8.1 Rapamycin effect on I3-eIF4F interaction 
HEK-293 cells were infected overnight in the presence of 2 µM rapamycin or DMSO 
solvent control, then 7-Methyl GTP-bound complexes were recovered from RNAseA-
treated soluble cell extracts, and associated proteins were analyzed by western blotting 
using antisera against eIF4G, eIF4E and I3. HEK-293 cells were used because viral 
infection has little effect on eIF4F levels in many actively cycling transformed cell lines 
where-in initiation complexes are largely pre-assembled (Walsh and Mohr, 2004), 
eliminating the complexity of analyzing potential differences in I3 binding under 
conditions where eIF4F levels were also significantly altered. 
As shown before (see section 3.2.2), rapamycin treatment effectively prevented 4E-BP1 
phosphorylation and release stimulated by VacV infection in both cap-bound and input 
samples (Fig. 3.3.23), but had no significant effect on eIF4F complex levels and the 
accumulation of I3 in infected cell extracts. In contrast, eIF4F-bound I3 was reduced 
approximately 3-fold in rapamycin-treated cultures. These findings demonstrated that 
maximal I3 binding to the eIF4F complex required cellular mTORC1 activity, although 
significant amounts of I3 remained associated with eIF4F in the presence of rapamycin. 
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Increasing volumes (1x and 2.5x) of input samples, shown in Fig. 3.3.23, were probed 
with anti-I3 antiserum to confirm quantitative antigen detection on blots, and minimal 
effects of rapamycin on I3 accumulation compared to its effects on association with 
eIF4F. 
 
 
Figure 3.3.23 Immunoblot illustrating the influence of rapamycin on I3 binding to eIF4F 
complex. (M = mock, V = VacV-infected, Rapa = rapamycin) 
 
To investigate this further, the effect of rapamycin on I3-eIF4F interaction was 
examined by binding assay using uninfected cell extracts. As demonstrated before, 
recombinant I3 interacts with eIF4F complexes purified from HEK-293 cell extracts 
using 7-Methyl GTP-sepharose 4B. To examine if mTORC1 inhibition affects this 
interaction, the same binding assay was performed using extracts prepared from HEK-
293 cells treated with DMSO solvent control or 2µM rapamycin overnight, and the 
samples were analyzed by western blotting. As shown in figure 3.3.24, mTORC1 
inhibitor reduced the efficiency of I3 binding. Notably, the effects on I3 binding and 
changes in 4E-BP1 association mediated by rapamycin were smaller than that in 
eIF4G 
I3 
eIF4E 
4E-BP1 
   M            V            V 
7M-Cap 
   M            V           V    M            V           V 
1 x Load 2.5 x Load 
Input 
DMSO      +              +             -              +             +             -              +            +             - 
Rapa        -               -              +             -              -             +               -            -             +                
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infected cells. This result confirmed that the effect of rapamycin on the association of I3 
with 7-Methyl GTP-bound complexes was not limited to the context of infection.  
 
 
Figure 3.3.24 Immunoblot illustrating the effect of 2 µM rapamycin on I3-eIF4F interaction in 
HEK-293 cell extracts. (Rapa = rapamycin) 
 
3.3.8.2 Rapamycin effect on I3-eIF4G association 
To examine if inhibition of mTORC1 affects the association of I3 with eIF4G during 
VacV infection, the immunoprecipitation of anti-eIF4G and anti-I3 bound complexes 
from cell extracts was carried out. To avoid background noticed on western blots after 
probing for I3 in eIF4G immune complexes (data not shown), the association of these 
two proteins was determined by metabolic labeling of the cells, as described in section 
3.3.1.  
HEK-293 cells were mock or VacV-infected at moi 5 in the presence of DMSO solvent 
control or 2 µM rapamycin, then labeled with [35S]methionine-cysteine for 1 h before 
making cell extracts. VacV replicates relatively fast in those actively dividing cells, thus 
eIF4G 
I3  
eIF4E 
4E-BP1 
Rapa        -             +   
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the infection was  ended after 8 hours, when I3 was still actively synthesized and readily 
detectable (see timecourse in section 3.1). Cells were lysed in NP-40 Buffer, nuclease 
treated and precleared with normal rabbit serum. After that samples were divided in two 
and immunoprecipitated with either anti-eIF4G or anti-I3 antiserum. The levels of 
eIF4G and eIF4F were analyzed by western blotting, while I3 levels were examined by 
exposing fixed and dried gel on X-ray film.    
 
 
Figure 3.3.25 Immunoblot illustrating the influence of rapamycin on I3 association with eIF4G 
complex. (M = mock, V = VacV-infected, Rapa = rapamycin) 
 
As demonstrated in Fig. 3.3.25, the same amounts of eIF4G were recovered with anti-
eIF4G bound complexes, and rapamycin did not affect the levels of eIF4E associated 
with eIF4G in infected cells, in agreement with our previous findings that eIF4F levels 
were not affected by rapamycin treatment in HEK-293 cells in cap-bound complexes 
   M           V          V 
eIF4G 
eIF4E 
35S-I3 
35S-I3 
4E-BP1 
DMSO       +          +            - 
Rapa         -            -           +  
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(Fig. 3.3.23). However, rapamycin did not affect I3-eIF4G binding in recovered anti-
eIF4G complexes (Fig. 3.3.25), whereas it did decrease the amounts of I3 bound to 
eIF4F in 7M GTP-sepharose assay (Fig. 3.3.23). In addition, intensity of I3 signal 
remained unchanged also in anti-I3-immunoprecipitated samples (Fig. 3.3.25), 
indicating that there were no differences in the rates of I3 synthesis that could influence 
the interpretation of the I3-eIF4G binding assay. Failure of rapamycin to inhibit 
mTORC1 in this particular experiment was also excluded as analysis of the input 
samples by western blotting demonstrated that rapamycin effectively blocked 4E-BP1 
phosphorylation (Fig. 3.3.23). 
 
3.3.9 Investigation of possible I3-eIF4E interaction 
The previous experiments demonstrated that I3 binding to eIF4F, but not accumulation 
was reduced by approximately 3-fold in rapamycin-treated cultures (Fig. 3.3.11), and 
that the association of I3 with 7-Methyl GTP-bound complexes was not limited to the 
context of infection (Fig. 3.3.12). In addition, in both cases the effects of rapamycin on 
I3 binding were proportional to the changes in 4E-BP1 binding to the cap, while no 
changes in eIF4G binding were observed. Therefore, the association of I3 with the 4E-
BP1 binding partner - eIF4E, was considered and investigated in the following 
experiment. 
First of all, eIF4E was batch-purified from BL21 cells on 7-Methyl GTP as described in 
Section 2. Then purified eIF4E was incubated for 1h with 200 ng his-I3, and the 
samples were analyzed by western blotting using anti-eIF4E and anti-I3 antisera. Figure 
3.3.26 shows that while I3 did not associate with 7-Methyl GTP resin alone, it was 
recovered with the cap in the presence of eIF4E suggesting an  I3-eIF4E interaction.  
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Subsequently, the ability of I3 to associate with eIF4E in the presence of eIF4G was 
examined. Since eIF4E interacts with the N-terminal fragment of eIF4G, the N-4G 
(aa157-626) used in the previous experiments was used to test the binding. Increasing 
amounts of a GST-fused N-4G was added into the binding reactions containing 7-
Methyl GTP-associated eIF4E and his-I3, and samples were analyzed by 
immunoblotting using anti-GST and anti-His antisera. As can be seen in figure 3.3.26, 
inclusion of N-4G did not affect the I3 binding to cap complexes, suggesting that I3 
association with eIF4E was not competitive at least for the large N-terminal fragment of 
eIF4G containing the eIF4E binding site. 
 
 
Figure 3.3.26 Immunoblot illustrating the I3 association with eIF4E in HEK-293 cells. N-4G 
was detected with anti-GST antibody, I3 was detected with anti-His antibody, eIF4E was 
detected with anti-eIF4E antibody. 7M GTP Sepharose alone (-) or batch absorbed with eIF4E 
(+) is indicated at the bottom of the panel. 
N-4G     -        -        0.2      0.5        2         4 µg  
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3.3.10 Inhibition of viral DNA polymerase by PAA and its influence on translation 
Our findings to date suggested that mTORC1 was activated by VacV and the viral 
protein I3 binds eIF4G and possibly eIF4E, also. We then examined the stage of viral 
infection at which these events occur by using PAA. 
Phosphonoacetic acid (PAA) is an organophosphorus compound that inhibits DNA 
polymerase. PAA preferentially inhibits viral but not essential eukaryotic DNA 
polymerases, which is the basis for the therapeutic use of this drug as an antiviral agent. 
There are many antibiotics and synthetic compounds that inhibit synthesis of DNA, 
such as oligomycin and chromomycin (Ward et al., 1965). However, these inhibitors 
interfere with DNA synthesis by forming a complex with template DNA. This type of 
interaction lacks specificity and results in inhibition of all DNA-primed enzymes. In 
contrast, PAA was shown not to interact with template DNA (Mao et al., 1975). The 
mechanism of blocking DNA synthesis appears to be similar in all types of viruses. 
PAA binds to the pyrophosphate exchange site of DNA polymerase and blocks 
formation of the 3’-5’-phosphodiester linkage, which prevents further elongation of 
viral DNA (Leinbach et al., 1976).  
PAA was found to inhibit the replication of a variety of animal viruses such as herpes 
simplex virus (Shipkowitz et al., 1973), cytomegalovirus (Huang, 1975), vaccinia virus 
(Bolden et al., 1975), Marek’s disease virus (Leinbach et al., 1976), Epstein-Barr virus 
(Nyormoi et al., 1976), and African swine fever virus (Moreno et al., 1978). In addition, 
Overby et al. (1977) noted that this drug reduced VacV plaque formation, although the 
level of inhibition was lower than that observed with herpesviruses. PAA was also 
shown to block the formation of viral factories, the distinct compartments of VacV 
replication, and to reduce 4E-BP1 phosphorylation during VacV infection, leading to 
 165 
the suggestion that late gene products or viral factory formation may be involved 
(Walsh et al., 2008). However, the full effect of this inhibitor on eIF4F complex 
formation has not been explored so far. 
 
3.3.10.1 The effect of PAA on eIF4F complex formation 
To examine the effect of PAA on eIF4F complex formation in more detail, 7-Methyl 
GTP-sepharose chromatography assay was performed. Serum-starved NHDFs, cells in 
which assembly of eIF4F during VacV infection is readily detected, were mock-infected 
or infected with VacV in the presence or absence of PAA, and the levels of eIF4E-
bound eIF4G and 4E-BP1 were examined as described before (Section 3.3.3).  
As reported previously, VacV infection stimulated 4E-BP1 phosphorylation and release 
from eIF4E, and increased the binding of eIF4G to eIF4E. In contrast, PAA did not 
significantly alter the ability of VacV to release 4E-BP1 from eIF4E, although it did 
affect the mobility of 4E-BP1 in input samples (Fig. 3.3.27). This suggested that the 
turnover or rate of 4E-BP1 phosphorylation was affected by PAA, but not enough to 
affect release from eIF4E. In agreement, PAA only partly reduced the phosphorylation 
of Akt at either T308 or S473 (Fig. 3.3.28). However, PAA significantly reduced VacV-
induced enhancement of eIF4G binding to eIF4E, demonstrating that eIF4F complex 
formation was stimulated at late stages of infection in conjunction with DNA replication 
and viral factory formation. 
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Figure 3.3.27 Immunoblot illustrating the effect of PAA on eIF4F complex formation in mock 
and VacV-infected serum-starved NHDFs. (M = mock, V = VacV-infected) 
 
 
 
Figure 3.3.28 Immunoblot illustrating the effect of PAA on Akt phosphorylation in mock and 
VacV-infected NHDFs. (M = mock, V = VacV-infected) 
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3.3.10.2 The effect of PAA on I3 binding 
We then examined whether PAA affected I3 binding to eIF4F complexes. HEK-293 
cells were used in this experiment as infecting NHDFs in the presence of PAA caused 
changes in eIF4F levels that would complicate the interpretation of binding results. 
HEK-293 cells were pretreated with PAA and mock-infected or infected with VacV for 
16 hours. Soluble cell extracts were treated with RNAse and a cap-pulldown assay was 
performed. Input and cap-bound samples were analyzed by western blotting (Fig 3.3.29 
a). I3 binding to eIF4F was not affected by PAA, demonstrating that it was bound to 
eIF4F early in infection. Western blotting of input samples against VacV proteins 
demonstrated that PAA had worked to block late stages of VacV infection (Fig. 3.3.29 
b). This suggested that I3 bound to eIF4F early in infection but that eIF4F assembly in 
NHDFs required late stage events. 
 
. 
Figure 3.3.29 (a) Immunoblot illustrating the effect of PAA on I3 binding to eIF4F in VacV-
infected HEK-293 cells. 
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Figure 3.3.29 (b) Immunoblot illustrating the effect of PAA on the total VacV protein 
accumulation. (M = mock, V = VacV-infected) 
 
3.3.10.3 The effect of PAA on VacV protein synthesis 
Next, the synthesis of VacV proteins in the presence of PAA was examined. Serum-
starved NHDFs were pre-treated for 1 h with PAA, then infected at moi 10 and 
metabolically labeled at 18-19 hpi followed by lysing in Laemmli buffer. The cell 
extracts were resolved by SDS-PAGE and fixed, dried gels were exposed to x-ray film.  
Analysis of the proteins actively translated during the labeling time showed that 
although PAA notably decreased cellular protein production, it effectively blocked the 
synthesis of viral proteins, as illustrated in figure 3.3.30. This result indicates the 
significance of DNA synthesis in VacV replication and protein synthesis. 
PAA treated samples showed that some viral proteins were actively translated while the 
virus failed to completely shut down host translation. It is possible that more complete 
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        M        V       V      
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50 - 
37 - 
25 - 
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host shut-off needs the formation of viral factories where translation factors are 
sequestered. 
 
 
Figure 3.3.30 Autoradiograph illustrating the PAA effect on the total rates of VacV protein 
synthesis. (M = mock, V = VacV-infected) 
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3.3.11 The effect of I3 on cellular translational rates 
To determine if I3 affected cellular translational rates, the control HEK-293 cells and 
cells expressing recombinant I3 (FLAG-I3) were metabolically labeled for 1 h and 
analyzed by SDS-PAGE. Figure 3.3.31 demonstrates that no significant differences in 
the pattern or rates of cellular protein synthesis were observed. 
 
 
Figure 3.3.31 Autoradiograph illustrating the I3 effect on cellular protein synthesis in 
metabolically labeled empty vector control (-) and FLAG-I3 (+) HEK-293 cells. Migration of 
molecular weight standards (in kDa) is indicated to the left. 
 
 
 
 
 
 
FLAG-I3     -       + 
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3.3.12 The effect of I3 on translation of viral RNA in vitro 
To examine the effect of I3 on viral translation, initially RNA was isolated from VacV-
infected HEK-293 cells. Next, rabbit reticulocyte lysates containing 35S-Methionine 
were programmed with 10 µg of total RNA isolated from infected cells in the presence 
of dialysis buffer alone or 200 ng purified his-I3, and the reactions were incubated at 
300C for 1h. After that the samples were boiled with equal volumes of 2x Laemmli 
buffer (the experiment to this stage was performed by Dr. Derek Walsh) and resolved 
by SDS-PAGE. The gels were fixed, dried and exposed to x-ray film. As shown in 
figure 3.3.32, the presence of I3 in in vitro translation reactions did not significantly 
affect the rates or patterns of viral protein synthesis.  
 
Figure 3.3.32 Autoradiograph illustrating the effect of recombinant I3 on translation of VacV 
RNA. Migration of molecular weight standards (in kDa) is indicated to the left. 
I3      -      + 
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3.3.13 Recruitment of translational factors to ssDNA 
We have shown that VacV-encoded I3 binds eIF4F in a PAA-insensitive manner yet 
eIF4G assembly and host shut-off were sensitive to PAA. It has been shown previously 
that eIF4G and eIF4E (Walsh et al., 2008) as well as I3 (Rochester and Traktman, 1998) 
redistribution are sensitive to inhibitors of DNA replication, which prevent viral factoy 
formation. Indeed, we demonstrated that eIF4G and I3 co-localize within factories. 
These findings suggest that I3 may not directly stimulate eIF4F formation but may act 
to retain eIF4F in factories once they form. 
As demonstrated earlier in this study, exogenously-expressed I3 associates with eIF4F 
in uninfected cells. Accumulation of I3 in factories is thought to be due to its binding to 
ssDNA, retaining it there. Thus, the possibility that I3 can mediate the recruitment of 
translation initiation factors to ssDNA in vitro was examined, mimicking what might 
happen in viral factories. 
Soluble cell extracts were prepared from FLAG-Actin- and FLAG-I3-expressing HEK-
293 cells, and a binding assay with recovering DNA on anti-biotin antibody-conjugated 
sepharose was carried out, as described in Section 2. The samples were then analyzed 
by immunoblotting using anti-eIF4G, anti-PABP, and anti-I3 antibodies. The results 
illustrated a low level of eIF4G bound to ssDNA in control extracts with FLAG-actin 
(Fig. 3.3.32). However, in the presence of I3 large amounts of eIF4G were recovered. 
Similarly to eIF4G, significantly greater amounts of PABP were also bound to the beads 
in the presence of I3. 
To verify the specificity of translation factor recruitment by I3 the association of RBM3 
was examined in the same samples. RBM3 is a cellular protein with both RNA and 
ssDNA binding properties that has been shown to potentially interact with VacV A2 
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protein, but not I3 (Derry et al., 1995; Dellis et al., 2004). While RBM3 was found 
associated with ssDNA in both extracts its association was modestly reduced in I3 
samples comparing to control extracts (Fig. 3.3.33), probably as a result of competition 
for binding from I3 itself.  
 
   
Figure 3.3.33 Immunoblot illustrating recruitment of translation factors to ssDNA by I3.  
 
 
These results suggested that I3 did not directly influence translation of cellular or viral 
mRNAs but is likely to play a role in the redistribution of factors to viral factories 
during infection. 
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3.3.14 Creating a VacV mutant lacking the I3L gene 
As a final point of this study we aimed to determine a role for I3 in regulating 
translation and manipulation of the eIF4F complex during infection. Previous attempts 
to generate I3L mutants by recombination were unsuccessful (Rochester and Traktman, 
1998). We attempted to create a viral mutant lacking the I3L gene using a novel 
DH10B/Vac-Bac/λ system established by Domi and Moss (2005). The DH10B/Vac-
Bac/λ system is a bacterial artificial chromosome (BAC) containing the entire VacV 
genome engineered in Escherichia coli by homologous recombination, using 
bacteriophage λ-encoded enzymes that mediate recombination process. This system 
uses recombinogenic engineering technology, which avoids the use of restriction 
enzymes or ligases and allows efficient recombination of BACs maintained in E. coli 
(Copeland et al., 2001; Britt et al., 2004). The system contains a mini-λ prophage 
encoding the red recombination system composed of 5’ to 3’ exonuclease (Exo), a 
single-strand DNA binding protein (Bet) and a nuclease inhibitor (Gam), under the 
control of the temperature-sensitive λ cI857 repressor (Yu et al., 2000; Court et al., 
2002).  
 
3.3.14.1 Deletion of the I3L ORF 
The I3L ORF was deleted from the VAC-BAC plasmid in two steps. In the first step 
I3L ORF in the VAC-BAC plasmid was replaced with the ampicillin (Amp) resistance 
gene by recombination in Escherichia coli. The Amp gene was amplified from pET 
plasmid by PCR using primers containing approximately 18 bp of the 5’ and 3’end of 
the Amp gene and 50 bp of homologous sequences flanking the region where I3L 
overlaps the adjacent I2L or I4L genes. Analysis of the PCR product by agarose gel 
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electrophoresis confirmed the amplification of the Amp gene with the expected size of 
approximate 700 bp (Fig. 3.3.34).  
 
 
Figure 3.3.34 Gel electrophoresis image showing PCR-amplified Amp gene containing the 
homologous sequences flanking the region where I3 overlaps with the adjacent I2 and I4 gene. 
(Amp = PCR amplified ampicillin) 
 
 
The PCR product was then gel purified and used to transform competent E.coli cells 
harboring VAC-BAC plasmid/λ (cells preparation described in Section 2) through 
electroporation, and ampicillin-resistant colonies were selected to isolate recombinant 
VAC-BAC that had taken up the Amp gene in place of I3. 
To confirm the presence of Amp insert in the VAC-BAC plasmid, the PCR using the 
Amp primers used for its amplification was performed (not shown). To confirm that the 
Amp gene replaced the I3L ORF, PCR was performed on wildtype (WT) and 
recombinant (∆I3L) VAC-BAC DNA using primers flanking the I3 gene in VacV. As 
can be seen in figure 3.3.35, the Amp ORF successfully replaced I3L ORF. The 
difference in sizes of the products results from the fact that the Amp gene is larger than 
I3L. 
 
1000bp  - 
500bp - 
  -    Amp  
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Figure 3.3.35 Gel electrophoresis image showing PCR-amplified sequences using primers in 
the adjacent I2 and I4 gene of VacV. (WT = wildtype VAC-BAC containing I3L gene, ∆I3L = 
recombinant VAC-BAC containing Amp gene in the place of I3L)   
 
 
3.3.14.2 Attempting to recover ∆I3L mutant virus 
The final step was to recover the infectious recombinant virus by transfecting BSC40 
cells with the VAC-BAC-∆I3L plasmid in a presence of 0.1 PFU per cell helper 
fowlpox virus (FPV). Because VAC-BAC plasmid does not contain viral enzymes 
needed to initiate replication, the fowlpox virus was used to provide the enzyme 
functions necessary. FPV is an avian poxvirus that does not replicate in mammalian 
cells and no recombination with the VacV genome was detected (Scheiflinger et al., 
1992). At 2 hpi cells were transfected with 1µg of the VAC-BAC or VAC-BAC-∆I3L. 
Transfected cells were incubated at 37o C for several days. During that time, viral 
plaque formation was expected to be seen in the transfects.  
 
After 5 days cytopathic effect and plaque formation were observed in cells transfected 
with wildtype VAC-BAC (two plaques can be seen in Fig. 3.3.36 a), but no cytopathic 
effect was seen either in the control well transfected with no DNA or in the cells 
containing VAC-BAC-∆I3L up to 10 days post-transfection (Fig. 3.3.36 b). To test if 
WT  ∆I3L   
500bp - 
1000bp - 
1500bp - 
Amp 
I3 
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exogenously added I3 could rescue the VacV-∆I3L mutant, cells were transfected with 
1µg of VAC-BAC-∆I3L and 1µg of his-tagged pCI-I3, but no cytopathic effect was 
observed up to 10 days post-transfection (Fig. 3.3.36 c). As can be seen in figures 3.37 
a-c, extending incubation time up to 17 days resulted in increased cytopathic effect in 
cells containing wildtype VAC-BAC, demonstrating the production of infectious, 
replicating virus (Fig. 3.3.37 a), while still no signs of virus replication were noticed in 
the presence of ∆I3L mutant (Fig. 3.3.37 b-c). These results suggest the inability of 
VacV replication in the absence of I3L.  
The experiment described above was carried out in two different types of cells (BSC40 
and HEK-293) and with the use of two independent preparations of VAC-BAC and 
VAC-BAC-∆I3L. Furthermore, three unsuccessful attempts of generation the VacV-
∆I3L mutant were carried out, but the virus lacking I3L gene did not replicate in the 
cells. Thus, our study confirmed the previous assumptions (Rochester and Traktman, 
1998) that I3L is an essential poxvirus gene. However, it is possible that I3 contains 
unknown promoters that regulate I2 expression that are lost when I3 is replaced by the 
Amp gene. This is something we need to investigate further before dismissing this 
approach. 
Furthermore, three independent siRNAs targeting the I3 mRNA failed to affect I3 
accumulation in HEK-293 or HeLa cells (not shown). Thus, further analysis of the role 
of I3 in regulating translation in infected cells will require more competent methods to 
affect I3 expression during infection or the generation of partial deletions in I3L that 
might allow virus to be recovered. 
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Figure 3.3.36 (a) Photograph of BCS40 cells transfected with VAC-BAC. Image was taken 10 
days post-transfection by phase contrast microscopy. 
 
 
Figure 3.3.36 (b) Photograph of BCS40 cells transfected with VAC-BAC-∆I3L. Image was 
taken 10 days post-transfection by phase contrast microscopy. 
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Figure 3.3.36 (c) Photograph of BCS40 cells transfected with VAC-BAC-∆I3L and pCI-I3. 
Image was taken 10 days post-transfection by phase contrast microscopy. 
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Figure 3.3.37 (a) Photograph of BCS40 cells transfected with VAC-BAC. Image was taken 17 
days post-transfection by phase contrast microscopy. 
 
 
Figure 3.3.37 (b) Photograph of BCS40 cells transfected with VAC-BAC-∆I3L. Image was 
taken 17 days post-transfection by phase contrast microscopy. 
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Figure 3.3.37 (c) Photograph of BCS40 cells transfected with VAC-BAC-∆I3L and pCI-I3. 
Image was taken 17 days post-transfection by phase contrast microscopy. 
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Section 4.0 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 183 
4.1 General overview 
Even the largest and most complex known viruses encoding hundreds of proteins 
remain dependent upon the host translational machinery. The reason is that viral 
genomes are not large enough to encode all of the factors necessary for translation, and 
viruses do not harbor functional ribosomes in their virions. Therefore, successful 
amplification of the viral genome requires competition between viral and cellular 
mRNAs for the host cell translation apparatus. As a result both RNA and DNA viruses 
developed a variety of sophisticated strategies to usurp host ribosomes.  
A major target for all RNA and DNA viruses is eIF4F, a key translation initiation 
complex (Schneider and Mohr, 2003; Mohr et al., 2007). Depending on the strategy 
used by a particular virus, eIF4F can be completely inactivated or actively stimulated by 
viral factors. As such, in addition to modulating cellular signaling pathways that 
regulate host translation factor activity, a growing number of viruses are being found to 
encode proteins that directly interact with the eIF4F complex. Furthermore, a number of 
viruses have been shown to generate substitutes for particular translation initiation 
factors (Groft and Burley, 2002; Burgui et al., 2007; Mir and Panganiban, 2008).  
VacV was previously shown to dynamically stimulate the activity of the eIF4F complex 
to promote viral translation. VacV infection results in inactivation of the translational 
repressor 4E-BP1 and stimulation of eIF4E assembly into an active eIF4F complex. 
VacV was also found to stimulate the eIF4G-associated kinase Mnk1 to promote eIF4E 
phosphorylation and enhance viral protein synthesis and replication (Walsh et al., 
2008). Moreover, VacV infection causes redistribution of cellular translational factors to 
the viral replication sites (Katsafanas and Moss, 2007; Walsh et al., 2008). However, 
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the strategies used by VacV to manipulate the eIF4F complex have not been established 
so far.  
In this study we evaluated the signaling pathways that regulate assembly of eIF4F 
complexes in VacV-infected cells. Furthermore, we propose that VacV-encoded I3 
protein plays a significant role in usurping cellular translational factors and their 
redistribution by VacV. 
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4.2 Signaling pathways regulating eIF4F complex assembly in VacV-infected cells 
Manipulation of intracellular signaling pathways is important for successful viral 
replication. In the case of poxviruses, regulation of signaling pathways has been shown 
to play a pivotal role in the biology of these pathogens (de Magalhaes et al., 2001; 
McFadden, 2005; Werden and McFadden, 2008). In addition, the strategies of altering 
signaling pathways appear to be virus specific and can differ within a virus family. For 
example, while both VacV and cowpox virus (CPXV) stimulate the MEK/extracellular 
signal-regulated kinase (ERK)/EGR-1 pathway, inhibition of this pathway affected 
VacV, but not CPXV replication (Silva et al., 2006).  
One of the key cellular signaling pathways that regulate the assembly of eIF4F 
complexes is phosphatidylinositol 3'-kinase–Akt–mammalian target of rapamycin 
(PI3K–Akt–mTOR). Mammalian DNA viruses have evolved a range of mechanisms to 
obtain the benefits from activating this pathway, including regulation of translation 
through the activation of mTOR. mTOR kinase has been found to associate with two 
functionally varying complexes named mTORC1 and mTORC2 (Sarbassov et al., 
2004). Vaccinia virus has recently been shown to stimulate mTORC1 and 
phosphorylate the translational repressor 4E-BP1 in a rapamycin-sensitive manner 
(Walsh et al., 2008). However, whether VacV activates mTORC1 directly or involves 
kinases regulating mTOR remained unknown so far. In this study, we aimed to 
determine if stimulation of mTOR by VacV involves activation of the host PI3 kinase, 
and investigate its impact on virus replication in various cell lines. 
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4.2.1 Role of PI3K signaling in poxvirus protein synthesis 
The PI3K pathway is the major pathway that controls mRNA translation, hence it is a 
significant target for many viruses trying to take control of the cell (Rahaus et al., 2006; 
Hale and Randall, 2007). However, a number of viruses such as measles virus and 
vesicular stomatitis virus do not require activation of PI3 kinase to replicate, stimulating 
rather its downstream substrates (Avota et al., 2001; Gruenberg et al., 2006; Dunn et 
al., 2009). Previous studies of poxvirus signaling have demonstrated that myxoma virus, 
a rabbit-specific poxvirus, stimulates Akt directly by the host range protein MT-5, 
without involving its upstream regulator PI3K (Wang and Zal, 2006; Stanford et al., 
2007; Werden et al., 2007). Importantly, this was insensitive to even high 
concentrations of the PI3K inhibitor, LY294002. Here, we showed that VacV activates 
upstream PI3K/Akt signaling to activate mTOR. The role of PI3K in regulating VacV 
translation was examined by using specific inhibitors of PI3K, LY294002 and 
Wortmannin (Povis et al., 1994; Vlahos et al., 1994).  
Looking at the kinases and substrates downstream of PI3K in infected cells 
demonstrated that LY294002 dramatically reduced phosphorylation of the crucial 
factors regulating translation such as Akt and the substrates of mTORC1: 4E-BP1 and 
p70S6 kinase (p70S6K) (Fig. 3.2.1, 3.2.3). Similarly, inhibition of mTORC1 activity by 
rapamycin resulted in blocked VacV-mediated phosphorylation of 4E-BP1, as expected 
and reported previously (Walsh et al., 2008), and prevented phosphorylation of 
p70S6K. However, in contrast to LY294002, rapamycin did not block phosphorylation 
of Akt, the upstream target of mTORC1 (Fig. 3.2.1); instead, rapamycin caused a 
modest increase in phosphorylation of this kinase. This increase might be due to the 
feedback mechanisms where mTORC1 inhibits Akt indirectly through mTORC2 (Julien 
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et al., 2010). These findings clearly demonstrate that VacV, unlike myxoma virus, does 
require the host PI3 kinase to stimulate downstream signaling to mTORC1. 
Inhibition of PI3K also significantly affected the formation of eIF4F complexes by 
preventing VacV-stimulated phosphorylation of translational repressor 4E-BP1 (Fig. 
3.2.5). Indeed, PI3K inhibition resulted in robust recruitment of 4E-BP1 to eIF4E 
exceeding the levels observed in the cells either uninfected or infected in the presence of 
rapamycin, and caused a corresponding strong reduction in the amount of eIF4G bound 
to eIF4E. In contrast, rapamycin treatment only modestly reduced the amounts of eIF4G 
bound to eIF4E, and did not stop the virus from increasing eIF4F levels above those in 
infected cells. Inhibition of VacV-induced phosphorylation of 4E-BP1 in the presence 
of rapamycin, and more complete hypophosphorylation caused by LY294002 was also 
observed in input samples. Although both drugs prevented VacV-induced 
phosphorylation of 4E-BP1 with similar efficiency, maintaining it at the levels observed 
in uninfected cells or below, looking at the total abundance of 4E-BP1 in low 
percentage gel demonstrated that rapamycin prevented its degradation in infected cells, 
as reported previously (Walsh et al., 2008), but accumulation of hypophosphorylated 
4E-BP1 occurred to a much greater extent in the presence of LY294002 (Fig. 3.2.6), 
despite the fact that both inhibitors blocked phosphorylation of p70S6K equally (Fig. 
3.2.3). This suggests that rapamycin prevents the virus-stimulated phosphorylation of 
4E-BP1, but LY294002 reduces this phosphorylation below the levels observed in 
uninfected cells. Recent data demonstrated that phosphorylation of 4E-BP1 leads to 
ubiquitination and degradation of this protein (Elia et al., 2008), which results in 
enhanced protein synthesis. In contrast, dephosphorylation of 4E-BP1 was shown to 
increase its stability (Schneider et al., 2005; Le Bouffant et al., 2006), which leads to 
inhibition of translational rates. This may explain the increased levels of 
 188 
hypophosphorylated 4E-BP1 in LY294002-treated cells accompanied by dramatically 
reduced translational rates caused by this drug. In addition, phosphorylation of eIF4E, 
known to enhance VacV replication (Walsh et al., 2008), was also suppressed in 
LY294002-treated cultures (Fig. 3.2.7), most likely due to the collapse of eIF4F 
complexes, which prevents proper positioning of the eIF4G-bound kinase Mnk1 in 
proximity to its substrate, eIF4E, similar to previous reports (Tuazon et al,, 1990; 
Pyronnet et al., 1999; Walsh and Mohr, 2006). Furthermore, we demonstrated that 
LY294002 did not cause significant changes in eIF4G phosphorylation, which is 
partially regulated by mTORC1 (Fig. 3.2.8). Thus, dramatic loss of phosphorylated 
forms of this scaffold protein is unlikely to contribute to the collapse of eIF4F. 
To this point, the VacV strategies to commandeer the host translation machinery were 
examined in rapamycin-sensitive way, showing the importance of the mammalian target 
of rapamycin (mTOR) in stimulation of 4E-BP1 phosphorylation (Walsh et al., 2008). 
A number of research teams noticed the stimulation of mTOR by numerous groups of 
viruses (Feigenblum and Schneider, 1996; Gingras and Sonenberg, 1997; Kudchodkar 
et al., 2004; Walsh and Mohr, 2004; Moody et al., 2005; Oh et al., 2006; Castello et al., 
2009). However, rapamycin treatment usually does not significantly affect virus 
replication or protein synthesis. Kudchodkar et al. (2004) showed that in cells infected 
with human cytomegalovirus (HCMV), rapamycin only partially affects 4E-BP1 
phosphorylation, and distorted composition of both mTORC1 and mTORC2 complexes 
in infected cells may explain this effect (Kudchodkar et al., 2004). In contrast, in cells 
infected with herpes simplex virus type 1 (HSV-1), rapamycin completely blocks 
phosphorylation and release of 4E-BP1, and has a modest effect on eIF4F formation and 
virus replication (Walsh and Mohr, 2004). The effects of rapamycin observed in this 
research are very similar, and suggest that 4E-BP1 abundance may be insufficient in 
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regulating virus replication, at least in NHDFs used in this study. In addition, the effects 
of LY294002 illustrate that rapamycin-insensitive signaling pathway controls both 4E-
BP1 phosphorylation and accumulation to suppress eIF4F formation in VacV-infected 
cells by an unknown mechanism that may involve mTORC2 kinase. 
Given their effects on eIF4F formation, the effect of LY294002 and rapamycin on total 
VacV translational rates, CPE and virus replication was examined. The role of PI3K in 
the VacV life cycle was evident in various experiments carried out in this study. 
Looking at the morphology of the cells treated with PI3K inhibitor before and during 
infection, and comparing them with infected cells treated with DMSO, clearly showed 
that cells were indeed infected in the presence of LY294002, but a reduced cytopathic 
effect suggested that VacV replication was strongly inhibited by this drug, but not by 
rapamycin (Fig. 3.2.10). These observations suggested that PI3 kinase, in contrast to 
rapamycin-sensitive mTORC1, is crucial for effective replication of VacV.  
While rapamycin did not affect viral protein synthesis, LY294002 robustly suppressed 
translational rates, even at high input doses of virus (Fig. 3.2.11). The effects on 
translation rates were also reflected in the abundance of late viral proteins and viral 
titers, which were dramatically reduced in LY294002-treated cells, but not in those 
treated with rapamycin. Low levels of translation observed in those samples, despite 
disruption and dramatically reduced levels of eIF4F complexes, may reflect suggestions 
that although VacV mRNAs require eIF4F for efficient protein synthesis, translational 
processes can still be carried out in infected cells in the absence of those complexes 
(Aldabe et al., 1995; Mulder et al., 1998; Shirokikh and Spirin, 2008).  
Stimulation of other kinases activated by VacV but occurring outside of the PI3K 
pathway, such as extracellular signal regulated kinase (Erk) (de Magalhaes et al., 2001), 
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was only slightly affected by PI3K inhibition (Fig. 3.2.4), proving that the inhibitors 
worked only for the specific proteins. The modest effect on Erk was likely due to effects 
on virus replication rather than off-target effects of the inhibitors. Indeed, the inhibitors 
were used at a lower concentration than those used by Wang and Zal (2006), Stanford et 
al. (2007) and Werden et al. (2007), and to which myxoma virus is resistant. As such, 
VacV and myxoma virus activate Akt by distinct mechanisms. 
 
4.2.2 Investigation of cellular stress response and apoptosis in LY294002-treated 
cells infected with VacV 
The PI3K/Akt/mTORC1 pathway regulates cellular processes such as cell growth, 
proliferation, protein synthesis and apoptosis (Lawlor and Alessi, 2001) that are 
important for viral replication. Therefore, manipulation of this pathway appears to be a 
common strategy used by many viruses to control protein synthesis and cell survival. 
This pathway would be particularly important for DNA viruses whose translation is cap 
dependent. However, the Akt signaling can also negatively affect viral replication. For 
example, activation of some kinases downstream of Akt signaling results in cellular 
stress responses that can inhibit mTORC1 (Lee and Esteban, 1994; Avruch et al., 2006).  
Here, we examined if inhibition of PI3K by LY294002 causes cellular stress response in 
VacV-infected cells. As mentioned previously (Section 3.2.3), increased 
phosphorylation of eIF2α can be caused by physiological stress and lead to disruption in 
translation or cell death. Therefore it is one of the widely used indicators of cellular 
stress responses and apoptosis (Clemens, 2001). However, the levels of phosphorylated 
forms of eIF2α in VacV-infected cells treated with DMSO solvent control, rapamycin or 
LY294002 showed no noticeable differences in those samples (Fig. 3.2.9). Furthermore, 
 191 
no changes in eIF4G abundance, a factor that is cleaved during apoptosis (Clemens et 
al., 1998), were noticed in those samples suggesting that cellular stress responses were 
not involved in inhibition of viral replication caused by this drug. Furthermore, studying 
the morphology of the cells showed no signs of apoptotic death and demonstrated that 
LY294002 actually protected the cells from morphological changes caused by the virus, 
suggesting that VacV replication cycle was robustly inhibited by this drug, while 
rapamycin did not seem to reduce virus replication (Fig. 3.2.10).  
Interestingly, shortly after publishing our findings (Zaborowska and Walsh, 2009), 
Soares et al. (2009) demonstrated that LY294002 caused apoptosis in mouse A31 cells 
infected with vaccinia or cowpox virus (CPXV). This group showed that inhibition of 
PI3 kinase by LY294002 during either VacV or CPXV infection increased the cleavage 
of proteins associated with the induction of apoptosis, such as the executioner caspase-3 
and PARP. Furthermore, inhibition of proapoptotic signals by zVAD.fmk prevented the 
cleavage of caspase-3 and increased viral replication. It was suggested that increased 
cytopathic effect in VacV- and CPXV-infected A31 cells treated with LY294002 was 
due to pharmacological inhibition of the antiapoptotic activity mediated by the 
PI3K/Akt pathway. However, our investigation of apoptosis in various human and 
monkey cell lines did not show any significant apoptotic effects of LY294002 (Fig. 
3.2.14). Our findings demonstrate that treating the cells with LY294002 did not result in 
the cleavage of caspase-7 or PARP, observed in the control cells treated with Akt 
inhibitor I (Akti)6.  In addition, no changes in cell morphology were observed in 
cultures infected in the presence of LY294002 suggesting that cells did not undergo 
apoptosis, in contrast to the cells treated with Akti (Fig. 3.2.13 a-c). Similarly, other 
groups investigating LY294002’s effect on VacV-infected human and monkey cells did 
                                                 
6
 Apoptotic death of the cells treated with Akti may be off-target effect of the drug or could be caused by 
Akt inhibition while PI3K is still active. However, here Akti served as a control for apoptosis. 
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not notice apoptotic death caused by this inhibitor (Dunn et al., 2009, Hu et al. 2009; 
McNulty et al., 2010). Therefore, apoptosis caused by LY294002 in VacV-infected 
cells appears to be specific only for certain mouse cell line(s).  
 
4.2.3 The role of mTOR in VacV protein synthesis 
At the time our results were being published, Thoreen and colleagues (2009) identified 
a new mTOR inhibitor named Torin1, a member of the pyridinonequinoline class of 
kinase inhibitors, which acts as a highly potent and selective inhibitor that suppresses 
both mTORC1 and mTORC2 complexes with IC50 values between 2 and 10nM through 
an ATP-competitive mechanism. Interestingly, this group demonstrated that the effects 
of Torin1 were independent of mTORC2 inhibition and were instead caused by 
suppression of rapamycin-resistant functions of mTORC1 that are crucial for cap-
dependent translation. Furthermore, the effects of Torin1 were at least partially 
mediated by mTORC1-dependent and rapamycin-resistant phosphorylation of 4E-BP1. 
We therefore tested whether Torin1 affected VacV infection of NHDFs as described in 
section 3.1.6. We showed that inhibition of mTORC1 and mTORC2 using Torin1 
completely disrupted eIF4F complexes both in infected and uninfected cells, 
demonstrating that PI3K activation of mTOR signaling was involved in the formation of 
eIF4F during VacV infection, and confirming that the effects of LY294002 were 
specific to this signaling pathway. In addition, Torin1 blocked phosphorylation of Akt 
and prevented VacV-induced phosphorylation of 4E-BP1 causing its accumulation at 
similar levels as LY294002 (Fig. 3.2.15) indicating that phosphorylation and 
accumulation of this translational repressor is regulated in rapamycin-insensitive 
manner. These findings demonstrate that treating VacV-infected cells with either Torin1 
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or LY294002 results in similar impact on the main signaling pathway regulating protein 
synthesis and leads to disruption of eIF4F. However, Torin1 did not significantly affect 
VacV protein synthesis (it affected translation better than rapamycin, but not as 
drastically as LY294002 or wortmannin) despite the fact that eIF4F was disrupted in the 
presence of this inhibitor, with the translational rates of VacV proteins only partly 
reduced (Fig. 3.2.17 a-b). This suggests that mTOR inactivation and eIF4F disruption 
contribute to the effects of LY294002 on VacV replication but that other PI3K-
dependent processes are involved in the effects of this inhibitor on virus replication. In 
terms of mTORC1 and mTORC2, Moorman and Shenk (2010) recently showed that 
Torin1, but not rapamycin, blocks mTOR signaling, disrupts assembly of eIF4F, and 
significantly decreases accumulation of viral proteins in human cytomegalovirus- and 
HSV-infected cells. However, these experiments were performed at moi 0.05 for three 
days, which amplifies small defects in virus replication. As such, the effects of mTOR 
inhibition in herpesvirus-infected cells appear to be similar to the effects in VacV-
infected cells. Our results suggest that VacV has a specifically low requirement for 
eIF4F to translate its mRNAs. This is in agreement with previous studies in transformed 
cell lines (Aldabe et al., 1995; Mulder et al., 1998) and a recent in vitro analysis that 
suggested that the unusual polyA-tract in the 5’UTR of VacV mRNAs may reduce their 
dependence on normal cap-dependent translation initiation processes (Shirokikh and 
Spirin, 2008). However, their seemingly low dependence on eIF4F may simply be 
similar to abundant, unstructured “housekeeping” mRNAs.  
Our findings do demonstrate that eIF4F activity enhances viral protein synthesis and is 
beneficial for virus replication, even if the effect of disrupting this critical complex is 
not as dramatic as might be expected. 
 
 194 
4.3 Direct manipulation of the eIF4F complex by vaccinia virus 
Given the importance of the eIF4F complex in regulating translation, a number of 
viruses encode proteins that directly interact with eIF4F to manipulate its function. 
Among RNA viruses, rotavirus-encoded protein NSP3 binds specifically to the 
conserved 3’end of viral mRNA and to the translation initiation protein eIF4G (Piron et 
al., 1998; Vende et al., 2000). In addition, eIF4G displays higher affinity for NSP3 than 
for PABP and as a consequence the interaction between eIF4G and PABP is disrupted 
in rotavirus-infected cells (Groft and Burley, 2002), which results in reduced efficiency 
of host mRNA translation and circularization-mediated enhancement of viral protein 
synthesis. Similarly, the expression of influenza virus NS1 protein has been shown to 
promote translation of viral but not cellular mRNAs by association with eIF4G (Aragon 
et al., 2000; Burgui et al., 2003). NS1 was found to recruit eIF4G to the 5’UTR of the 
viral mRNA, allowing the preferential translation of the influenza virus messengers. 
Further study demonstrated that influenza virus-encoded polymerase competes with 
eIF4E to bind to the cellular cap structures and eIF4G, and suggested the role of viral 
polymerase as a substitute for the eIF4E factor with the aim to promote viral mRNA 
translation (Burgui et al., 2007). Hantavirus in turn took this approach even further and 
has been recently shown to replace the entire cellular eIF4F complex with the viral 
nucleocapsid protein (N) (Mir and Panganiban, 2008). N protein was shown to directly 
interact with 5’mRNA cap replacing eIF4E function, and with 43S pre-initiation 
complex functionally replacing eIF4G activity. N was also able to substitute as an RNA 
helicase in rabbit reticulocyte lysates, functionally replacing eIF4A activity. Thus N 
protein acts as a viral translation initiation factor with all of the properties of the eIF4F 
complex. N-mediated translation initiation is a viral strategy comparable to IRES. While 
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IRES is a cis-acting element that functionally supplants the requirement for cap-
dependent translation, N is a trans-acting element that replaces eIF4F.  
In the case of DNA viruses, adenovirus-encoded 100k protein was shown to inhibit 
phosphorylation of eIF4E at Ser209 and block cellular protein synthesis during the late 
phase of infection by preventing the association of the eIF4E kinase Mnk1 with the 
scaffold protein eIF4G (Cuesta et al, 2000). In addition, Xi et al. (2004) demonstrated 
that 100k binds to eIF4G to promote translation of viral mRNAs via ribosome shunting, 
whereby the ribosomes jump to the start codon rather than scanning the mRNA. 
Another example is ICP6 protein encoded by HSV-1 virus (Walsh and Mohr, 2006), 
which has homology to the cellular chaperone Hsp27 that regulates eIF4F levels during 
stress (Cuesta et al., 2000). ICP6 was shown to promote the assembly of eIF4F 
complexes and is thought to directly promote the association of eIF4E with the N 
terminus of eIF4G without involving other cellular or viral components (Walsh and 
Mohr, 2006). 
Looking at the growing number of viruses encoding factors that interact with the 
scaffold protein eIF4G suggests that it is a common strategy used by both RNA and 
DNA viruses to directly manipulate the key translation initiation complex eIF4F. How 
vaccinia virus, the prototypical poxvirus, controls the host translational apparatus 
remained unknown so far. Our findings demonstrated that, in addition to activating the 
signal pathways that regulate eIF4F, VacV also encodes a protein that directly interacts 
with this complex.  
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4.3.1 Redistribution of selected proteins during VacV infection 
An unusual feature of VacV is that, although it is a DNA virus, it replicates exclusively 
in the cytoplasm of the infected cell. During VacV infection a number of selected 
cellular proteins such as molecular chaperone Hsp90 (Hung et al., 2002), Cyclophilin A 
(Castro et al., 2003), G3BP/Caprin-1 (p137) heterodimer (Katsafanas and Moss, 2007), 
Topoisomerase II (Lin et al., 2008), and DNA Ligase I (Paran et al., 2009) have been 
shown to redistribute to viral factories suggesting their importance in VacV replication. 
Amongst cellular translational factors, the components of eIF4F complex, eIF4G and 
eIF4E were found to be dramatically redistributed and accumulated within the viral 
factories, while the poly(A)-binding protein (PABP) and ribosomal proteins appear to 
accumulate mostly around the factories (Katsafanas and Moss, 2007; Walsh et al., 
2008). In contrast, a number of other RNA-binding proteins do not redistribute during 
infection. Therefore, rearrangement of cellular proteins during VacV infection appears 
to be selective and most likely mediated by specific functions, like in the case of the 
recruitment of cellular topoisomerase II by viral DNA ligase described by Lin et al. 
(2008). 
 Apart from VacV, African swine fever virus (ASFV)  is the only other DNA virus that 
replicates exclusively in the cytoplasm and it also causes relocalization of both eIF4G 
and eIF4E to viral factories (Castello et al., 2009). In addition, immunofluorescence 
technique revealed redistribution of other initiation and elongation factors such as eIF3, 
eIF2, eEF2 and ribosomes, and their accumulation within and around the virosomes, 
suggesting that viral replication, transcription, translation and morphogenesis occur in 
close proximity in ASFV virosomes. Consequently, all these processes appear to be 
tightly coupled, taking place in discrete cytoplasmic areas to maximize their efficiency. 
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The same group investigated redistribution of the mitochondrial network during ASFV 
infection using MitoTracker probes, which are a series of mitochondrion-selective dyes 
that are retained during cell fixation. While mitochondria appeared uniformly 
distributed in the cytoplasm of uninfected cells, their accumulation at the periphery of 
ASFV factories was evident at 16 hpi, suggesting that ATP synthesis is also coupled 
with viral replication and protein synthesis (Castello et al., 2009). 
 
VacV proteins also accumulate in the sites of replication. For instance, VacV-encoded 
E3, a double-stranded RNA-binding protein that prevents activation of PKR and RNase 
L innate immune defenses (Chang et al., 1992; Rivas et al., 1998), was found to 
associate with factories. In addition, the fact that viral-encoded transcription factors also 
accumulate within the virosomes led to the suggestion that poxvirus transcription and 
translation are linked, but probably not directly coupled as in bacteria (Katsafanas and 
Moss, 2007). Several other VacV early proteins encoded by genes B1R, H5R (Beaud 
and Beaud, 1997) and early/intermediate protein encoded by I3L (Rochester and 
Traktman, 1998) were also found to associate with the factories; moreover, it was 
suggested that those proteins are simultaneously the precursors of sites of viral DNA 
synthesis, since the factories incorporated BrdU upon washout of a viral DNA 
replication inhibitor (Domi and Beaud, 2000). One or more of these proteins may play a 
role in redistribution of host factors to viral factories. 
 
4.3.2 Discovery of a VacV protein that associates with eIF4F 
In the beginning of the investigation of redistribution of translation factors caused by 
VacV we speculated that a specific viral protein or cellular protein induced by the virus 
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might interact with eIF4F and/or other factors involved in protein synthesis and trigger 
their relocation in infected cells. Screening the components of the eIF4F complex in 
VacV-infected normal human diploid fibroblasts (NHDFs) resulted in discovery of a 
34-kDa protein actively translated and associated with anti-eIF4G immune complexes at 
16 but not 24 hpi (Fig. 3.3.1 a-b), which suggested that it is either no longer synthesized 
or no longer associated with eIF4G at late stages of infection. In contrast, the 34-kDa 
protein did not associate with anti-PABP immune complexes immunoprecipitated from 
the cell extracts (Fig. 3.3.2). The 34-kDa protein was then identified by mass 
spectrometry as an ssDNA-binding phosphoprotein (I3) encoded by VacV I3L ORF 
(Fig. 3.3.4 b).  
I3 has been shown previously to be an early-to-intermediate stage protein (Rochester 
and Traktman, 1998), which agrees with the idea that it is not actively synthesized at 
late stages of infection (Fig. 3.3.1 b). Furthermore, I3 shows strong affinity for ssDNA 
and was revealed to associate with ribonucleotide reductase, suggesting an interaction 
with the nucleotide synthetic machinery at the replication fork and its potential role in 
DNA replication and/or repair (Davis and Mathews, 1993; Rochester and Traktman, 
1998; Domi and Beaud, 2000; Welsch et al., 2003). In addition, I3 phosphorylation on 
serine residues does not alter its binding properties for ssDNA (Rochester and 
Traktman, 1998). The function of I3 is poorly understood, although previous 
observations lead to the suggestion that I3 plays an essential role in the vaccinia virus 
infectious cycle, most likely as a viral SSB (Rochester and Traktman, 1998), but other 
functions of I3 can not be excluded.  
The interaction between I3 and eIF4G was verified by performing the reverse 
immunoprecipitation using anti-I3 antiserum. At first, eIF4G was not recovered with 
anti-I3 immune complexes, most likely because the antibody epitope and eIF4G binding 
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site are the same region, or because direct binding of an antibody to I3 alters its 
structure causing release of bound factors, such as eIF4G. Generating a stable cell line 
over-expressing FLAG-tagged I3 allowed us to immunoprecipitate anti-FLAG immune 
complexes from infected and uninfected cells expressing FLAG-I3, together with 
associated eIF4G. As shown in figure 3.3.14, FLAG-I3 clearly bound to eIF4G in 
uninfected cells. In addition, viral I3 competed away the recombinant I3 from binding to 
eIF4G, which resulted in the loss of eIF4G association with FLAG-immune complexes 
in infected cells. This could be the effect of much lower expression of recombinant 
versus viral I3 detected by anti-I3 antiserum in input samples. However, the fact that 
eIF4G can be recovered together with FLAG-I3 complexes suggests an interaction 
between those two proteins that does not require other viral factors.    
Our discovery that I3 interacts with eIF4G was verified by an alternative, non-immune 
based assay. eIF4F complexes were recovered from infected HEK-293 cells by 7-
Methyl GTP-sepharose 4B chromatography and the samples were then analyzed by 
immunoblotting. As shown in figure 3.3.5, while no I3 was detected in mock-infected 
sample, it clearly associated with eIF4F complexes in infected cells. In addition, the 
binding of I3 was competitively inhibited by the addition of free 7-Methyl GTP to the 
extracts. The fact that I3 was bound to eIF4F in HEK-293 cells at this time point 
suggested that I3 did remain associated with eIF4F at the late stages of infection reached 
by 16 h in HEK-293 cells. This further supported the idea that the lack of 35S-labelled I3 
in eIF4G immune complexes at 24 hpi in serum-starved NHDFs simply reflected the 
fact that its synthesis declined at late stages. 
Furthermore, recovering cap-bound complexes from uninfected HEK-293 cells over-
expressing I3 by performing 7-Methyl GTP-sepharose 4B chromatography 
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demonstrated that I3 was able to bind to eIF4F on its own, in the absence of other viral 
proteins and enzymes (Fig. 3.3.15). Direct interaction of I3 with cap complexes was 
also verified by adding purified I3 to HEK-293 cell extracts (Fig. 3.3.16). These results 
strongly confirmed the specificity of I3-eIF4F interaction. The ability of I3 to directly 
interact with eIF4G was investigated further by performing in vitro binding assays. 
 
4.3.3 Identification of I3- and eIF4G-binding domains 
Having identified I3 as a viral protein associating with translational factor eIF4G we 
then precisely investigated this interaction. By a series of experiments using purified 
proteins we demonstrated that I3 binds to eIF4G by direct interaction, moreover, this 
binding occurred in the absence of other viral proteins.  
As demonstrated in Section 3.3.5, recovering cap complexes from uninfected HEK-293 
cell extracts confirmed the ability of purified, his-tagged I3 to associate with eIF4F in 
vitro (Fig. 3.3.16). Therefore, a binding assay with eIF4G fragments could be carried 
out with the aim to determine whether I3 associates with eIF4G directly or whether it 
involves other factors that mediate that reaction. The binding assays were performed 
using his-I3 and three GST-tagged fragments of eIF4G: N-(aa157-626), M-(aa627-
1045), and C-(aa1045-1560) terminal, and GST-bound complexes were recovered by 
glutathione-sepharose 4B. Analysis of the samples by immunoblotting suggested that 
the I3-binding site is localized on the C-terminal fragment of eIF4G. It is worth to 
mention that RNA-binding domains of eIF4G are located mostly in the M-fragment, 
while the direct interaction with I3 occurred with the C-terminal part of the gene, 
indicating that this interaction did not involve the nucleic acid-binding regions of 
eIF4G. Moreover, I3 does not appear to compete with either eIF4E or PABP for the 
 201 
binding site of eIF4G, as their domains are situated within the N-terminal fragment. C-
terminal part of eIF4G contains, however, the Mnk1/2 binding domains, and Ad 100k 
protein also binds the C-terminus to evict Mnk1/2 and inhibit translation (Cuesta et al., 
2000). However, the competition between Mnk1/2 and I3 can be excluded on account of 
the fact that VacV was shown to stimulate the eIF4E kinase during infection to promote 
eIF4E phosphorylation (Walsh et al., 2008). This suggests that I3 seems to bind a region 
of C-4G distinct from that of Mnk1/2 and Ad 100k. 
Identification of the region of I3 involved in its association with eIF4G was then 
performed by the same binding assay, using five his-tagged deletion fragments of I3 as 
described in Section 3.3.7, and GST-tagged C-terminal fragment of eIF4G (C-4G). 
Sample analysis by immunoblotting using anti-his and anti-GST antisera demonstrated 
that only the fragment labeled F1 (aa1-216) and deleted within the C-terminal region of 
I3 was found to associate with C-4G in vitro, despite its low abundance in the reaction 
observed in input samples (Fig. 3.3.21). Noteworthy is the fact that the predicted nucleic 
acid-binding domain of I3 is located within amino acids 91-154 (Rochester and 
Traktman, 1998), which is a part of the fragment F2 and distinct from the region 
required for binding to C-4G (Fig. 3.3.22). Moreover, the C-terminus of I3 containing 
the putative eIF4G binding site has been shown to be highly acidic (Davis and 
Mathews, 1993), similar to other ssDNA-binding proteins such as bacteriophage T4 
gene 32 protein, where a role in replication has been demonstrated (Chase and 
Williams, 1986). In addition, this region of the gene 32 protein was also shown to 
mediate interactions with other proteins (Krassa et al., 1991), suggesting that it shares 
similar features with VacV I3.  
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Surprisingly, the large fragment F5 deleted in its N-terminal domain but containing 
amino acid sequences from region 160-216 failed to restore binding to C-4G. The 
possible reason is that the loss of N-terminal region resulted in changing the protein 
structure that is no longer able to interact with eIF4G, or it could be that both domains 
are involved in binding. Although the binding assay still needs to be optimized, finding 
the region of I3 responsible for its interaction with eIF4G provides an important issue 
for future study.  
Study of I3 interactions demonstrated that this protein directly associates with the key 
cellular translational factor eIF4G and with cap complexes, suggesting its role as an 
important tool used by the virus to commandeer crucial components of the host 
translational apparatus.  
 
4.4 Inhibition of host mTORC1 activity and its influence on I3-eIF4F interaction 
It was shown previously that VacV infection stimulates the activity of mTORC1 
complex which results in inactivation of the translational repressor 4E-BP1 by 
phosphorylation leading to stimulation of eIF4F complex formation (Walsh et al., 
2008). Treating cells with the mTORC1 inhibitor - rapamycin - effectively prevented 
inactivation of 4E-BP1 and partially reduced the production of infectious virus, as can 
be seen in figure 3.2.12. Here, we established that inhibition of mTORC1 also affects 
the interaction between I3 and eIF4F complexes. 
 
4.4.1 Effect of rapamycin on I3 association with eIF4F complexes 
To examine I3-eIF4F interaction in the presence of rapamycin, 7-Methyl GTP-bound 
complexes were recovered from infected HEK-293 cells, and associated proteins were 
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analyzed by western blotting. As shown previously, rapamycin effectively prevented 
phosphorylation of 4E-BP1 mediated by VacV but did not alter the levels of eIF4F 
complexes and had no significant effect on the accumulation of I3 in infected cell 
extracts (Fig. 3.3.23). However, rapamycin did reduce the levels of I3 bound to eIF4F 
approximately 3-fold, although significant amounts of I3 remained associated with 
eIF4F, which was not disrupted by rapamycin. Similarly, binding of recombinant, his-
tagged I3 to eIF4F was partially reduced when cap complexes were recovered from 
uninfected cell extracts treated with rapamycin (Fig. 3.3.24), demonstrating that the 
effect of rapamycin is not limited to the context of infection. These results indicate that 
I3 continues to associate with the major initiation complex in the presence of 
rapamycin, which would explain why this inhibitor did not affect the total VacV 
translational rates or total levels of I3, as illustrated in figure 3.2.11. Furthermore, our 
results do demonstrate that although rapamycin did not drastically affect interaction 
between I3 and cap complexes, maximal I3 binding required the activity of cellular 
mTORC1.  
 
4.4.2 Effect of rapamycin on I3 association with eIF4G 
We then examined whether the same effects were observed when the association of I3 
with eIF4F complexes was performed by immunoprecipitation of eIF4G from infected 
cells. Western blot analysis demonstrated that eIF4G and eIF4E levels remained 
unaltered in infected cells with or without the presence of rapamycin (Fig. 3.3.25), 
indicating that eIF4F complex is not disrupted by rapamycin in HEK-293 cells. 
Surprisingly, in contrast to findings with 7-Methyl GTP-sepharose, rapamycin did not 
affect the levels of 35S-labeled I3 associated with eIF4G indicating that I3 association 
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with the scaffold protein in infected cells is not regulated by mTORC1 complexes. This 
outcome could explain our previous findings that rapamycin, in contrast to LY294002, 
does not affect VacV protein synthesis or accumulation of viral proteins (Fig. 3.2.11). 
The fact that inhibition of mTORC1 results in reduction of I3 levels associated with 7-
Methyl GTP cap complexes, but not with eIF4G itself, could reflect differences in the 
sensitivity of assays used in those experiments. However, each assay was directly 
recovering different components of the eIF4F complex, namely eIF4E and eIF4G, 
which suggests the possibility of I3 interaction with other factors bound to the cap. 
Taking into consideration that during VacV infection viral I3, as well as cellular eIF4G 
and eIF4E were shown to accumulate within the sites of viral replication (Rochester and 
Traktman, 1998; Katsafanas and Moss, 2007; Walsh et al., 2008), we tested whether I3 
might also associate with the cap-binding protein eIF4E.  
 
4.4.3 Investigation of possible I3-eIF4E interaction 
To test if I3 could bind to eIF4E, a binding assay using his-I3 and batch-purified eIF4E 
was carried out. As demonstrated in figure 3.3.26, I3 did associate with the 7-Methyl 
GTP cap complexes in the presence of eIF4E, and in the absence of the remaining eIF4F 
components. This result suggests that I3 might have the ability to associate with both 
eIF4G and eIF4E factors, although this implication needs to be verified by performing 
in vitro binding assays using purified eIF4E protein and I3 fragments. 
On the assumption that I3 does interact with eIF4E, we examined whether the efficiency 
of this binding is affected by the presence of eIF4G. To do this, increasing amounts of a 
GST-tagged N-terminal fragment of eIF4G (N-4G) containing the eIF4E binding site, 
but bereft of the binding site for I3, was added to the binding reactions. Western blotting 
 205 
analysis of the samples demonstrated that inclusion of N-4G did not change the levels 
of I3 bound to the cap complexes (Fig. 3.3.26). I3 binding did not increase as I3 binds 
the C-terminal domain of eIF4G. This experiment demonstrated that association of I3 
with eIF4E was not competitive at least for the N-terminal fragment of eIF4G, and 
suggested that I3 can interact with both free and eIF4G-associated eIF4E. 
Those results suggest that most likely the interaction between I3 and eIF4E does occur. 
Moreover, our observations imply that the effect of rapamycin on association between 
I3 and cap-complexes might reflect competition between I3 and 4E-BP1 for binding to 
free eIF4E that is not a part of eIF4F complex. This would explain why inhibition of 
mTORC1 did not affect I3 binding to eIF4G but it did reduce the I3 association with 
cap-complexes. Furthermore, it was suggested that eIF4E has a larger footprint for 4E-
BP1 than that of eIF4G, which partially overlaps the eIF4G-binding domain (Matsuo et 
al., 1997; Tomoo et al., 2006; Moerke et al., 2007).  If that is the case, with its larger 
footprint on eIF4E, 4E-BP1 could potentially affect the association of proteins with 
eIF4E that are not affected by binding of eIF4G.  
 
4.5 Regulation of PABP in VacV-infected cells 
In addition to enhancing the levels of eIF4F, VacV also stimulates the recruitment of 
PABP to eIF4F complexes in infected cells (Walsh et al., 2008). As reported previously, 
in contrast to eIF4G and eIF4E proteins that accumulate inside the factories (Rochester 
and Traktman, 1998; Katsafanas and Moss, 2007; Walsh et al., 2008), only small 
amounts of PABP are recruited into these sites of viral replication (Walsh et al. 2008). 
However, the redistribution and localization of large pools of PABP near the factories 
suggest that PABP might play a role in VacV protein synthesis. Our findings imply that 
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low abundance of PABP found in the factories might be the result of its interaction with 
eIF4F complexes bound to I3 protein. 
As demonstrated previously by performing cap-assays, VacV infection causes increased 
formation of eIF4F complexes and recruitment of PABP, while the overall abundances 
of eIF4F components as well as PABP remain constant in infected and uninfected cells 
(Walsh et al., 2008). This study confirmed the increased formation of eIF4F complexes 
and recruitment of PABP by immunoprecipitation, demonstrating increased recovery of 
eIF4E in eIF4G and PABP immune complexes recovered from infected cells. In 
addition, only low levels of eIF4E were detected in PABP immune complexes 
recovered from both mock and infected cells (Fig. 3.3.3), suggesting that only small 
amounts of the total cellular pool of PABP were in fact associated with eIF4F 
complexes, at least in NHDFs. This would explain the fact that only very little of PABP 
was found accumulated within viral factories, most likely as a result of its association 
with I3-bound eIF4F complexes. Similarly, it is possible that PABP complexes contain 
small amounts of I3 as part of the eIF4F-associated portion of PABP that was not 
detected by the assay. The fact that I3 was able to mediate the recruitment of eIF4G-
bound PABP to ssDNA in vitro (Fig. 3.3.33) appears to confirm that assumption. 
Therefore, this study demonstrates that although I3 was not able to directly associate 
with PABP, it could effectively recruit eIF4F complexes associated with PABP. Indeed, 
our findings demonstrate that binding domains for I3 and PABP are located on different 
termini of eIF4G, suggesting that those two proteins are likely to be able to interact with 
the scaffold protein simultaneously.   
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4.6 Function of I3 in regulating translation 
The precise function(s) of I3 remain poorly understood. Rochester and Traktman (1998) 
identified I3 as a viral single-stranded DNA (ssDNA) binding protein (SSB), and its 
role as a viral SSB has been considered. The fact that I3 is intensively synthesized 
before and during DNA replication, its accumulation in the sites of viral DNA 
replication and high-affinity binding to ssDNA makes it an ideal candidate for a viral 
SSB. 
Single-stranded DNA-binding proteins (SSBs) are crucial elements in cells of all living 
organisms. SSB proteins associate with ssDNA in a sequence independent manner, 
preventing ssDNA from forming secondary structures and from degradation by 
nucleases (Greipel et al., 1989). As such, SSBs participate in all processes involving 
ssDNA, such as replication, repair and recombination, playing a role of a 
multifunctional protein (Greipel et al., 1989; Meyer and Laine, 1990; Moore et al., 
1991; Alani et al., 1992). SSB proteins occur in prokaryotes and eukaryotes and share 
sequences as well as biochemical and structural characteristics. 
During their investigation of the potential role of I3 as an SSB carried out by Rochester 
and Traktman (1998), the analogy of I3 to the cellular Replication Protein A (RPA), 
which acts as a human SSB, has been considered. RPA is a heterotrimeric single-
stranded DNA-binding protein (SSB) that is highly conserved in eukaryotes and plays a 
critical role in many aspects of nucleic acid metabolism. RPA homologues have been 
identified in all eukaryotic organisms examined and interact with and/or modify the 
activities of multiple proteins (Wold MS, 1997), such as the components of the repair 
machinery as well as the replication machinery (He et al., 1995; Li et al., 1995; 
Nagelhus et al., 1997). Similarly, I3 might associate with such viral enzymes as the 
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uracil DNA glycosylase (UDG). Verification of such an interaction would clarify the 
fact that UDG, similarly to I3, was shown to be essential for DNA replication (Stuart et 
al., 1993; Millns et al., 1994).  
Furthermore, earlier studies showed the interaction between I3 and VacV ribonucleotide 
reductase, suggesting that I3 may interact with the nucleotide synthetic machinery at the 
replication fork. It was also considered whether I3 is involved in promoting poxviral 
recombination (Tseng et al., 1999). Furthermore, David and Mathews (1993) observed 
that I3, similarly to SSB of bacteriophage T4 (gene 32 protein), has a highly acidic C-
terminus. This fragment of gene 32 protein is responsible for mediating interactions 
with other proteins. Similarly, we demonstrated that the C-terminal region of I3 
interacts with the scaffold protein eIF4G.  
Studies to date of the function of I3 in VacV life cycle were limited to its role in viral 
replication as a viral SSB protein. The results described in our study provide the first 
evidence of I3’s interaction with key cellular proteins mediating protein synthesis.  
   
4.6.1 Role of I3 in stimulating translation 
This study demonstrated that I3 associated with the eIF4F complex at early-to-
intermediate stages of infection (Fig. 3.3.1, 3.3.2), when the majority of viral proteins 
are synthesized, and was not affected by PAA (Fig. 3.3.29). However, PAA did affect 
eIF4F formation in infected cells (Fig. 3.3.27), suggesting that I3 was not capable of 
directly stimulating the formation of eIF4F complexes. In addition, looking at the 
translational rates of control HEK-293 cells and cells expressing recombinant I3 
demonstrated that no significant changes in rates or patterns of cellular protein synthesis 
were observed in the presence of I3 (Fig. 3.3.33). We also examined whether I3 affects 
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translation of RNA isolated from VacV-infected cells in vitro using rabbit reticulocyte 
lysates programmed with RNA isolated from infected HEK-293 cells. As illustrated in 
figure 3.3.34, similarly to the effects of I3 on host protein synthesis, the presence of I3 
did not significantly influence the rates or patterns of viral protein synthesis. As such, I3 
does not appear to have any significant direct effect on the translation of either host or 
viral messages. 
 
4.6.2 Role of I3 in recruitment of translational factors to the factories 
Although I3 did not influence translation directly, our findings demonstrate that it is 
likely to be involved in indirect regulation of translation by associating with 
translational factors and retaining them within viral factories. While redistribution of 
translational factors eIF4G, eIF4E and PABP caused by VacV has been previously 
described (Katsafanas and Moss, 2007; Walsh et al., 2008), the mechanism of this 
movement remained unknown so far. By performing immunofluorescence assay using 
VacV-infected cells expressing GFP-tagged I3 we demonstrated that it colocalized 
within viral factories together with the scaffold protein eIF4G (Fig. 3.3.8), suggesting 
direct involvement of I3 in redistribution of eIF4G, and most likely eIF4E shown to 
colocalize with eIF4G within the virosomes (Walsh et al., 2008). We examined the role 
of ssDNA in the ability of I3 to associate with translational factors and their 
relocalization to the factories.  
I3 was shown to have high affinity for ssDNA, which appears to explain its retention in 
viral factories (Rochester and Traktman, 1998; Tseng et al., 1999; Domi and Beaud, 
2000). By performing binding assay using exogenously added ssDNA we demonstrated 
that I3 is able to selectively recruit host translation initiation factors to ssDNA in vitro 
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(Fig. 3.3.32). Specificity of recruitment of translational factors by I3 was verified by 
looking at the association of RBM3, the cellular protein interacting with both RNA and 
ssDNA, in the same samples. As illustrated in figure 3.3.32, binding of RBM3 to 
ssDNA was visibly reduced in the presence of I3, most likely as a consequence of 
competition from I3 for binding to ssDNA. In addition to confirming the specificity of 
I3 function in recruiting translation factors, this also demonstrated that I3 was not 
simply stabilizing the input ssDNA in extracts and, thereby, non-specifically mediating 
the increased recovery of nucleotide-binding proteins in general. The fact that I3 
possessed the ability to directly bind and recruit specific factors to ssDNA and co-
localize with them to distinct sites of viral replication suggests a novel approach 
adopted by a DNA virus to manipulate the translation initiation complex eIF4F.  
 
4.6.2.1 Effect of PAA on eIF4F complex formation 
Recently a number of viruses have been shown to increase the levels of eIF4F to 
promote viral protein synthesis. Although many DNA viruses are now known to 
inactivate 4E-BP1, several DNA viruses including HSV-1, HCMV, and VacV are able 
to mediate eIF4F complex formation through additional, rapamycin-insensitive 
mechanisms due to enhancement of eIF4G binding to eIF4E, which can occur in the 
absence of significant release of the repressor 4E-BP1 (Kudchodkar et al., 2004; Walsh 
and Mohr, 2004; Walsh et al., 2005; Zaborowska and Walsh, 2009). Interestingly, in 
HSV-1-infected cells the release of 4E-BP1 alone does not appear to be sufficient to 
promote eIF4F complex formation in the absence of the viral eIF4F chaperone ICP6 
(Walsh and Mohr, 2006). Similarly, we show that stimulation of eIF4F complex 
formation in VacV-infected cells was reduced in the presence of PAA in spite of 
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efficient release of 4E-BP1 from eIF4E (Fig. 3.3.27). In addition, PAA did not 
significantly affect the ability of I3 to interact with eIF4F (Fig. 3.3.29) suggesting that, 
in contrast to HSV-1-encoded ICP6 protein, I3 binding alone is not sufficient to 
promote initiation complex formation. PAA blocks viral factory formation and 
redistribution of eIF4G (Walsh et al., 2008) suggesting that I3 might increase the 
formation of eIF4F complexes in cell types where the rates of complex formation are 
low by concentrating host translation factors within viral factories to enhance the 
efficiency of viral protein synthesis. Similar process of eIF4F assembly was also 
observed in serum-starved NHDFs infected with human cytomegalovirus (HCMV) 
(Walsh et al., 2005). HCMV induces an increase in the overall abundance of eIF4F 
components and promotes assembly of eIF4F complexes. However, in contrast to HSV-
1, HCMV does not appear to encode any protein involved in promoting the formation of 
eIF4F and, in contrast to VacV, does not redistribute host translation factors.  
It is likely that increased levels of eIF4F complexes observed in VacV-infected serum-
starved NHDFs, which contain low levels of translation factors (Arias et al., 2009), are 
caused by changes in the on-off rates of eIF4E:eIF4G interaction under more 
concentrated conditions within viral factories. I3 is unlikely to affect on-off rates of 
eIF4E:eIF4G interaction directly and in the presence of PAA, when no viral factories 
are formed to accumulate the factors, thus the levels of eIF4F complexes remain 
unaltered compared to those in uninfected cells.  
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4.6.3 VacV ∆I3L mutant 
The literature to date, as well as the results obtained in this study, indicate the 
importance of I3 protein in VacV replication and protein synthesis. The attempt to 
generate a VacV mutant lacking I3L gene by recombination, carried out in P. 
Traktman’s laboratory (Rochester and Traktman, 1998), was unsuccessful. Similarly, 
this study shows that using a Vac-Bac/λ system developed by Domi and Moss (2005) 
also failed to recover ∆I3L mutant virus, although it was possible to replace I3L ORF 
with the gene encoding ampicillin (Fig. 3.3.35), and recover wild-type virus from the 
BAC system (Fig. 3.36-a, 3.37-a). Furthermore, several different siRNAs targeting the 
I3 mRNA failed to affect I3 accumulation in HEK-293 or HeLa cells (not shown). 
These outcomes suggest that the I3L gene product is essential during the vaccinia virus 
infectious cycle. However, despite the fact that the assay was performed in three 
repeats, it is possible that inability to recover ∆I3L mutant was caused by spontaneous 
mutation within the viral genome. Unfortunately, because of time limitation more 
thorough analysis of VacV ∆I3L mutants could not be performed. However, further 
investigation of I3 function based on Vac-Bac/λ system would be highly recommended. 
Furthermore, due to incredibly fast headway in developing new techniques in molecular 
biology, it may be possible to develop new techniques of creating viral mutants that 
would allow efficient studies of the role of this multifunctional protein in VacV life 
cycle. 
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5.1 Conclusion  
In this study we demonstrate that PI 3-kinase plays a critical role in regulating protein 
production during VacV infection, at least in part by controlling the abundance and 
activity of 4E-BP1, the translational repressor. We also show that 4E-BP1 
phosphorylation and abundance is regulated by unknown rapamycin-insensitive 
mechanism regulated by PI3K, inhibition of which results in dramatic suppression of 
both the eIF4F complex formation and the total translational rates in VacV-infected 
cells.  
Inhibition of both mTORC1 and mTORC2 complexes using a novel inhibitor Torin1 
resulted in suppression of eIF4F formation but did not dramatically affect VacV protein 
synthesis, suggesting VacV has a low requirement for eIF4F to translate its mRNAs, as 
reported previously. However, we show that eIF4F activity enhances viral protein 
synthesis and is beneficial to virus replication.  
Moreover, we provide the first evidence of interaction between VacV-encoded protein 
I3 and cellular translational factors. This study shows that I3 binds to eIF4G by direct 
interaction with its C-terminal region, and likely interacts with eIF4E as well. We 
demonstrate that I3 is capable of specifically recruiting initiation factors eIF4G and 
PABP to ssDNA and co-localizes with eIF4G within viral factories. In addition PAA, a 
DNA polymerase inhibitor, did not significantly affect the ability of I3 to interact with 
eIF4F but it did suppress viral factory formation and eIF4F complex formation, 
suggesting that I3 binding alone is not sufficient to promote complex assembly. I3 did 
not appear to affect host or viral mRNA translation. As such, we propose that I3 
regulates translation factor redistribution to viral factories during infection. 
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Furthermore, mTORC1 inhibition by rapamycin only modestly affected VacV 
translation and the association of I3 with eIF4F, while it did prevent VacV-induced 
phosphorylation of 4E-BP1. However, our results indicate that maximal efficiency of 
VacV protein synthesis and I3 binding required the activity of cellular mTORC1.  
Our attempts to recover a VacV mutant lacking the I3L gene using Vac-Bac/λ system 
were unsuccessful, although we did replace I3L ORF with the gene encoding ampicillin. 
In addition, siRNA targeting I3 mRNA did not affect I3 accumulation. These findings 
indicate that I3L is an essential gene in VacV replication, in agreement with the 
previous reports.  
In overall conclusion, this study proposes a novel function of VacV-encoded protein I3 
in translation and therefore suggests a novel approach adopted by a DNA virus to 
manipulate the translation initiation complex eIF4F. However, the exact mechanism of 
this process remains to be investigated further. 
 
 
 
 
 
 
 
 
 
 
 
 216 
5.2 Future directions  
 
 In the case of signaling, more extensive investigation of Torin1 effect on 
PI3K signaling pathway during VacV infection should be carried out. 
 Study the mechanism of the PI3K activation by VacV. 
 It would be recommended to investigate the possible interaction between I3 
and eIF4E by performing the binding assays with purified proteins. 
 It is possible that I3 binds also the other host cell factors, in addition to 
translation factors. Analysis of anti-I3 immune complexes recovered from 
infected cells would be interesting. 
 Further studies of the exact mechanism by which cellular translational 
factors are redistributed during VacV infection and the role of ssDNA in this 
mechanism would be highly recommended. 
 It would be also interesting to study the possible interaction between I3 and 
microtubules responsible for intracellular transport. 
 Further research based on the Vac-Bac/λ system using multiple repeats of 
VacV ∆I3L mutant preparation could result in recovering the mutant virus 
and allow to study the function of I3 in VacV protein synthesis. 
 Finally, it would be recommended to study the role of PABP in VacV 
infectious cycle, starting from identifying the unknown protein associated 
with anti-PABP immune complexes in infected cells, noticed in figure 3.3.2.  
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